CUMULATIVE
SUPPLEMENT 12
JAN'96-DEC'96



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DATABASE MANAGEMENT

SUBSCRIBE NOW!

Available in March 1997

New 17th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION
1997

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION

Cumulative Supplement 12

DECEMBER 1996

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION

CUMULATIVE SUPPLEMENT 12
DECEMBER 1996

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 16th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing shaded print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the shaded print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 16th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 17th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval

on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release;transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 CHANGE OF A THERAPEUTIC EQUIVALENT CODE FOR A DRUG ENTITY

Propantheline Bromide

In Cumulative Supplement 1 of the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 16th Edition, (Orange Book), the Agency proposed to change the therapeutic equivalence code for propantheline bromide oral tablets from a drug product not presenting a bioequivalence problem **(AA)** to a drug product with a potential bioequivalence problem **(BP)**.

The Agency solicited comments from interested persons to be received no later than 60 days from the first day of the month following the publication of Cumulative Supplement 1. The proposal did not elicit any comments from the readers. In addition, the two firms who hold an active ANDA and are marketing the drug product were contacted to inform them that the codes for their propantheline drug products were going to be changed. Since there were no comments submitted by the readers or by the two firms who hold an active ANDA, the therapeutic equivalence code for propantheline bromide tablets will be changed to one reflecting a potential bioequivalence problem. Therefore, all oral propantheline bromide tablets will be changed in this month's Cumulative Supplement from **(AA)** to **(BP)** to reflect it has a potential for a bioequivalence problem.

An acceptable *in vivo* bioequivalence study, among other information, will be required to change the code from **(BP)** to **(AB)** for an already approved ANDA listed in the Orange Book. Any ANDA submission must contain an acceptable *in vivo* bioequivalence study for filing purposes.

1.4 REFERENCE LISTED DRUG

A reference listed drug (21 CFR 314.94(a)(3) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to different reference listed drugs. However, in some instances when multiple NDAs are approved for a single drug product, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. A firm wishing to market a generic version of an NDA listed drug that is not designated as the reference listed may petition the Agency through the Citizen Petition procedure (see 21 CFR 10.25(a) and CFR 10.30). When the Citizen Petition is approved, the second NDA will be designated as an additional reference listed drug and the petitioner may submit an Abbreviated New Drug Application citing the designated reference listed drug. Section 1.7, *Therapeutic Equivalence Evaluations Codes* of the *Introduction* to the *Approved Drug Products with Therapeutic Equivalence Evaluations* publication explains the coding system for multisource drug products listed under the same heading with two reference listed drugs.

The concept of having only one reference listed drug was intended to apply to drug products in which bioequivalence is demonstrated through *in vivo* methodology. It was not intended to apply to two NDA drug products in which the *in vivo* determination of bioequivalence is self evident and a waiver of *in vivo* bioequivalence is granted by the agency. These types of drug products are assigned therapeutic equivalence codes, e.g., of **AN**, **AT**, **AA**. Therefore, drug products that do not represent a bioequivalence problem with two or more NDAs will have the reference listed drug designation assigned to each NDA.

The reference listed drug is identified by the symbol "+" in the Prescription Drug Product List. These identified reference listed drugs represent the best judgement of the Division of Bioequivalence at this time. The prescription Drug Product List identifies reference drugs for oral dosage forms, injectables, ophthalmics, otics, and topical products. It is recommended that a firm planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, contact the Division of Bioequivalence, OFFICE OF GENERIC DRUGS, to confirm the appropriate reference listed drug.

1.5 COURT ORDER REGARDING ABBOTT U.S. PATENT NO. 4112097, (TERAZOSIN HCL)

On April 9, 1996, the United States District Court for the Northern District of Illinois (Eastern Division) issued an order in the case of Abbott Labs v. Geneva Pharmaceuticals, Inc., directing Abbott to remove U.S. Patent No. 4112097 from the Orange Book. To comply with that order, Abbott has requested that FDA remove patent 4112097 from the Orange Book. The FDA complied with this request in the March 1996 cumulative supplement. On April 9, 1996, Abbott appealed the district court's decision to the U.S. Court of Appeals for the Federal Circuit.

1.6 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

As a result of the April 4, 1996, decision of the United States Court of Appeals for the Federal Circuit in Merck, et al. v. Kessler, patent expiration dates for certain patents subject to patent term extensions under the Uruguay Round Agreements Act and to the patent term extension provisions at 35 U.S.C. § 156 may be changed. FDA is publishing a notice in the *Federal Register* advising NDA and NADA applicants that patent expiration dates changed by the Merck decision must be submitted within 60 days. Because there may be changes in listed patents as a result of the Merck decision, users of this publication should consult the most recent supplement, and are encouraged to confirm that patent information upon which they intend to rely is current. (See the *Patent and Exclusivity Addendum* to the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 16th Edition that explains the background information on this court decision).

1.7 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs

[New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
1ST TEXAS PHARMACEUTICALS INC SUB SCHERER LABORATORIES (1ST TX)	SCHERER LABORATORIES, INC (SCHERER)
BARRE NATIONAL INC (BARRE)	ALPHARMA USPD INC (ALPHARMA)
BEN VENUE (BEN VENUE LABORATORIES INC)	BEDFORD (BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC)
BIOCRAFT (BIOCRAFT LABORATORIES INC)	TEVA (TEVA PHARMACEUTICALS USA)
BOEHRINGER MANNHEIM PHARMACEUTICALS CORP (BOEHRINGER MANNHEIM)	BOEHRINGER MANNHEIM CORPORATION THERAPEUTICS DIVISION (BOEHRINGER MANNHEIM)
CETUS BEN VENUE (CETUS BEN VENUE THERAPEUTICS)	BEDFORD (BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC)
DAVID BULL LABORATORIES PARTY LTD (BULL D)	FH FAULDING AND CO LTD (FAULDING) **THEN CHANGED TO** FAULDING PHARMACEUTICAL CO (FAULDING)
HOECHST ROUSSEL PHARMACEUTICALS INC (HOECHST ROUSSEL)	HOECHST MARION ROUSSEL INC (HOECHST MARION RSSL)
KM LEE LABORORATORIES INC (KM LEE)	KM LEE LABORATORIES INC (LEE KM)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
PHARMACIA INC (PHARMACIA)	PHARMACIA AND UPJOHN CO (PHARMACIA AND UPJOHN)
SCHWARZ PHARMA KREMERS URBAN CO SUB SCHWARZ PHARMA AG (SPKU)	SCHWARZ PHARMA INC (SCHWARZ PHARMA)
UPJOHN CO (UPJOHN)	PHARMACIA AND UPJOHN CO (PHARMACIA AND UPJOHN)
UPJOHN MANUFACTURING CO (UPJOHN)	PHARMACIA AND UPJOHN CARIBE INC (PHARMACIA AND UPJOHN)

1.8 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is now available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are now available on Internet and are updated each October and April: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; and Appendices. The update in October will include drug products that have been approved through August and the update in April will include drug products that have been approved through December.

These files may be accessed on the Internet's World Wide Web. FDA's Internet site replaces the Agency's electronic bulletin board and offers more information, in a more user-friendly form. To access the CDER Home Page, use this Uniform Resource Locator (URL): http://www.fda.gov/cder. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

The Prescription Drug Products and OTC Drug Product files will be available on a monthly basis in the near future.

1.9 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1995) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1995	JUN 1996	SEP 1996	DEC 1996
DRUG PRODUCTS LISTED	9286	9384	9403	9392
SINGLE SOURCE	2217 (23.9%)	2323 (24.8%)	2331 (24.8%)	2383 (25.4%)
MULTISOURCE	7069 (76.1%)	7061 (75.2%)	7072 (75.2%)	7009 (74.6%)
THERAPEUTICALLY EQUIVALENT	6437 (69.3%)	6490 (69.2%)	6519 (69.3%)	6463 (68.8%)
NOT THERAPEUTICALLY EQUIVALENT	440 (4.7%)	468 (5.0%)	449 (4.8%)	442 (4.7%)
EXCEPTIONS[1]	192 (2.1%)	103 (1.0%)	104 (1.1%)	104 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	--	15	14	19
NUMBER OF APPLICANTS	586	621	636	650

CATEGORIES COUNTED	DEC 1996*
DRUG PRODUCTS LISTED	9392
SINGLE SOURCE	2383 (25.4%)
MULTISOURCE	6905 (73.5%)
THERAPEUTICALLY EQUIVALENT	6463 (68.8%)
NOT THERAPEUTICALLY EQUIVALENT	442 (4.7%)
EXCEPTIONS[1]	104 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	19
NUMBER OF APPLICANTS	650

[1]Amino acid-containing products of varying composition (see Introduction, page xvi of the List).

*Exceptions were originally included in the total count of the Multisource Drug Products. Beginning with December 1996, exceptions will no longer be included in the Multisource Drug Products total count, but will be included in the total count of the Drug Products Listed.

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL
BUTALBITAL AND ACETAMINOPHEN

AB	HALSEY	325MG;50MG	N89568 001 OCT 05, 1988	
@		325MG;50MG	N89568 001 OCT 05, 1988	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
ESGIC-PLUS

+	MIKART	500MG;50MG;40MG	N40085 001 MAR 28, 1996	

TABLET; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	MIKART	500MG;50MG;40MG	N89451 001 MAY 23, 1988	
+		500MG;50MG;40MG	N89451 001 MAY 23, 1988	

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL
DHC PLUS

AA	PURDUE FREDERICK	356.4MG;30MG;16MG	N88584 001 MAR 04, 1986	
+		356.4MG;30MG;16MG	N88584 001 MAR 04, 1986	

SYNALGOS-DC-A

AA	+ WYETH AYERST	356.4MG;30MG;16MG	N89166 001 MAY 14, 1986	
@		356.4MG;30MG;16MG	N89166 001 MAY 14, 1986	

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	HI TECH PHARMA	120MG/5ML;12MG/5ML	N40119 001 APR 26, 1996	
AA	MOVA	120MG/5ML;12MG/5ML	N40098 001 SEP 20, 1996	

TYLENOL W/ CODEINE

AA	JOHNSON RW	120MG/5ML;12MG/5ML	N85057 001	

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL
TYLENOL W/ CODEINE

AA	+ JOHNSON RW	120MG/5ML;12MG/5ML	N85057 001	

SUSPENSION; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

> ADD > AA	CARNRICK	120MG/5ML;12MG/5ML	N86024 001	
> DLT >				
ACETAMINOPHEN W/ CODEINE PHOSPHATE				
> DLT > AA	BARRE	120MG/5ML;12MG/5ML	N85883 001	
CAPITAL AND CODEINE				
> ADD > AA	ALPHARMA	120MG/5ML;12MG/5ML	N85883 001	
> DLT > AA	CARNRICK	120MG/5ML;12MG/5ML	N86024 001	

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	BARR	300MG;15MG	N85795 001	
AA		300MG;30MG	N85794 001	
@		300MG;15MG	N85795 001	
@		300MG;30MG	N85794 001	
AA	GENEVA PHARMS	300MG;30MG	N85291 002	
AA		300MG;60MG	N85964 001	
@		300MG;30MG	N85291 002	
@		300MG;60MG	N85964 001	
AA	HALSEY	300MG;60MG	N86549 001	
@		300MG;60MG	N86549 001	
AA	LEMMON	300MG;15MG	N88627 001 MAR 06, 1985	
AA		300MG;30MG	N88628 001 MAR 06, 1985	
AA		300MG;60MG	N88629 001 MAR 06, 1985	
AA	MIKART	300MG;30MG	N89238 001 FEB 25, 1986	
AA		300MG;60MG	N89244 001 FEB 25, 1986	
@		300MG;60MG	N89244 001 FEB 25, 1986	
AA	TEVA	300MG;15MG	N88627 001 MAR 06, 1985	
AA		300MG;30MG	N88628 001 MAR 06, 1985	
AA		300MG;60MG	N88629 001 MAR 06, 1985	

ACETAMINOPHEN AND CODEINE PHOSPHATE #3

AA	MIKART	300MG;30MG	N89238 001 FEB 25, 1986	

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE #3			
AA	SUPERPHARM	300MG;30MG	N89184 001	
			OCT 18, 1985	
	@	300MG;30MG	N89184 001	
			OCT 18, 1985	
	ACETAMINOPHEN AND CODEINE PHOSPHATE #4			
AA	SUPERPHARM	300MG;60MG	N89185 001	
			OCT 18, 1985	
	@	300MG;60MG	N89185 001	
			OCT 18, 1985	
	ACETAMINOPHEN W/ CODEINE			
AA	BARR	300MG;60MG	N87653 001	
			APR 13, 1982	
	@	300MG;60MG	N87653 001	
			APR 13, 1982	
	ACETAMINOPHEN W/ CODEINE PHOSPHATE			
AA	HALSEY	300MG;15MG	N83871 001	
AA		300MG;30MG	N83872 001	
	@	300MG;15MG	N83871 001	
	@	300MG;30MG	N83872 001	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

	ANEXSIA			
AA	KING PHARMS	500MG;5MG	N89160 001	
			APR 23, 1987	
AA	MALLINCKRODT CHEM	500MG;5MG	N89160 001	
			APR 23, 1987	
	ANEXSIA 10/660			
	MALLINCKRODT	660MG;10MG	N40084 003	
			JUL 29, 1996	
AA +	MALLINCKRODT CHEM	660MG;10MG	N40084 003	
			JUL 29, 1996	
	ANEXSIA 7.5/650			
AA	KING PHARMS	650MG;7.5MG	N89725 001	
			SEP 30, 1987	
AA	MALLINCKRODT CHEM	650MG;7.5MG	N89725 001	
			SEP 30, 1987	
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	KING PHARMS	500MG;5MG	N40084 002	> DLT >
			JUN 01, 1995	> DLT >
AA		750MG;7.5MG	N40084 001	> ADD >
			JUN 01, 1995	> ADD >

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

	HYDROCODONE BITARTRATE AND ACETAMINOPHEN		
AA	MALLINCKRODT CHEM	500MG;5MG	N40084 002
			JUN 01, 1995
AA		750MG;7.5MG	N40084 001
			JUN 01, 1995
AA	ROYCE LABS	500MG;2.5MG	N40123 003
			MAR 04, 1996
AA		500MG;5MG	N40122 001
			MAR 04, 1996
AA		500MG;7.5MG	N40123 004
			MAR 04, 1996
AA		650MG;7.5MG	N40123 001
			MAR 04, 1996
AA		650MG;10MG	N40123 002
			MAR 04, 1996
AA		750MG;7.5MG	N40122 002
			MAR 04, 1996
AA	UCB	650MG;7.5MG	N40134 001
			NOV 21, 1996
AA	VINTAGE PHARMS	500MG;7.5MG	N40144 001
			FEB 22, 1996
AA		650MG;10MG	N40143 001
			FEB 22, 1996
AA		750MG;7.5MG	N40157 001
			APR 12, 1996
	LORTAB		
+	GRAHAM	500MG;10MG	N40100 001
			JAN 26, 1996
+	UCB	500MG;10MG	N40100 001
			JAN 26, 1996
	VICODIN HP		
AA	KNOLL PHARM	660MG;10MG	N40117 001
			SEP 23, 1996

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

	OXYCODONE AND ACETAMINOPHEN		
AA	HALSEY	500MG;5MG	N89994 001
			MAY 04, 1989
	@	500MG;5MG	N89994 001
			MAY 04, 1989
AA	VINTAGE PHARMS	500MG;5MG	N40106 001
			JUL 30, 1996

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	VINTAGE PHARMS	**325MG;5MG**		**N40105 001** JUL 30, 1996

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
PROPOXYPHENE HCL AND ACETAMINOPHEN

> ADD > **AA**	ROYCE LABS	**650MG;65MG**		**N40139 001** DEC 16, 1996

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB	SUPERPHARM	**650MG;100MG**		**N71319 001** JAN 06, 1987
	@	650MG;100MG		N71319 001 JAN 06, 1987

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC
ACETIC ACID

AT	MORTON GROVE	**2%**		**N40166 001** JUL 26, 1996

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC
HYDROCORTISONE AND ACETIC ACID

AT	MORTON GROVE	**2%;1%**		**N40168 001** AUG 30, 1996

ACITRETIN

CAPSULE; ORAL
SORIATANE

	ROCHE	10MG		N19821 001 OCT 28, 1996

ACITRETIN

CAPSULE; ORAL
SORIATANE

+	ROCHE	25MG		N19821 002 OCT 28, 1996

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL
SEMPREX-D

+	GLAXO WELLCOME	8MG;60MG		N19806 001 MAR 25, 1994
+	MEDEVA	8MG;60MG		N19806 001 MAR 25, 1994

ADAPALENE

GEL; TOPICAL
DIFFERIN

+	GALDERMA	0.1%		N20380 001 MAY 31, 1996

SOLUTION; TOPICAL
DIFFERIN

+	GALDERMA	0.1%		N20338 001 MAY 31, 1996

ALBENDAZOLE

TABLET; ORAL
ALBENZA

+	SMITHKLINE BEECHAM	200MG		N20666 001 JUN 11, 1996

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL

AB	ARMSTRONG PHARMS	**0.09MG/INH**		**N72273 001** AUG 14, 1996
AB	MEDISOL	**0.09MG/INH**		**N74072 001** AUG 01, 1996

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION
PROVENTIL-HFA
+ 3M — EQ 0.09MG BASE/INH — N20503 001 AUG 15, 1996

SOLUTION; INHALATION
VENTOLIN

AN		GLAXO WELLCOME	EQ 0.083% BASE	N19773 001 APR 23, 1992
AN	+		EQ 0.083% BASE	N19773 001 APR 23, 1992
AN			EQ 0.5% BASE	N19269 002 JAN 16, 1987
AN	+		EQ 0.5% BASE	N19269 002 JAN 16, 1987

SYRUP; ORAL
PROVENTIL

AA		SCHERING	EQ 2MG BASE/5ML	N18062 001 JAN 19, 1983
AA	+		EQ 2MG BASE/5ML	N18062 001 JAN 19, 1983

TABLET; ORAL
ALBUTEROL SULFATE

AB		LEMMON	EQ 2MG BASE	N72938 001 MAR 30, 1990
AB			EQ 4MG BASE	N72939 001 MAR 30, 1990
AB		TEVA	EQ 2MG BASE	N72938 001 MAR 30, 1990
AB			EQ 4MG BASE	N72939 001 MAR 30, 1990

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION
COMBIVENT
+ BOEHRINGER INGELHEIM — EQ 0.09MG BASE/INH; 0.018MG/INH — N20291 001 OCT 24, 1996

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

AB	BARR	100MG	N70466 001 DEC 24, 1985
AB		300MG	N70467 001 DEC 24, 1985
@		100MG	N70466 001 DEC 24, 1985
@		300MG	N70467 001 DEC 24, 1985

ALLOPURINOL SODIUM

INJECTABLE; INJECTION
ZYLOPRIM
+ GLAXO WELLCOME — EQ 500MG BASE/VIAL — N20298 001 MAY 17, 1996

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	NOVOPHARM	2MG	N74085 004 FEB 26, 1996

ALPROSTADIL

INJECTABLE; INJECTION
CAVERJECT
PHARMACIA AND UPJOHN — 0.005MG/VIAL — N20379 003 JUN 27, 1996

SUPPOSITORY; URETHRAL
MUSE
VIVUS

	0.125MG	N20700 001 NOV 19, 1996
	0.25MG	N20700 002 NOV 19, 1996
	0.5MG	N20700 003 NOV 19, 1996
+	1MG	N20700 004 NOV 19, 1996

AMINO ACIDS

INJECTABLE; INJECTION
AMINOSYN-HF 8%
ABBOTT 8% N20345 001 APR 04, 1996

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER
CLINTEC NUTR 15% N20512 001 AUG 30, 1996

HEPATASOL 8%
BAXTER HLTHCARE 8% N20360 001 APR 04, 1996

AMINOPHYLLINE

TABLET; ORAL
AMINOPHYLLINE
@ PHOENIX LABS NY 100MG N85409 001
@ 200MG N85410 001
@ VINTAGE PHARMS 100MG N85409 001
@ 200MG N85410 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL
BP HALSEY 25MG N85922 001
@ 25MG N85922 001
ENDEP
AB ROCHE 150MG N85303 001
@ 150MG N85303 001

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL
AB BARR EQ 12.5MG BASE;5MG N70765 001 DEC 10, 1986
AB EQ 25MG BASE;10MG N70766 001 DEC 10, 1986
@ EQ 12.5MG BASE;5MG N70765 001 DEC 10, 1986
@ EQ 25MG BASE;10MG N70766 001 DEC 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL
AB BARR 10MG;2MG N71077 001 NOV 12, 1986
AB 10MG;4MG N71078 001 NOV 12, 1986
AB 25MG;2MG N70297 001 NOV 12, 1986
AB 25MG;4MG N71079 001 NOV 12, 1986
@ 10MG;2MG N71077 001 NOV 12, 1986
@ 10MG;4MG N71078 001 NOV 12, 1986
@ 25MG;2MG N70297 001 NOV 12, 1986
@ 25MG;4MG N71079 001 NOV 12, 1986

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

AMLEXANOX

PASTE; DENTAL
APHTHASOL
+ BLOCK DRUG 5% N20511 001 DEC 17, 1996

AMMONIUM LACTATE

CREAM; TOPICAL
LAC-HYDRIN
BRISTOL MYERS EQ 12% BASE N20508 001 AUG 29, 1996
WESTWOOD SQUIBB EQ 12% BASE N20508 001 AUG 29, 1996

AMOXICILLIN

CAPSULE; ORAL
AMOXIL
AB SMITHKLINE BEECHAM 500MG N62216 004
@ 250MG N62216 003
LAROTID
AB SMITHKLINE BEECHAM 250MG N62216 003
AB 500MG N62216 004

AMOXICILLIN

TABLET, CHEWABLE; ORAL
AMOXICILLIN

AB	APOTHECON	125MG		N64131 001
				MAY 06, 1996
AB		250MG		N64131 002
				MAY 06, 1996
AB	CLONMEL HLTH CARE	125MG		N64139 001
				JAN 29, 1996
AB		250MG		N64139 002
				JAN 29, 1996
> ADD > AB	NOVOPHARM	125MG		N64031 001
> ADD >				DEC 19, 1996
> ADD > AB		250MG		N64031 002
> ADD >				DEC 19, 1996

AMOXICILLIN; CLAVULANATE POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
AUGMENTIN '200'

+	SMITHKLINE BEECHAM	200MG/5ML; EQ 28.5MG BASE/5ML	N50725 001
			MAY 31, 1996

AUGMENTIN '400'

+	SMITHKLINE BEECHAM	400MG/5ML; EQ 57MG BASE/5ML	N50725 002
			MAY 31, 1996

TABLET; ORAL
AUGMENTIN '875'

+	SMITHKLINE BEECHAM	875MG;EQ 125MG BASE	N50720 001
			FEB 13, 1996

TABLET, CHEWABLE; ORAL
AUGMENTIN '200'

+	SMITHKLINE BEECHAM	200MG;EQ 28.5MG BASE	N50726 001
			MAY 31, 1996

AUGMENTIN '400'

+	SMITHKLINE BEECHAM	400MG;EQ 57MG BASE	N50726 002
			MAY 31, 1996

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
ADDERALL 10

	RICHWOOD PHARM	2.5MG;2.5MG;2.5MG;2.5MG	N11522 007
			FEB 13, 1996

ADDERALL 20

+	RICHWOOD PHARM	5MG;5MG;5MG;5MG	N11522 008
			FEB 13, 1996

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
BIPHETAMINE 12.5

	@ FISONS	EQ 6.25MG BASE; EQ 6.25MG BASE	N10093 007
	@ MEDEVA PHARMS	EQ 6.25MG BASE; EQ 6.25MG BASE	N10093 007

BIPHETAMINE 20

	@ FISONS	EQ 10MG BASE;EQ 10MG BASE	N10093 003
	@ MEDEVA PHARMS	EQ 10MG BASE;EQ 10MG BASE	N10093 003

BIPHETAMINE 7.5

	@ FISONS	EQ 3.75MG BASE; EQ 3.75MG BASE	N10093 009
	@ MEDEVA PHARMS	EQ 3.75MG BASE; EQ 3.75MG BASE	N10093 009

AMPHOTERICIN B

INJECTABLE; INJECTION
AMPHOTERICIN B

> ADD > AP	SANOFI WINTHROP	50MG/VIAL		N64141 001
> ADD >				DEC 23, 1996

INJECTABLE, LIPID COMPLEX; INJECTION
AMPHOTEC

+	SEQUUS PHARMS	50MG/VIAL	N50729 001
			NOV 22, 1996
+		100MG/VIAL	N50729 002
			NOV 22, 1996

SUSPENSION; ORAL
FUNGIZONE

+	BRISTOL MYERS SQUIBB	100MG/ML	N50341 003

AMPICILLIN SODIUM

INJECTABLE; INJECTION

	OMNIPEN-N			
AP	WYETH AYERST	EQ 2GM BASE/VIAL	N60626 005	
AP	+	EQ 2GM BASE/VIAL	N60626 005	
	PENBRITIN-S			
AP	WYETH AYERST	EQ 125MG BASE/VIAL	N50072 001	
AP		EQ 250MG BASE/VIAL	N50072 002	
AP		EQ 500MG BASE/VIAL	N50072 003	
AP		EQ 1GM BASE/VIAL	N50072 004	
AP	+	EQ 2GM BASE/VIAL	N50072 005	
	@	EQ 125MG BASE/VIAL	N50072 001	
	@	EQ 250MG BASE/VIAL	N50072 002	
	@	EQ 500MG BASE/VIAL	N50072 003	
	@	EQ 1GM BASE/VIAL	N50072 004	
	@	EQ 2GM BASE/VIAL	N50072 005	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

	PFIZERPEN-A			
AB	PFIZER	EQ 250MG BASE	N62050 001	
AB		EQ 500MG BASE	N62050 002	
	@	EQ 250MG BASE	N62050 001	> ADD >
	@	EQ 500MG BASE	N62050 002	> ADD >

> ADD >

POWDER FOR RECONSTITUTION; ORAL

> ADD >

	PFIZERPEN-A			
AB	PFIZER	EQ 125MG BASE/5ML	N62049 001	
AB		EQ 250MG BASE/5ML	N62049 002	
	@	EQ 125MG BASE/5ML	N62049 001	
	@	EQ 250MG BASE/5ML	N62049 002	

> ADD >

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

POWDER FOR RECONSTITUTION; ORAL

	POLYCILLIN-PRB			
AB	+ APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	N61898 001	
	@	EQ 3.5GM BASE/BOT;1GM/BOT	N61898 001	
	PROBAMPACIN			
AB	BIOCRAFT	EQ 3.5GM BASE/BOT;1GM/BOT	N61741 001	
	+	EQ 3.5GM BASE/BOT;1GM/BOT	N61741 001	

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

	BUTALBITAL, ASPIRIN & CAFFEINE			
AB	HALSEY	325MG;50MG;40MG	N89448 001	DEC 01, 1986
	@	325MG;50MG;40MG	N89448 001	DEC 01, 1986

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

	INVAGESIC			
AB	INVAMED	385MG;30MG;25MG	N74817 001	NOV 27, 1996
	INVAGESIC FORTE			
AB	INVAMED	770MG;60MG;50MG	N74817 002	NOV 27, 1996
	NORGESIC			
AB	3M	385MG;30MG;25MG	N13416 003	OCT 27, 1982
	NORGESIC FORTE			
AB	+ 3M	770MG;60MG;50MG	N13416 004	OCT 27, 1982
	ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE			
AB	EON LABS MFG	385MG;30MG;25MG	N74654 001	DEC 31, 1996
AB		770MG;60MG;50MG	N74654 002	DEC 31, 1996

ASPIRIN; CARISOPRODOL

TABLET; ORAL

	CARISOPRODOL AND ASPIRIN			
AB	EON LABS MFG	325MG;200MG	N40116 001	APR 25, 1996

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

	CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE			
AB	EON LABS MFG	325MG;200MG;16MG	N40118 001	APR 16, 1996
	SOMA COMPOUND W/ CODEINE			
AB	+ WALLACE PHARMS	325MG;200MG;16MG	N12366 002	JUL 11, 1983

> ADD > ATORVASTATIN CALCIUM

> ADD > TABLET; ORAL
> ADD > LIPITOR
> ADD > PARKE DAVIS EQ 10MG BASE N20702 001
> ADD > DEC 17, 1996
> ADD > EQ 20MG BASE N20702 002
> ADD > DEC 17, 1996
> ADD > + EQ 40MG BASE N20702 003
> ADD > DEC 17, 1996

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
> ADD > **ATRACURIUM BESYLATE**
> ADD > **AP** ABBOTT **10MG/ML** **N74632 001**
> ADD > DEC 23, 1996
> ADD > **AP** **10MG/ML** **N74633 001**
> ADD > DEC 23, 1996

TRACRIUM
> ADD > **AP** + GLAXO WELLCOME **10MG/ML** **N18831 001**
> ADD > NOV 23, 1983

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
AA BARR 0.025MG;2.5MG **N85506 001**
@ 0.025MG;2.5MG N85506 001

LOGEN
AA SUPERPHARM 0.025MG;2.5MG **N88962 001**
MAY 10, 1985
@ 0.025MG;2.5MG N88962 001
MAY 10, 1985

LOW-QUEL
AA HALSEY 0.025MG;2.5MG **N85211 001**
@ 0.025MG;2.5MG N85211 001

AZATHIOPRINE

TABLET; ORAL
AZATHIOPRINE
AB ROXANE **50MG** **N74069 001**
FEB 16, 1996

IMURAN
AB + GLAXO WELLCOME **50MG** **N16324 001**

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL
ASTELIN
+ WALLACE EQ 0.125MG BASE/INH N20114 001
NOV 01, 1996

AZITHROMYCIN DIHYDRATE

TABLET; ORAL
ZITHROMAX
+ PFIZER EQ 250MG BASE N50711 001
JUL 18, 1996
+ EQ 600MG BASE N50730 001
JUN 12, 1996

AZTREONAM

INJECTABLE; INJECTION
AZACTAM
+ BRISTOL MYERS SQUIBB 500MG/VIAL N50580 001
DEC 31, 1986
+ 1GM/VIAL N50580 002
DEC 31, 1986
+ 2GM/VIAL N50580 003
DEC 31, 1986
+ SQUIBB 500MG/VIAL N50580 001
DEC 31, 1986
+ 1GM/VIAL N50580 002
DEC 31, 1986
+ 2GM/VIAL N50580 003
DEC 31, 1986

BACITRACIN

OINTMENT; OPHTHALMIC
BACITRACIN
AT ALTANA **500 UNITS/GM** **N61212 001**
+ 500 UNITS/GM N61212 001
AT + LILLY **500 UNITS/GM** **N60687 001**
@ 500 UNITS/GM N60687 001

BACLOFEN

INJECTABLE; INTRATHECAL
LIORESAL
+ MEDTRONIC 0.05MG/ML N20075 003 NOV 07, 1996

TABLET; ORAL
BACLOFEN
AB CHELSEA LABS **10MG** **N74698 001** AUG 20, 1996
AB **20MG** **N74698 002** AUG 20, 1996
AB ROSEMONT **10MG** **N74584 001** AUG 19, 1996
AB **20MG** **N74584 002** AUG 19, 1996

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION
> ADD > VANCERIL DOUBLE STRENGTH
> ADD > + SCHERING 0.084MG/INH N20486 001 DEC 24, 1996
> ADD >

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL
BECONASE AQ
BN + GLAXO WELLCOME EQ 0.042MG DIPROP/INH N19389 001 JUL 27, 1987
BN EQ 0.042MG DIPROP/INH N19389 001 JUL 27, 1987

VANCENASE AQ
BN SCHERING EQ 0.042MG DIPROP/INH N19589 001 DEC 23, 1987
BN + EQ 0.042MG DIPROP/INH N19589 001 DEC 23, 1987
+ EQ 0.084MG DIPROP/INH N20469 001 JUN 26, 1996

BENTIROMIDE

SOLUTION; ORAL
CHYMEX
SAVAGE LABS 500MG/7.5ML N18366 001 DEC 29, 1983

BENTIROMIDE

SOLUTION; ORAL
CHYMEX
@ SAVAGE LABS 500MG/7.5ML N18366 001 DEC 29, 1983

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE
> ADD > **AA** ROSEMONT **0.5MG** **N40103 001** DEC 12, 1996
> ADD > **AA** **1MG** **N40103 002** DEC 12, 1996
> ADD > **AA** **2MG** **N40103 003** DEC 12, 1996
> ADD >

BETA-CAROTENE

CAPSULE; ORAL
SOLATENE
+ ROCHE 30MG N17589 001
@ 30MG N17589 001

BETAINE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
CYSTADANE
+ ORPHAN MEDCL 1GM/SCOOPFUL N20576 001 OCT 25, 1996

BETAMETHASONE BENZOATE

CREAM; TOPICAL
UTICORT
+ PARKE DAVIS 0.025% N16998 002
@ 0.025% N16998 002

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

	HELIDAC			
+	PROCTER AND GAMBLE	262.4MG;250MG;500MG	N50719 001	AUG 15, 1996

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

	BLENOXANE			
AP	+ BRISTOL MYERS SQUIBB	**EQ 15 UNITS BASE/VIAL**	**N50443 001**	
	+	EQ 15 UNITS BASE/VIAL	N50443 001	
	BLEOMYCIN SULFATE			
AP	PHARMACIA AND UPJOHN	**EQ 15 UNITS BASE/VIAL**	**N64084 001**	JUN 01, 1996
	+	EQ 30 UNITS BASE/VIAL	N64084 002	JUN 01, 1996

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

	ALPHAGAN			
+	ALLERGAN	0.2%	N20613 001	SEP 06, 1996

BROMPHENIRAMINE MALEATE

TABLET; ORAL

	DIMETANE			
AA	+ ROBINS AH	**4MG**	**N10799 003**	
	@ WHITEHALL ROBINS	4MG	N10799 003	

BUCLIZINE HYDROCHLORIDE

TABLET; ORAL

	BUCLADIN-S			
	STUART	50MG	N10911 006	
	@	50MG	N10911 006	

BUMETANIDE

TABLET; ORAL

	BUMETANIDE			
AB	EON LABS MFG	**0.5MG**	**N74700 001**	NOV 21, 1996
AB		**1MG**	**N74700 002**	NOV 21, 1996
AB		**2MG**	**N74700 003**	NOV 21, 1996

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

	BUPRENEX			
AP	+ RECKITT AND COLMAN	**EQ 0.3MG BASE/ML**	**N18401 001**	
	BUPRENORPHINE HCL			
AP	SANOFI WINTHROP	**EQ 0.3MG BASE/ML**	**N74137 001**	JUN 03, 1996

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	WELLBUTRIN			
+	GLAXO WELLCOME	50MG	N20358 001	OCT 04, 1996
+		100MG	N20358 002	OCT 04, 1996
+		150MG	N20358 003	OCT 04, 1996

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

	BUSPAR			
+	BRISTOL MYERS SQUIBB	10MG	N18731 002	SEP 29, 1986
		10MG	N18731 002	SEP 29, 1986
+		15MG	N18731 003	APR 22, 1996
	@	30MG	N18731 004	APR 22, 1996

BUTABARBITAL SODIUM

ELIXIR; ORAL
SARISOL
AA HALSEY 30MG/5ML N84723 001
@ 30MG/5ML N84723 001

TABLET; ORAL
SARISOL NO. 1
AA HALSEY 15MG N84719 001
@ 15MG N84719 001
SARISOL NO. 2
AA HALSEY 30MG N84719 002
@ 30MG N84719 002

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL
MENTAX
+ PENEDERM 1% N20524 001
OCT 18, 1996

> ADD > CABERGOLINE

> ADD > TABLET; ORAL
> ADD > DOSTINEX
> ADD > + PHARMACIA AND UPJOHN 0.5MG N20664 001
> ADD > DEC 23, 1996

CALCIPOTRIENE

CREAM; TOPICAL
DOVONEX
+ BRISTOL MYERS SQUIBB 0.005% N20554 001
JUL 22, 1996

CALCITONIN, HUMAN

INJECTABLE; INJECTION
CIBACALCIN
+ CIBA 0.5MG/VIAL N18470 001
OCT 31, 1986
@ 0.5MG/VIAL N18470 001
OCT 31, 1986

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
AT FRESENIUS 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 002
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
AT FRESENIUS 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 003
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
AT FRESENIUS 25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 007
JUN 24, 1988
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
AT FRESENIUS 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 001
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
AT FRESENIUS 25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N18379 004
JUL 07, 1982
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
AT FRESENIUS 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N18379 005
JUL 07, 1982
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
AT FRESENIUS 25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N18379 008
JUN 24, 1988
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
AT FRESENIUS 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N18379 006
JUL 07, 1982
INPERSOL W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
AT FRESENIUS 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 002
INPERSOL W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
AT FRESENIUS 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 003

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

	INPERSOL W/ DEXTROSE 3.5% IN PLASTIC CONTAINER			
AT	FRESENIUS	25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML	N18379 007	JUN 24, 1988
	INPERSOL W/ DEXTROSE 4.25% IN PLASTIC CONTAINER			
AT	FRESENIUS	25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML	N18379 001	
	INPERSOL-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER			
AT	FRESENIUS	25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 004	JUL 07, 1982
	INPERSOL-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER			
AT	FRESENIUS	25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 005	JUL 07, 1982
	INPERSOL-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER			
AT	FRESENIUS	25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 008	JUN 24, 1988
	INPERSOL-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER			
AT	FRESENIUS	25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 006	JUL 07, 1982

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INTRATHECAL

	ELLIOTTS B SOLUTION			
+	ORPHAN MEDCL	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML; 1.9MG/ML;7.3MG/ML; 0.2MG/ML	N20577 001	SEP 27, 1996

CAPTOPRIL

TABLET; ORAL

	CAPOTEN			
AB	BRISTOL MYERS SQUIBB	100MG	N18343 003	
AB	+	100MG	N18343 003	
		75MG	N18343 007	JUN 13, 1995
	+	150MG	N18343 004	JUN 13, 1995
	@	75MG	N18343 007	JUN 13, 1995
	@	150MG	N18343 004	JUN 13, 1995
	CAPTOPRIL			
AB	BAKER NORTON	12.5MG	N74590 004	AUG 30, 1996
AB		25MG	N74590 002	AUG 30, 1996
AB		50MG	N74590 001	AUG 30, 1996
AB		100MG	N74590 003	AUG 30, 1996
AB	BIOCRAFT	12.5MG	N74433 001	FEB 13, 1996
AB		25MG	N74433 002	FEB 13, 1996
AB		50MG	N74433 003	FEB 13, 1996
AB		100MG	N74433 004	FEB 13, 1996
AB	CHELSEA LABS	12.5MG	N74576 001	APR 23, 1996
AB		25MG	N74576 002	APR 23, 1996
AB		50MG	N74576 003	APR 23, 1996
AB		100MG	N74576 004	APR 23, 1996
AB	COPLEY PHARM	12.5MG	N74462 001	FEB 13, 1996
AB		25MG	N74462 002	FEB 13, 1996
AB		50MG	N74462 003	FEB 13, 1996
AB		100MG	N74462 004	FEB 13, 1996
AB	DANBURY PHARMA	12.5MG	N74386 001	MAY 23, 1996

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	DANBURY PHARMA	25MG	N74386 002	MAY 23, 1996
AB		50MG	N74386 003	MAY 23, 1996
AB		100MG	N74386 004	MAY 23, 1996
AB	ENDO LABS	12.5MG	N74418 001	FEB 13, 1996
AB		25MG	N74418 002	FEB 13, 1996
AB		50MG	N74418 003	FEB 13, 1996
AB		100MG	N74418 004	FEB 13, 1996
AB	EON LABS MFG	12.5MG	N74519 001	FEB 13, 1996
AB		25MG	N74519 002	FEB 13, 1996
AB		50MG	N74519 003	FEB 13, 1996
AB		100MG	N74519 004	FEB 13, 1996
AB	HALLMARK PHARMS	12.5MG	N74477 001	FEB 13, 1996
AB		25MG	N74477 002	FEB 13, 1996
AB		50MG	N74477 003	FEB 13, 1996
AB		100MG	N74477 004	FEB 13, 1996
AB	INVAMED	12.5MG	N74481 001	FEB 13, 1996
AB		25MG	N74481 002	FEB 13, 1996
AB		50MG	N74481 003	FEB 13, 1996
AB		100MG	N74481 004	FEB 13, 1996
AB	LEMMON	12.5MG	N74483 001	FEB 13, 1996
AB		25MG	N74483 002	FEB 13, 1996
AB		50MG	N74483 003	FEB 13, 1996

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	LEMMON	100MG	N74483 004	FEB 13, 1996
AB	MOVA	12.5MG	N74423 001	FEB 13, 1996
AB		25MG	N74423 002	FEB 13, 1996
AB		50MG	N74423 003	FEB 13, 1996
AB		100MG	N74423 004	FEB 13, 1996
AB	MYLAN	12.5MG	N74434 001	FEB 13, 1996
AB		25MG	N74434 002	FEB 13, 1996
AB		50MG	N74434 003	FEB 13, 1996
AB		100MG	N74434 004	FEB 13, 1996
AB	NOVOPHARM	12.5MG	N74322 001	FEB 13, 1996
AB		25MG	N74322 002	FEB 13, 1996
AB		50MG	N74322 003	FEB 13, 1996
AB		100MG	N74322 004	FEB 13, 1996
AB	PAR PHARM	12.5MG	N74493 001	FEB 13, 1996
AB		25MG	N74493 002	FEB 13, 1996
AB		50MG	N74493 003	FEB 13, 1996
AB		100MG	N74493 004	FEB 13, 1996
AB	ROYCE LABS	12.5MG	N74451 001	FEB 13, 1996
AB		25MG	N74451 002	FEB 13, 1996
AB		50MG	N74451 003	FEB 13, 1996
AB		100MG	N74451 004	FEB 13, 1996
AB	WEST WARD	12.5MG	N74505 001	FEB 13, 1996

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	WEST WARD	25MG	N74505 002	FEB 13, 1996
AB		50MG	N74505 003	FEB 13, 1996
AB		100MG	N74505 004	FEB 13, 1996

CARBAMAZEPINE

TABLET; ORAL
CARBAMAZEPINE

AB	TARO	200MG	N74649 001	OCT 03, 1996

TABLET, EXTENDED RELEASE; ORAL
TEGRETOL-XR

+	CIBA GEIGY	100MG	N20234 001	MAR 25, 1996
+		200MG	N20234 002	MAR 25, 1996
+		400MG	N20234 003	MAR 25, 1996

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

> ADD >	AA	ROYCE LABS	350MG	N40152 001	DEC 03, 1996
> ADD >	AA	WEST WARD	350MG	N40124 001	JAN 24, 1996

CARMUSTINE

IMPLANT; INTRACRANIAL
GLIADEL

+	GUILFORD PHARMS	7.7MG	N20637 001	SEP 23, 1996

CEFACLOR

CAPSULE; ORAL
CEFACLOR

AB	BIOCRAFT	EQ 250MG BASE	N64081 001	SEP 16, 1996
AB		EQ 500MG BASE	N64081 002	SEP 16, 1996
AB	MARSAM	EQ 250MG BASE	N64148 001	MAY 23, 1996
AB		EQ 500MG BASE	N64148 002	MAY 23, 1996
AB	NOVOPHARM	EQ 250MG BASE	N64145 001	JUN 24, 1996
AB		EQ 500MG BASE	N64145 002	JUN 24, 1996

TABLET, EXTENDED RELEASE; ORAL
CECLOR CD

+	LILLY	EQ 375MG BASE	N50673 001	JUN 28, 1996
+		EQ 500MG BASE	N50673 002	JUN 28, 1996

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

+	BAXTER	EQ 10MG BASE/ML	N50566 003	JUN 08, 1983
+		EQ 20MG BASE/ML	N50566 004	JUN 08, 1983
@	BAXTER HLTHCARE	EQ 10MG BASE/ML	N50566 003	JUN 08, 1983
@		EQ 20MG BASE/ML	N50566 004	JUN 08, 1983

CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)

INJECTABLE; INJECTION
MAXIPIME

+	BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N50679 001	JAN 18, 1996
+		EQ 1GM BASE/VIAL	N50679 002	JAN 18, 1996
+		EQ 2GM BASE/VIAL	N50679 003	JAN 18, 1996

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

	CEPTAZ			
*	GLAXO WELLCOME	500MG/VIAL	N50646 001 SEP 27, 1990	
@		500MG/VIAL	N50646 001 SEP 27, 1990	

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

	CEFTAZIDIME SODIUM IN PLASTIC CONTAINER			
AP	BAXTER	**EQ 10MG BASE/ML**	**N63221 001 APR 29, 1993**	
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N63221 001 APR 29, 1993	
	FORTAZ IN PLASTIC CONTAINER			
AP	* GLAXO WELLCOME	**EQ 10MG BASE/ML**	**N50634 001 APR 28, 1989**	
@		EQ 10MG BASE/ML	N50634 001 APR 28, 1989	

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

	CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER			
*	FUJISAWA	EQ 20MG BASE/ML	N50589 003 APR 13, 1995	
*		EQ 40MG BASE/ML	N50589 004 APR 13, 1995	
	CEFIZOX IN PLASTIC CONTAINER			
+	FUJISAWA	EQ 20MG BASE/ML	N50589 003 APR 13, 1995	
+		EQ 40MG BASE/ML	N50589 004 APR 13, 1995	

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

	ROCEPHIN			
	ROCHE	EQ 500MG BASE/VIAL	N62654 001 APR 30, 1987	
@		EQ 500MG BASE/VIAL	N62654 001 APR 30, 1987	

CEPHALEXIN

CAPSULE; ORAL

	CEFANEX			
AB	APOTHECON	**EQ 250MG BASE**	**N63063 001 SEP 29, 1989**	
AB		**EQ 500MG BASE**	**N63063 002 SEP 29, 1989**	
	CEPHALEXIN			
AB	APOTHECON	**EQ 250MG BASE**	**N63063 001 SEP 29, 1989**	
AB		**EQ 500MG BASE**	**N63063 002 SEP 29, 1989**	
AB	YOSHITOMI	**EQ 250MG BASE**	**N62872 001 JUN 20, 1988**	
AB		**EQ 500MG BASE**	**N62871 001 JUL 05, 1988**	
@		EQ 250MG BASE	N62872 001 JUN 20, 1988	
@		EQ 500MG BASE	N62871 001 JUL 05, 1988	

TABLET; ORAL

	CEPHALEXIN			
AB	BARR	**EQ 250MG BASE**	**N62826 001 AUG 17, 1987**	
AB		**EQ 500MG BASE**	**N62827 001 AUG 17, 1987**	
@		EQ 250MG BASE	N62826 001 AUG 17, 1987	
@		EQ 500MG BASE	N62827 001 AUG 17, 1987	

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

	KEFTAB			
*	LILLY	EQ 250MG BASE	N50614 001 OCT 29, 1987	
*		EQ 333MG BASE	N50614 003 MAY 16, 1988	
@		EQ 250MG BASE	N50614 001 OCT 29, 1987	
@		EQ 333MG BASE	N50614 003 MAY 16, 1988	

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

+	BAXTER	EQ 20MG BASE/ML	N62422 003 JAN 31, 1984
		EQ 20MG BASE/ML	N62422 005 JUL 16, 1991
		EQ 20MG BASE/ML	N62730 001 MAR 05, 1987
+		EQ 40MG BASE/ML	N62422 004 JAN 31, 1984
		EQ 40MG BASE/ML	N62422 006 JUL 16, 1991
		EQ 40MG BASE/ML	N62730 002 MAR 05, 1987
@	BAXTER HLTHCARE	EQ 20MG BASE/ML	N62422 003 JAN 31, 1984
@		EQ 20MG BASE/ML	N62422 005 JUL 16, 1991
@		EQ 20MG BASE/ML	N62730 001 MAR 05, 1987
@		EQ 40MG BASE/ML	N62422 004 JAN 31, 1984
@		EQ 40MG BASE/ML	N62422 006 JUL 16, 1991
@		EQ 40MG BASE/ML	N62730 002 MAR 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

+	BAXTER	EQ 20MG BASE/ML	N62422 001 JAN 31, 1984
+		EQ 40MG BASE/ML	N62422 002 JAN 31, 1984
@	BAXTER HLTHCARE	EQ 20MG BASE/ML	N62422 001 JAN 31, 1984
@		EQ 40MG BASE/ML	N62422 002 JAN 31, 1984

CEPHRADINE

CAPSULE; ORAL

CEPHRADINE

AB	BARR	250MG	N62850 001 APR 22, 1988
AB		500MG	N62851 001 APR 22, 1988
@		250MG	N62850 001 APR 22, 1988

CEPHRADINE

CAPSULE; ORAL

CEPHRADINE

@	BARR	500MG	N62851 001 APR 22, 1988

POWDER FOR RECONSTITUTION; ORAL

CEPHRADINE

AB	BARR	125MG/5ML	N62858 001 MAY 19, 1988
AB		250MG/5ML	N62859 001 MAY 19, 1988
@		125MG/5ML	N62858 001 MAY 19, 1988
@		250MG/5ML	N62859 001 MAY 19, 1988

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

ZYRTEC

+	PFIZER	5MG/5ML	N20346 001 SEP 27, 1996

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

AB	HALSEY	5MG	N85340 001
AB		10MG	N85339 001
AB		25MG	N84685 001
@		5MG	N85340 001
@		10MG	N85339 001
@		25MG	N84685 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT	HI TECH PHARMA	0.12%	N74356 001 MAY 07, 1996

CHLOROTRIANISENE

CAPSULE; ORAL
TACE

+	HOECHST MARION RSSL	25MG	N11444 001	
@		25MG	N11444 001	

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION
CHLOR-TRIMETON

AP	+ SCHERING PLOUGH	10MG/ML	N08826 001	
	@	10MG/ML	N08826 001	

CHLORPHENIRAMINE MALEATE

AP	STERIS	10MG/ML	N86096 001	
	+	10MG/ML	N86096 001	

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
TUSSIONEX

+	FISONS	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	N19111 001 DEC 31, 1987	
+	MEDEVA PHARMS	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	N19111 001 DEC 31, 1987	

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL
CHLORPROMAZINE HCL

BP	KV PHARM	10MG	N85750 002 JAN 04, 1982	> DLT >
BP		25MG	N85751 001	> DLT >
BP		50MG	N85484 001	> DLT >
BP		100MG	N85752 001	> ADD >
BP		200MG	N85748 002 JAN 04, 1982	
@		10MG	N85750 002 JAN 04, 1982	
@		25MG	N85751 001	
@		50MG	N85484 001	
@		100MG	N85752 001	
@		200MG	N85748 002 JAN 04, 1982	

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE

AB	BARR	100MG	N88812 001 OCT 19, 1984
AB		100MG	N89446 001 NOV 17, 1986
AB		250MG	N88813 001 OCT 19, 1984
AB		250MG	N89447 001 NOV 17, 1986
@		100MG	N88812 001 OCT 19, 1984
@		100MG	N89446 001 NOV 17, 1986
@		250MG	N88813 001 OCT 19, 1984
@		250MG	N89447 001 NOV 17, 1986
AB	HALSEY	100MG	N89321 001 JAN 16, 1986
AB		250MG	N88662 001 JAN 09, 1986
@		100MG	N89321 001 JAN 16, 1986
@		250MG	N88662 001 JAN 09, 1986
AB	SUPERPHARM	250MG	N88695 001 SEP 17, 1984
@		250MG	N88695 001 SEP 17, 1984

CHLORPROTHIXENE

INJECTABLE; INJECTION
TARACTAN

+	ROCHE	12.5MG/ML	N12487 001
@		12.5MG/ML	N12487 001

TABLET; ORAL
TARACTAN

	ROCHE	10MG	N12486 005
		25MG	N12486 004
		50MG	N12486 003
+		100MG	N12486 001
@		10MG	N12486 005
@		25MG	N12486 004

CHLORPROTHIXENE

TABLET; ORAL

	TARACTAN			
	@ ROCHE	50MG	N12486 003	
	@	100MG	N12486 001	

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE			
AB	EARR	25MG	N87292 001	
AB		50MG	N87293 001	
	@	25MG	N87292 001	
	@	50MG	N87293 001	
AB	SUPERPHARM	50MG	N87247 001	FEB 09, 1983
	@	50MG	N87247 001	FEB 09, 1983

CHLORZOXAZONE

TABLET; ORAL

	CHLORZOXAZONE			
AA	CHELSEA LABS	500MG	N40137 001	AUG 09, 1996

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	COPLEY PHARM	EQ 4GM RESIN/PACKET	N74554 001	OCT 02, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74554 002	OCT 02, 1996
AB	EON LABS MFG	EQ 4GM RESIN/PACKET	N74557 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74557 002	AUG 15, 1996
	CHOLESTYRAMINE LIGHT			
AB	EON LABS MFG	EQ 4GM RESIN/PACKET	N74558 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74558 002	AUG 15, 1996
	LOCHOLEST			
AB	EON LABS	EQ 4GM RESIN/PACKET	N74557 001	AUG 15, 1996

CHOLESTYRAMINE

POWDER; ORAL

	LOCHOLEST			
AB	EON LABS	EQ 4GM RESIN/SCOOPFUL	N74557 002	AUG 15, 1996
AB		EQ 4GM RESIN/PACKET	N74561 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74561 002	AUG 15, 1996
	@ EON LABS MFG	EQ 4GM RESIN/PACKET	N74561 001	AUG 15, 1996
	@	EQ 4GM RESIN/SCOOPFUL	N74561 002	AUG 15, 1996
	LOCHOLEST LIGHT			
AB	EON LABS	EQ 4GM RESIN/PACKET	N74558 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74558 002	AUG 15, 1996
AB		EQ 4GM RESIN/PACKET	N74562 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74562 002	AUG 15, 1996
	@ EON LABS MFG	EQ 4GM RESIN/PACKET	N74562 001	AUG 15, 1996
	@	EQ 4GM RESIN/SCOOPFUL	N74562 002	AUG 15, 1996
	PREVALITE			
AB	UPSHER SMITH	EQ 4GM RESIN/PACKET	N73263 001	FEB 22, 1996
	QUESTRAN			
AB	+ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N16640 001	
AB		EQ 4GM RESIN/SCOOPFUL	N16640 003	
	QUESTRAN LIGHT			
AB	+ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N19669 001	DEC 05, 1988
AB		EQ 4GM RESIN/PACKET	N19669 001	DEC 05, 1988
AB		EQ 4GM RESIN/SCOOPFUL	N19669 003	DEC 05, 1988

CHROMIC CHLORIDE

INJECTABLE; INJECTION

	CHROMIC CHLORIDE			
AP	FUJISAWA	EQ 0.004MG CHROMIUM/ML	N19271 001	MAY 05, 1987

CHROMIC CHLORIDE

INJECTABLE; INJECTION

	CHROMIC CHLORIDE			
	@ FUJISAWA	EQ 0.004MG CHROMIUM/ML	N19271 001	MAY 05, 1987
	CHROMIC CHLORIDE IN PLASTIC CONTAINER			
AP	+ ABBOTT	EQ 0.004MG CHROMIUM/ML	N18961 001	JUN 26, 1986
	+	EQ 0.004MG CHROMIUM/ML	N18961 001	JUN 26, 1986

CIDOFOVIR

INJECTABLE; INJECTION

	VISTIDE			
	+ GILEAD	EQ 75MG BASE/ML	N20638 001	JUN 26, 1996

CIMETIDINE

TABLET; ORAL

	CIMETIDINE			
AB	DANBURY PHARMA	200MG	N74349 001	AUG 30, 1996
AB		300MG	N74349 002	AUG 30, 1996
AB		400MG	N74349 003	AUG 30, 1996
AB		800MG	N74316 001	FEB 28, 1996
AB	INVAMED	200MG	N74506 001	JAN 24, 1996
AB		300MG	N74506 002	JAN 24, 1996
AB		400MG	N74506 003	JAN 24, 1996
AB		800MG	N74506 004	JAN 24, 1996
AB	ZENITH GOLDLINE	200MG	N74401 001	MAY 30, 1995
AB		300MG	N74401 002	MAY 30, 1995
AB		400MG	N74401 003	MAY 30, 1995
AB	ZENITH LABS	200MG	N74401 001	MAY 30, 1995

CIMETIDINE

TABLET; ORAL

	CIMETIDINE			
AB	ZENITH LABS	300MG	N74401 002	MAY 30, 1995
AB		400MG	N74401 003	MAY 30, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CIMETIDINE HCL			
AP	MOVA	EQ 300MG BASE/2ML	N74428 001	APR 25, 1996

SOLUTION; ORAL

	CIMETIDINE HCL			
AA	LEMMON	EQ 300MG BASE/5ML	N74610 001	SEP 26, 1996
	TAGAMET			
AA	SMITHKLINE BEECHAM	EQ 300MG BASE/5ML	N17924 001	
AA	+	EQ 300MG BASE/5ML	N17924 001	

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

	CIPRO			
	BAYER	EQ 100MG BASE	N19537 001	APR 08, 1996

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

	CLINDAMYCIN PHOSPHATE			
AT	STIEFEL	EQ 1% BASE	N64108 001	SEP 27, 1996

SWAB; TOPICAL

	CLEOCIN			
AT	PHARMACIA AND UPJOHN	EQ 1% BASE	N50537 002	FEB 22, 1994
	CLINDETS			
AT	STIEFEL	EQ 1% BASE	N64136 001	SEP 30, 1996

CLOBETASOL PROPIONATE

CREAM; TOPICAL

		CLOBETASOL PROPIONATE			
AB		FOUGERA	**0.05%**		**N74392 001**
					SEP 30, 1996
AB		TARO	**0.05%**		**N74249 001**
					JUL 08, 1996

OINTMENT; TOPICAL

		CLOBETASOL PROPIONATE			
AB		FOUGERA	**0.05%**		**N74407 001**
					FEB 23, 1996
AB		TARO	**0.05%**		**N74248 001**
					JUL 12, 1996

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

		CLODERM			
> ADD >	+	CTR LABS	0.1%		N17765 001
> DLT >	+	HERMAL PHARM	0.1%		N17765 001

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

		ANAFRANIL			
AB		CIBA GEIGY	**25MG**		**N19906 001**
					DEC 29, 1989
AB	+		**50MG**		**N19906 002**
					DEC 29, 1989
AB			**75MG**		**N19906 003**
					DEC 29, 1989
		CLOMIPRAMINE HCL			
AB		CIRCA	**25MG**		**N74600 001**
					NOV 27, 1996
AB			**50MG**		**N74600 002**
					NOV 27, 1996
AB			**75MG**		**N74600 003**
					NOV 27, 1996
AB		GENEVA PHARMS	**25MG**		**N74364 001**
					MAR 29, 1996
AB			**50MG**		**N74364 002**
					MAR 29, 1996
AB			**75MG**		**N74364 003**
					MAR 29, 1996

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

		CLOMIPRAMINE HCL			
> ADD >	**AB**	TARO	**25MG**		**N74694 001**
> ADD					DEC 31, 1996
> ADD >	**AB**		**50MG**		**N74694 002**
> ADD >					DEC 31, 1996
> ADD >	**AB**		**75MG**		**N74694 003**
> ADD >					DEC 31, 1996

CLONAZEPAM

TABLET; ORAL

		CLONAZEPAM			
AB		LEMMON	**0.5MG**		**N74569 001**
					SEP 10, 1996
AB			**1MG**		**N74569 002**
					SEP 10, 1996
AB			**2MG**		**N74569 003**
					SEP 10, 1996
AB		PUREPAC PHARM	**0.5MG**		**N74869 001**
					OCT 31, 1996
AB			**1MG**		**N74869 002**
					OCT 31, 1996
AB			**2MG**		**N74869 003**
					OCT 31, 1996
		KLONOPIN			
AB		ROCHE	**0.5MG**		**N17533 001**
AB			**1MG**		**N17533 002**
AB	+		**2MG**		**N17533 003**

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

		DURACLON			
	+	FUJISAWA	0.1MG/ML		N20615 001
					OCT 02, 1996

TABLET; ORAL

		CLONIDINE HCL			
AB		BARR	**0.2MG**		**N70924 001**
					SEP 04, 1987
AB			**0.3MG**		**N70923 001**
					SEP 04, 1987
	@		0.2MG		N70924 001
					SEP 04, 1987

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

	CLONIDINE HCL			
	@ BARR	0.3MG	N70923 001	
			SEP 04, 1987	
AB	WARNER CHILCOTT	**0.1MG**	**N72138 001**	
			JUN 13, 1988	
AB		**0.2MG**	**N72139 001**	
			JUN 13, 1988	
AB		**0.3MG**	**N72140 001**	
			JUN 13, 1988	
	@	0.1MG	N72138 001	
			JUN 13, 1988	
	@	0.2MG	N72139 001	
			JUN 13, 1988	
	@	0.3MG	N72140 001	
			JUN 13, 1988	

CLOTRIMAZOLE

SOLUTION; TOPICAL

	CLOTRIMAZOLE			
AT	LEMMON	**1%**	**N73306 001**	
			FEB 28, 1995	
AT	TARO	**1%**	**N74580 001**	
			JUL 29, 1996	
AT	TEVA	**1%**	**N73306 001**	
			FEB 28, 1995	

CLOZAPINE

TABLET; ORAL

	CLOZAPINE			
AB	CREIGHTON	**25MG**	**N74546 001**	
			AUG 30, 1996	
AB		**100MG**	**N74546 002**	
			AUG 30, 1996	
	CLOZARIL			
AB	+ SANDOZ	**25MG**	**N19758 001**	
			SEP 26, 1989	
AB		**100MG**	**N19758 002**	
			SEP 26, 1989	

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHERAZINE VC W/ CODEINE			
AA	HALSEY	**10MG/5ML;5MG/5ML; 6.25MG/5ML**	**N88870 001**	
			MAR 02, 1987	
	@	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88870 001	
			MAR 02, 1987	
	PROMETHAZINE VC W/ CODEINE			
AA	CENCI	**10MG/5ML;5MG/5ML; 6.25MG/5ML**	**N88816 001**	
			NOV 22, 1985	
	@	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88816 001	
			NOV 22, 1985	

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PROMETHAZINE W/ CODEINE			
AA	CENCI	**10MG/5ML;6.25MG/5ML**	**N88814 001**	
			NOV 22, 1985	
	@	10MG/5ML;6.25MG/5ML	N88814 001	
			NOV 22, 1985	

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

	TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE			
AA	CENCI	**10MG/5ML;30MG/5ML; 1.25MG/5ML**	**N89018 001**	
			JUL 23, 1986	
	@	10MG/5ML;30MG/5ML; 1.25MG/5ML	N89018 001	
			JUL 23, 1986	

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE; INJECTION

	ACTHREL		
+	FERRING LABS	EQ 0.1MG BASE/VIAL	N20162 001
			MAY 23, 1996

CROMOLYN SODIUM

CAPSULE; ORAL

GASTROCROM

	*	FISONS	100MG	N19188 001 DEC 22, 1989
	+	MEDEVA PHARMS	100MG	N19188 001 DEC 22, 1989

CONCENTRATE; ORAL

GASTROCROM

	*	FISONS	100MG/5ML	N20479 001 FEB 29, 1996
	+	MEDEVA PHARMS	100MG/5ML	N20479 001 FEB 29, 1996

SOLUTION/DROPS; OPHTHALMIC

CROLOM

AT		BAUSCH AND LOMB	4%	N74443 001 JAN 30, 1995
	+		4%	N74443 001 JAN 30, 1995

OPTICROM

AT	*	FISONS	4%	N18155 001 OCT 03, 1984
	@		4%	N18155 001 OCT 03, 1984

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

	+	NASTECH	0.5MG/INH	N19722 001 NOV 05, 1996

INJECTABLE; INJECTION

BETALIN 12

AP		LILLY	0.1MG/ML	N80855 001
AP			1MG/ML	N80855 002
	@		0.1MG/ML	N80855 001
	@		1MG/ML	N80855 002

CYANOCOBALAMIN

AP		DELL LABS	0.1MG/ML	N80689 002
AP			1MG/ML	N80689 003
			0.03MG/ML	N80689 001
	@		0.03MG/ML	N80689 001
	@		0.1MG/ML	N80689 002
	@		1MG/ML	N80689 003

CYCLOSPORINE

CAPSULE; ORAL

NEORAL

BP		SANDOZ	25MG	N50715 001 JUL 14, 1995
BP			50MG	N50715 003 JUL 14, 1995
BP	*		100MG	N50715 002 JUL 14, 1995

SANDIMMUNE

BP		SANDOZ	25MG	N50625 001 MAR 02, 1990
BP			50MG	N50625 003 NOV 23, 1992
BP	*		100MG	N50625 002 MAR 02, 1990
			25MG	N50625 001 MAR 02, 1990
			50MG	N50625 003 NOV 23, 1992
	+		100MG	N50625 002 MAR 02, 1990

CAPSULE, MICROEMULSION; ORAL

NEORAL

		SANDOZ	25MG	N50715 001 JUL 14, 1995
			50MG	N50715 003 JUL 14, 1995
	+		100MG	N50715 002 JUL 14, 1995

SOLUTION; ORAL

NEORAL

BP	*	SANDOZ	100MG/ML	N50716 001 JUL 14, 1995

SANDIMMUNE

BP	*	SANDOZ	100MG/ML	N50574 001 NOV 14, 1983
	+		100MG/ML	N50574 001 NOV 14, 1983

SOLUTION, MICROEMULSION; ORAL

NEORAL

	+	SANDOZ	100MG/ML	N50716 001 JUL 14, 1995

CYCLOTHIAZIDE

TABLET; ORAL
ANHYDRON
+ LILLY 2MG N13157 002
@ 2MG N13157 002

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
CYPROHEPTADINE HCL
AA HALSEY 2MG/5ML N89199 001 JUL 03, 1986
@ 2MG/5ML N89199 001 JUL 03, 1986

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN
+ PHARMACIA AND UPJOHN 5,000 IU/0.2ML N20287 003 MAR 18, 1996

> ADD > DANAPAROID SODIUM

> ADD > INJECTABLE; INJECTION
> ADD > ORGARAN
> ADD > + ORGANON 750 UNITS/0.6ML N20430 001 DEC 24, 1996
> ADD >

DANAZOL

CAPSULE; ORAL
DANAZOL
AB BARR 200MG N74582 001 AUG 09, 1996

DANOCRINE
AB + SANOFI WINTHROP 200MG N17557 002

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME
+ NEXSTAR EQ 2MG BASE/ML N50704 002 APR 08, 1996

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL
AB EON LABS MFG 10MG N74430 001 FEB 09, 1996
AB 150MG N74430 002 FEB 09, 1996

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
STIMATE
+ ARMOUR PHARM 0.15MG/INH N20355 001 MAR 07, 1994
+ CENTEON 0.15MG/INH N20355 001 MAR 07, 1994

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
ORTHO-CEPT
JOHNSON RW 0.15MG;0.03MG N20301 001 DEC 14, 1992
+ 0.15MG;0.03MG N20301 001 DEC 14, 1992

DESOXIMETASONE

OINTMENT; TOPICAL
DESOXIMETASONE
AB TARO 0.25% N74286 001 JUN 07, 1996

TOPICORT
AB + HOECHST MARION RSSL 0.25% N18763 001 SEP 30, 1983

DEXAMETHASONE

CONCENTRATE; ORAL
DEXAMETHASONE INTENSOL
+ ROXANE 1MG/ML N88252 001 SEP 01, 1983

DEXAMETHASONE

SOLUTION; ORAL
DEXAMETHASONE INTENSOL

	ROXANE	0.5MG/0.5ML	N88252 001	SEP 01, 1993

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
DEXACIDIN

AT	CIBA	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62566 001	FEB 22, 1985
AT	IOLAB	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62566 001	FEB 22, 1985

SUSPENSION/DROPS; OPHTHALMIC
DEXACIDIN

AT	CIBA	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62544 001	OCT 29, 1984
AT	IOLAB	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62544 001	OCT 29, 1984

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

AT	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	N40069 001	JUL 26, 1996

DEXFENFLURAMINE HYDROCHLORIDE

CAPSULE; ORAL
REDUX

+	INTERNEURON	15MG	N20344 001	APR 29, 1996

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE

AA	HALSEY	10MG	N83930 001	

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE

@	HALSEY	10MG	N83930 001	
AA	MM MAST	5MG	N86521 001	
@		5MG	N86521 001	
AA	+ REXAR	10MG	N84051 002	
+		10MG	N84051 002	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PHERAZINE DM

AA	HALSEY	15MG/5ML;6.25MG/5ML	N88913 001	MAR 02, 1987
@		15MG/5ML;6.25MG/5ML	N88913 001	MAR 02, 1987

PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE

AA	HI TECH PHARMA	15MG/5ML;6.25MG/5ML	N40027 001	JUL 31, 1996

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 60% IN PLASTIC CONTAINER

AP	BAXTER	60GM/100ML	N20047 002	JUL 02, 1991
@	BAXTER HLTHCARE	60GM/100ML	N20047 002	JUL 02, 1991

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

MCGAW	10GM/100ML;200MG/100ML	N18386 001	
@	10GM/100ML;200MG/100ML	N18386 001	

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

MCGAW	10GM/100ML;450MG/100ML	N18229 001	
@	10GM/100ML;450MG/100ML	N18229 001	

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MCGAW	2.5GM/100ML;900MG/100ML	N18376 001	
@	2.5GM/100ML;900MG/100ML	N18376 001	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

	MD-76			
AP	MALLINCKRODT	66%;10%	N19292 001	SEP 29, 1989
	MD-76R			
AP	+ MALLINCKRODT MEDCL	66%;10%	N19292 001	SEP 29, 1989

DIATRIZOATE SODIUM

SOLUTION; URETERAL

	HYPAQUE SODIUM 20%			
AT	NYCOMED	20%	N09561 002	
		20%	N09561 002	

DIAZEPAM

TABLET; ORAL

	DIAZEPAM			
AB	ZENITH GOLDLINE	2MG	N71307 001	DEC 10, 1986
AB		5MG	N71321 001	DEC 10, 1986
AB		10MG	N70362 001	SEP 04, 1985
AB		10MG	N71322 001	DEC 10, 1986
AB	ZENITH LABS	2MG	N71307 001	DEC 10, 1986
AB		5MG	N71321 001	DEC 10, 1986
AB		10MG	N70362 001	SEP 04, 1985
AB		10MG	N71322 001	DEC 10, 1986

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM			
AB	NOVOPHARM	75MG	N74390 001	AUG 15, 1996
AB	PUREPAC PHARM	50MG	N74514 001	MAR 26, 1996

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM			
AB	PUREPAC PHARM	75MG	N74514 002	MAR 26, 1996

TABLET, EXTENDED RELEASE; ORAL

	VOLTAREN-XR			
	+ GEIGY	100MG	N20254 001	MAR 08, 1996

DICLOXACILLIN SODIUM

CAPSULE; ORAL

	DICLOXACILLIN SODIUM			
AB	APOTHECON	EQ 250MG BASE	N61454 001	
AB	+	EQ 250MG BASE	N61454 001	
AB		EQ 500MG BASE	N61454 003	
AB	+	EQ 500MG BASE	N61454 003	
	PATHOCIL			
AB	+ WYETH AYERST	EQ 250MG BASE	N50011 002	
AB		EQ 250MG BASE	N50011 002	
AB	+	EQ 500MG BASE	N50011 003	MAR 28, 1983
AB		EQ 500MG BASE	N50011 003	MAR 28, 1983

POWDER FOR RECONSTITUTION; ORAL

	DICLOXACILLIN SODIUM			
AB	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001	
AB	+	EQ 62.5MG BASE/5ML	N61455 001	
	PATHOCIL			
AB	+ WYETH AYERST	EQ 62.5MG BASE/5ML	N50092 001	
AB		EQ 62.5MG BASE/5ML	N50092 001	

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

	DICYCLOMINE HCL			
AB	LANNETT	10MG	N84285 001	

INJECTABLE; INJECTION

	BENTYL PRESERVATIVE FREE			
AP	HOECHST MARION RSSL	10MG/ML	N08370 002	OCT 15, 1984

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL
DICYCLOMINE HCL

AB	WEST WARD	20MG	N40161 001	OCT 01, 1996

DIETHYLCARBAMAZINE CITRATE

> DLT >	TABLET; ORAL			
> DLT >	HETRAZAN			
> DLT >	LEDERLE	50MG	N06459 001	
> ADD >	@	50MG	N06459 001	

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL

AB	GENEVA PHARMS	500MG	N74604 001	JUN 10, 1996
AB	PUREPAC PHARM	250MG	N74285 001	MAY 07, 1996
AB		500MG	N74285 002	MAY 07, 1996

DIGOXIN

INJECTABLE; INJECTION
DIGOXIN

AP	SANOFI WINTHROP	0.25MG/ML	N40093 001	MAY 16, 1996

DIGOXIN PEDIATRIC

AP	SANOFI WINTHROP	0.1MG/ML	N40092 001	APR 25, 1996

LANOXIN

+	GLAXO WELLCOME	0.1MG/ML	N09330 004	

LANOXIN PEDIATRIC

AP	+ GLAXO WELLCOME	0.1MG/ML	N09330 004	

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION
CARDIZEM

AP	+ HOECHST MARION RSSL	5MG/ML	N20027 001	OCT 24, 1991

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION
DILTIAZEM HCL

AP	BEDFORD	5MG/ML	N74617 001	FEB 28, 1996

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL
TIAMATE

+	MERCK	EQ 120MG HCL	N20506 001	OCT 04, 1996
+		EQ 180MG HCL	N20506 002	OCT 04, 1996
+		EQ 240MG HCL	N20506 003	OCT 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL
TECZEM

+	MERCK	EQ 180MG HCL;5MG	N20507 001	OCT 04, 1996

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA	HALSEY	50MG	N87914 001	JUN 04, 1984
	@	50MG	N87914 001	JUN 04, 1984

ELIXIR; ORAL
BELIX

AA	HALSEY	12.5MG/5ML	N86586 001	OCT 03, 1983
	@	12.5MG/5ML	N86586 001	OCT 03, 1983

DIBENIL

AA	CENCI	12.5MG/5ML	N88304 001	DEC 16, 1983
	@	12.5MG/5ML	N88304 001	DEC 16, 1983

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL
DIPHENHYDRAMINE HCL

AA	**CENCI**	**12.5MG/5ML**	**N87941 001 DEC 17, 1982**
@		12.5MG/5ML	N87941 001 DEC 17, 1982

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE

AP	ELKINS SINN	**5MG/ML**	**N74521 001 OCT 18, 1996**

IV PERSANTINE

AP	+ BOEHRINGER INGELHEIM	**5MG/ML**	**N19817 001 DEC 13, 1990**

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE

AB	**BARR**	**EQ 100MG BASE**	**N70351 001 DEC 17, 1985**
AB		**EQ 150MG BASE**	**N70352 001 DEC 17, 1985**
@		EQ 100MG BASE	N70351 001 DEC 17, 1985
@		EQ 150MG BASE	N70352 001 DEC 17, 1985

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE

B*	**KV PHARM**	**EQ 100MG BASE**	**N71929 001 AUG 19, 1988**
@		EQ 100MG BASE	N71929 001 AUG 19, 1988

NORPACE CR

AB	**SEARLE**	**EQ 100MG BASE**	**N18655 001 JUL 20, 1982**
		EQ 100MG BASE	N18655 001 JUL 20, 1982

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL

AP	ABBOTT	**EQ 1.25GM BASE/100ML**	**N74634 001 SEP 27, 1996**
AP	ELKINS SINN	**EQ 12.5MG BASE/ML**	**N74381 001 SEP 26, 1996**

DOCETAXEL

INJECTABLE; INJECTION
TAXOTERE

+	RHONE POULENC	EQ 40MG BASE/ML	N20449 001 MAY 14, 1996

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
ARICEPT

	EISAI	5MG	N20690 002 NOV 25, 1996
+		10MG	N20690 001 NOV 25, 1996

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

AP	SANOFI WINTHROP	**40MG/ML**	**N74403 001 MAY 23, 1996**

DOXYCYCLINE HYCLATE

TABLET; ORAL
DOXYCYCLINE HYCLATE

AB	**SUPERPHARM**	**EQ 100MG BASE**	**N62494 001 FEB 20, 1985**
@		EQ 100MG BASE	N62494 001 FEB 20, 1985

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

AP		ABBOTT	2.5MG/ML; EQ 0.05MG BASE/ML	N71982 001 MAY 04, 1988
AP	+		2.5MG/ML; EQ 0.05MG BASE/ML	N71982 001 MAY 04, 1988
		INNOVAR		
AP	+	JANSSEN	2.5MG/ML; EQ 0.05MG BASE/ML	N16049 001
	@		2.5MG/ML; EQ 0.05MG BASE/ML	N16049 001

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

AP		STERIS	10MG/ML	N40044 001 MAR 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

AP		STERIS	10MG/ML	N40043 001 MAR 20, 1996

TENSILON PRESERVATIVE FREE

AP	+	ROCHE	10MG/ML	N07959 002

> ADD > ENALAPRIL MALEATE; FELODIPINE

> ADD > TABLET, EXTENDED RELEASE; ORAL

> ADD > LEXXEL

> ADD > + ASTRA MERCK 5MG;5MG N20668 001 DEC 27, 1996

> ADD >

ENCAINIDE HYDROCHLORIDE

CAPSULE; ORAL

ENKAID

@		BRISTOL	25MG	N18981 002 DEC 24, 1986
@			35MG	N18981 003 DEC 24, 1986
		BRISTOL MYERS SQUIBB	25MG	N18981 002 DEC 24, 1986

ENCAINIDE HYDROCHLORIDE

CAPSULE; ORAL

ENKAID

		BRISTOL MYERS SQUIBB	35MG	N18981 003 DEC 24, 1986

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL W/ EPINEPHRINE

AP		ABBOTT	0.01MG/ML;1%	N83154 001
	@		0.01MG/ML;1%	N83154 001

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

AB		BARR	1MG	N88891 001 NOV 01, 1985
	@		1MG	N88891 001 NOV 01, 1985

TABLET; SUBLINGUAL

ERGOLOID MESYLATES

AA		BARR	0.5MG	N87407 001
AA			1MG	N87552 001
	@		0.5MG	N87407 001
	@		1MG	N87552 001
> DLT > AA		KV PHARM	0.5MG	N85899 001
> DLT > AA			1MG	N85900 001
> ADD >	@		0.5MG	N85899 001
> ADD >	@		1MG	N85900 001

ERYTHROMYCIN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT		ADV REMEDIES	0.5%	N64030 001 JUL 18, 1996

OINTMENT; TOPICAL

AKNE-MYCIN

> ADD >	+	CTR LABS	2%	N50584 001

> ADD > JAN 10, 1985

ERYTHROMYCIN

OINTMENT; TOPICAL
AKNE-MYCIN
> DLT > + HERMAL PHARM 2% N50584 001
> DLT > JAN 10, 1985

SOLUTION; TOPICAL
ERYTHRO-STATIN
AT HI TECH PHARMA 2% N64101 001
OCT 22, 1996

SWAB; TOPICAL
ERYCETTE
AT + J AND J 2% N50594 001
FEB 15, 1985
AT + JOHNSON RW 2% N50594 001
FEB 15, 1985
ERYTHROMYCIN
AT STIEFEL 2% N64126 001
JUL 03, 1996
AT 2% N64128 001
JUL 03, 1996

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL
ERYTHROMYCIN ESTOLATE
AB BARR EQ 125MG BASE N62162 001
@ EQ 125MG BASE N62162 001
ILOSONE
> DLT > AB + DISTA EQ 250MG BASE N61897 002
> DLT > EQ 125MG BASE N61897 001
> ADD > AB + LILLY EQ 250MG BASE N61897 002
> ADD > EQ 125MG BASE N61897 001

SUSPENSION; ORAL
ERYTHROMYCIN ESTOLATE
AB BARR EQ 125MG BASE/5ML N62169 001
OCT 17, 1990
AB EQ 250MG BASE/5ML N62169 002
OCT 17, 1990
@ EQ 125MG BASE/5ML N62169 001
OCT 17, 1990
@ EQ 250MG BASE/5ML N62169 002
OCT 17, 1990
ILOSONE
> DLT > @ DISTA EQ 125MG BASE/5ML N61894 001

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL
ILOSONE
> DLT > @ DISTA EQ 250MG BASE/5ML N61894 002
AB LILLY EQ 125MG BASE/5ML N50010 001
AB + EQ 250MG BASE/5ML N50010 002
> ADD > @ EQ 125MG BASE/5ML N61894 001
> ADD > @ EQ 250MG BASE/5ML N61894 002

SUSPENSION/DROPS; ORAL
ILOSONE
> DLT > + DISTA EQ 100MG BASE/ML N61894 003
> ADD > + LILLY EQ 100MG BASE/ML N61894 003

TABLET; ORAL
ILOSONE
> DLT > + DISTA EQ 500MG BASE N61896 001
> ADD > + LILLY EQ 500MG BASE N61896 001

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROCIN
AP ABBOTT EQ 500MG BASE/VIAL N62586 001
JAN 04, 1988
AP EQ 1GM BASE/VIAL N62586 002
JAN 04, 1988
@ EQ 500MG BASE/VIAL N62586 001
JAN 04, 1988
@ EQ 1GM BASE/VIAL N62586 002
JAN 04, 1988

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
> ADD > ALORA
> ADD > BX THERATECH 0.05MG/24HR N20655 001
> ADD > DEC 20, 1996
> ADD > BX 0.075MG/24HR N20655 002
> ADD > DEC 20, 1996
> ADD > BX 0.1MG/24HR N20655 003
> ADD > DEC 20, 1996
ESTRADIOL
AB MENOREST 0.0375MG/24HR N20538 001
JUL 31, 1996

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	ESTRADIOL			
AB	MENOREST	**0.05MG/24HR**	**N20538 003**	
			JUL 31, 1996	
AB		**0.075MG/24HR**	**N20538 002**	
			JUL 31, 1996	
AB		**0.1MG/24HR**	**N20538 004**	
			JUL 31, 1996	
> ADD >	FEMPATCH			
> ADD >	+ PARKE DAVIS	0.025MG/24HR	N20417 001	
> ADD >			DEC 03, 1996	
	VIVELLE			
AB	+ CIBA GEIGY	**0.0375MG/24HR**	**N20323 001**	
			OCT 28, 1994	
AB	+	**0.05MG/24HR**	**N20323 002**	
			OCT 28, 1994	
AB	+	**0.075MG/24HR**	**N20323 003**	
			OCT 28, 1994	
AB	+	**0.1MG/24HR**	**N20323 004**	
			OCT 28, 1994	

INSERT, EXTENDED RELEASE; VAGINAL

	ESTRING		
	+ PHARMACIA AND UPJOHN	0.0075MG/24HR	N20472 001
			APR 26, 1996

TABLET; ORAL

	ESTRACE			
AB	BRISTOL MYERS SQUIBB	**0.5MG**	**N81295 001**	
			JUN 30, 1993	
AB		**1MG**	**N84499 001**	
AB	+	**2MG**	**N84500 001**	
	ESTRADIOL			
AB	WATSON LABS	**0.5MG**	**N40114 003**	
			MAR 14, 1996	
AB		**1MG**	**N40114 001**	
			MAR 14, 1996	
AB		**2MG**	**N40114 002**	
			MAR 14, 1996	

ESTRONE

INJECTABLE; INJECTION

	ESTROGENIC SUBSTANCE		
BP	+ WYETH AYERST	2MG/ML	N83488 001
	@	2MG/ML	N83488 001

ESTRONE

INJECTABLE; INJECTION

	NATURAL ESTROGENIC SUBSTANCE-ESTRONE		
BP	STERIS	2MG/ML	N85237 001
			NOV 23, 1982
	+	2MG/ML	N85237 001
			NOV 23, 1982

ESTROPIPATE

TABLET; ORAL

	ESTROPIPATE			
AB	BARR	**0.75MG**	**N40135 001**	
			NOV 27, 1996	
AB		**1.5MG**	**N40135 002**	
			NOV 27, 1996	
AB		**3MG**	**N40135 003**	
			NOV 27, 1996	

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

	ETHAMOLIN		
	+ CYPROS	50MG/ML	N19357 001
			DEC 22, 1988
	+ SPKU	50MG/ML	N19357 001
			DEC 22, 1988

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

	ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/35-21		
AB	WATSON LABS	**0.035MG;1MG**	**N72720 001**
			DEC 30, 1991
	ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/50-21		
AB	WATSON LABS	**0.05MG;1MG**	**N72722 001**
			DEC 30, 1991
	ZOVIA 1/35E-21		
AB	WATSON LABS	**0.035MG;1MG**	**N72720 001**
			DEC 30, 1991
	ZOVIA 1/50E-21		
AB	WATSON LABS	**0.05MG;1MG**	**N72722 001**
			DEC 30, 1991

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/35-28

AB	WATSON LABS	0.035MG;1MG	N72721 001	DEC 30, 1991

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/50-28

AB	WATSON LABS	0.05MG;1MG	N72723 001	DEC 30, 1991

ZOVIA 1/35E-28

AB	WATSON LABS	0.035MG;1MG	N72721 001	DEC 30, 1991

ZOVIA 1/50E-28

AB	WATSON LABS	0.05MG;1MG	N72723 001	DEC 30, 1991

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET; ORAL-28

LOESTRIN FE 1.5/30

+	PARKE DAVIS	0.03MG;75MG;1.5MG	N17355 001	

LOESTRIN FE 1/20

+	PARKE DAVIS	0.02MG;75MG;1MG	N17354 001	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

AB	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71041 001	SEP 24, 1991
AB	+	0.035MG,0.035MG;0.5MG,1MG	N71041 001	SEP 24, 1991

ORTHO-NOVUM 7/14-21

AB	+ JOHNSON RW	0.035MG,0.035MG;0.5MG,1MG	N19004 001	APR 04, 1984
	@	0.035MG,0.035MG;0.5MG,1MG	N19004 001	APR 04, 1984

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

ESTROSTEP 21

+	PARKE DAVIS	0.02MG,0.03MG,0.035MG;1MG,1MG, 1MG	N20130 001	OCT 09, 1996

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

ESTROSTEP FE

+	PARKE DAVIS	0.02MG,0.03MG,0.035MG;1MG,1MG, 1MG	N20130 002	OCT 09, 1996

LOESTRIN FE 1.5/30

+	PARKE DAVIS	0.03MG;1.5MG	N17355 001	

LOESTRIN FE 1/20

+	PARKE DAVIS	0.02MG;1MG	N17354 001	

ETODOLAC

TABLET; ORAL

LODINE

+	WYETH AYERST	400MG	N18922 004	JUL 29, 1993
		400MG	N18922 004	JUL 29, 1993
+		500MG	N18922 005	JUN 28, 1996

TABLET, EXTENDED RELEASE; ORAL

LODINE XL

+	WYETH AYERST	400MG	N20584 001	OCT 25, 1996
+		600MG	N20584 002	OCT 25, 1996

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

AP	+ ABBOTT	2MG/ML	N18227 001	SEP 07, 1982

ETOMIDATE

AP	BEDFORD	2MG/ML	N74593 001	NOV 04, 1996

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

AP	GENSIA	20MG/ML	N74529 001	JUL 24, 1996

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

AP	IMMUNEX	20MG/ML	N74513 001 MAR 14, 1996
AP	LEDERLE	20MG/ML	N74513 001 MAR 14, 1996
AP	PHARMACHEMIE (NL)	20MG/ML	N74227 001 FEB 22, 1996
AP	STERIS	20MG/ML	N74228 001 OCT 15, 1996

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION
ETOPOPHOS

+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996

EVANS BLUE

INJECTABLE; INJECTION
EVANS BLUE

@	PARKE DAVIS	0.5%	N08041 001

FAMCICLOVIR

TABLET; ORAL
FAMVIR

	SMITHKLINE BEECHAM	250MG	N20363 001 APR 26, 1996

FAMOTIDINE

INJECTABLE; INJECTION
PEPCID IV PRESERVATIVE FREE

+	MERCK	10MG/ML	N19510 004 NOV 04, 1986

PEPCID PRESERVATIVE FREE

+	MERCK	10MG/ML	N19510 004 NOV 04, 1986

FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE

AP	STERIS	EQ 0.05MG BASE/ML	N73488 001 JUN 30, 1992
@		EQ 0.05MG BASE/ML	N73488 001 JUN 30, 1992

FERUMOXIDES

INJECTABLE; INJECTION
FERIDEX I.V.

+	ADV MAGNETICS	EQ 11.2MG IRON/ML	N20416 001 AUG 30, 1996

FERUMOXSIL

SUSPENSION; ORAL
GASTROMARK

+	ADV MAGNETICS	EQ 0.175MG IRON/ML	N20410 001 DEC 06, 1996

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL
ALLEGRA

+	HOECHST MARION RSSL	60MG	N20625 001 JUL 25, 1996

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR

	3M	50MG	N18830 004 AUG 23, 1988
		100MG	N18830 001 OCT 31, 1985
+		150MG	N18830 003 JUN 03, 1988
@		50MG	N18830 004 AUG 23, 1988
@		100MG	N18830 001 OCT 31, 1985

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR

@ 3M	150MG	N18830 003	
		JUN 03, 1988	
@	200MG	N18830 002	
		OCT 31, 1985	

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT	+ HAMILTON PHARMA CA	0.01%	N12787 004	
AT	+	0.025%	N12787 002	
AT	+	0.025%	N12787 005	
	+	0.2%	N16161 002	
	SYNALAR			
AT	+ SYNTEX	0.01%	N12787 004	
AT	+	0.025%	N12787 002	
AT	+	0.025%	N12787 005	
	SYNALAR-HP			
	+ SYNTEX	0.2%	N16161 002	

OINTMENT; TOPICAL

	FLUOCINOLONE ACETONIDE		
AT	+ HAMILTON PHARMA CA	0.025%	N13960 001
	SYNALAR		
AT	+ SYNTEX	0.025%	N13960 001

SOLUTION; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT	+ HAMILTON PHARMA CA	0.01%	N15296 001	
	SYNALAR			
AT	+ SYNTEX	0.01%	N15296 001	

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL
NEO-SYNALAR

> DLT >	+ HAMILTON PHARMA CA	0.025%;EQ 3.5MG BASE/GM	N60700 001	
> ADD >	+ SYNTEX	0.025%;EQ 3.5MG BASE/GM	N60700 001	

FLUOCINONIDE

CREAM; TOPICAL

	FLUOCINONIDE			
AB	+ HAMILTON PHARMA CA	0.05%	N16908 002	
AB	TARO	0.05%	N72494 001	
			JAN 19, 1989	
AB	TICAN	0.05%	N72494 001	
			JAN 19, 1989	
	FLUOCINONIDE EMOLLIENT BASE			
AB	HAMILTON PHARMA CA	0.05%	N16908 003	
	LIDEX			
AB	+ SYNTEX	0.05%	N16908 002	
	LIDEX-E			
AB	SYNTEX	0.05%	N16908 003	

GEL; TOPICAL

	FLUOCINONIDE		
AB	+ HAMILTON PHARMA CA	0.05%	N17373 001
	LIDEX		
AB	+ SYNTEX	0.05%	N17373 001

OINTMENT; TOPICAL

	FLUOCINONIDE		
AB	+ HAMILTON PHARMA CA	0.05%	N16909 002
	LIDEX		
AB	+ SYNTEX	0.05%	N16909 002

SOLUTION; TOPICAL

	FLUOCINONIDE			
AT	+ HAMILTON PHARMA CA	0.05%	N18849 001	
			APR 06, 1984	
> ADD > AT	TARO	0.05%	N74799 001	
> ADD >			DEC 31, 1996	
	LIDEX			
AT	+ SYNTEX	0.05%	N18849 001	
			APR 06, 1984	

FLUOROURACIL

INJECTABLE; INJECTION

	ADRUCIL			
AP	+ PHARMACIA	50MG/ML	N40023 001	
			OCT 18, 1991	
AP	PHARMACIA AND UPJOHN	50MG/ML	N40023 001	
			OCT 18, 1991	
	FLUOROURACIL			
AP	ROCHE	50MG/ML	N12209 001	

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

AP	+ ROCHE	50MG/ML	N12209 001	

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
FLUPHENAZINE DECANOATE

AO	BEDFORD	25MG/ML	N74531 001 AUG 30, 1996	
AO	GENSIA	25MG/ML	N74795 001 SEP 10, 1996	

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
FLUPHENAZINE HCL

AA	PHARM ASSOC	5MG/ML	N74725 001 SEP 16, 1996	

ELIXIR; ORAL
FLUPHENAZINE HCL

AA	PHARM ASSOC	2.5MG/5ML	N40146 001 AUG 21, 1996	

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL

AB	BARR	15MG	N70454 001 AUG 04, 1986	
AB		30MG	N70455 001 AUG 04, 1986	> ADD >
	@	15MG	N70454 001 AUG 04, 1986	> ADD > > ADD >
	@	30MG	N70455 001 AUG 04, 1986	> ADD > > ADD >
AB	SUPERPHARM	15MG	N71659 001 AUG 04, 1988	
AB		30MG	N71660 001 AUG 04, 1988	
	@	15MG	N71659 001 AUG 04, 1988	

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL

	@ SUPERPHARM	30MG	N71660 001 AUG 04, 1988
AB	WARNER CHILCOTT	15MG	N71767 001 DEC 04, 1987
AB		30MG	N71768 001 DEC 04, 1987
	@	15MG	N71767 001 DEC 04, 1987
	@	30MG	N71768 001 DEC 04, 1987

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION
FLOVENT

	GLAXO WELLCOME	0.044MG/INH	N20548 001 MAR 27, 1996
		0.11MG/INH	N20548 002 MAR 27, 1996
	+	0.22MG/INH	N20548 003 MAR 27, 1996

FOLIC ACID

TABLET; ORAL
FOLIC ACID

AA	HALSEY	1MG	N83598 001
	@	1MG	N83598 001

FOSFOMYCIN TROMETHAMINE

GRANULE, FOR RECONSTITUTION; ORAL
MONUROL

	+ ZAMBON	EQ 3GM BASE/PACKET	N50717 001 DEC 19, 1996

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
CEREBYX

	+ PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N20450 001 AUG 05, 1996

FUROSEMIDE

TABLET; ORAL

	FUROSEMIDE		
AB	BARR	20MG	N70043 001 SEP 26, 1985
AB		40MG	N18790 001 NOV 29, 1983
AB		80MG	N70100 001 JAN 26, 1988
@		20MG	N70043 001 SEP 26, 1985
@		40MG	N18790 001 NOV 29, 1983
@		80MG	N70100 001 JAN 26, 1988
AB	SUPERPHARM	20MG	N18370 002 JUN 26, 1984
AB		40MG	N18370 001 FEB 10, 1983
@		20MG	N18370 002 JUN 26, 1984
@		40MG	N18370 001 FEB 10, 1983
AB	ZENITH GOLDLINE	20MG	N18413 001 NOV 30, 1983
AB		40MG	N18413 002 NOV 30, 1983
AB	ZENITH LABS	20MG	N18413 001 NOV 30, 1983
AB		40MG	N18413 002 NOV 30, 1983

GANCICLOVIR

IMPLANT; IMPLANTATION

	VITRASERT		
+	CHIRON VISION	4.5-6.4MG	N20569 001 MAR 04, 1996
+		4.5MG	N20569 001 MAR 04, 1996

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

	CYTOVENE IV		
+	ROCHE	EQ 500MG BASE/VIAL	N19661 001 JUN 23, 1989

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

	CYTOVENE IV		
+	SYNTEX	EQ 500MG BASE/VIAL	N19661 001 JUN 23, 1989

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

	GEMZAR		
+	LILLY	EQ 200MG BASE/VIAL	N20509 001 MAY 15, 1996
+		EQ 1GM BASE/VIAL	N20509 002 MAY 15, 1996

GENTAMICIN SULFATE

INJECTABLE; INJECTION

	GENTAMICIN SULFATE		
AP	ABBOTT	EQ 60MG BASE/100ML	N62413 006 AUG 11, 1983
AP		EQ 70MG BASE/100ML	N62413 007 AUG 11, 1983
AP		EQ 80MG BASE/100ML	N62413 008 AUG 11, 1983
AP		EQ 90MG BASE/100ML	N62413 009 AUG 11, 1983
AP		EQ 100MG BASE/100ML	N62413 010 AUG 11, 1983
AP		EQ 1.2MG BASE/ML	N62413 001 AUG 11, 1983
AP		EQ 1.4MG BASE/ML	N62413 002 AUG 11, 1983
AP		EQ 1.6MG BASE/ML	N62413 003 AUG 11, 1983
AP		EQ 1.8MG BASE/ML	N62413 004 AUG 11, 1983
AP		EQ 2MG BASE/ML	N62413 005 AUG 11, 1983
@		EQ 60MG BASE/100ML	N62413 006 AUG 11, 1983
@		EQ 70MG BASE/100ML	N62413 007 AUG 11, 1983
@		EQ 80MG BASE/100ML	N62413 008 AUG 11, 1983

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE

	@ ABBOTT	EQ 90MG BASE/100ML	N62413 009 AUG 11, 1983	
	@	EQ 100MG BASE/100ML	N62413 010 AUG 11, 1983	
	@	EQ 1.2MG BASE/ML	N62413 001 AUG 11, 1983	
	@	EQ 1.4MG BASE/ML	N62413 002 AUG 11, 1983	
	@	EQ 1.6MG BASE/ML	N62413 003 AUG 11, 1983	
	@	EQ 1.8MG BASE/ML	N62413 004 AUG 11, 1983	
	@	EQ 2MG BASE/ML	N62413 005 AUG 11, 1983	

OINTMENT; OPHTHALMIC
GENTACIDIN

AT	CIBA	**EQ 0.3% BASE**	**N62501 001** JUL 26, 1984	
AT	IOLAB	**EQ 0.3% BASE**	**N62501 001** JUL 26, 1984	

SOLUTION/DROPS; OPHTHALMIC
GENTACIDIN

AT	CIBA	**EQ 0.3% BASE**	**N62480 001** MAR 30, 1984	
AT	IOLAB	**EQ 0.3% BASE**	**N62480 001** MAR 30, 1984	

> ADD > GLATIRAMER ACETATE

> ADD > INJECTABLE; INJECTION
> ADD > COPAXONE

> ADD >	+ TEVA	20MG/VIAL	N20622 001 DEC 20, 1996	

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

AB	NOVOPHARM	**5MG**	**N74387 001** MAR 04, 1996	

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

AB	NOVOPHARM	**10MG**	**N74387 002** MAR 04, 1996	

GLUTETHIMIDE

TABLET; ORAL
GLUTETHIMIDE

	HALSEY	250MG	N89458 001 OCT 10, 1986	
	@	250MG	N89458 001 OCT 10, 1986	

GLYBURIDE

TABLET; ORAL
GLYNASE

AB	PHARMACIA AND UPJOHN	**3MG**	**N20051 002** MAR 04, 1992	
	+	6MG	N20051 004 SEP 24, 1993	
AB	+ UPJOHN	**3MG**	**N20051 002** MAR 04, 1992	
	@	6MG	N20051 004 SEP 24, 1993	

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

AP	ABBOTT	**0.2MG/ML**	**N89393 001** JUN 15, 1988	
	@	0.2MG/ML	N89393 001 JUN 15, 1988	

GOSERELIN ACETATE

IMPLANT; IMPLANTATION
ZOLADEX

	+ ZENECA	EQ 10.8MG BASE	N20578 001 JAN 11, 1996	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	BAUSCH AND LOMB	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N64047 001 JAN 31, 1996

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

AB	BARR	0.5MG	N71156 001 JAN 02, 1987
AB		1MG	N71157 001 JAN 02, 1987
AB		2MG	N71172 001 JAN 02, 1987
AB		5MG	N71212 001 JAN 07, 1988
AB		10MG	N71173 001 JAN 07, 1988
AB		20MG	N71177 001 JAN 07, 1988
@		0.5MG	N71156 001 JAN 02, 1987
@		1MG	N71157 001 JAN 02, 1987
@		2MG	N71172 001 JAN 02, 1987
@		5MG	N71212 001 JAN 07, 1988
@		10MG	N71173 001 JAN 07, 1988
@		20MG	N71177 001 JAN 07, 1988

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALDOL DECANOATE 100

+	JOHNSON RW	EQ 100MG BASE/ML	N18701 002 OCT 31, 1989

HALOPROGIN

CREAM; TOPICAL
HALOTEX

+	WESTWOOD SQUIBB	1%	N16942 001
@		1%	N16942 001

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH

AP	SOLOPAK	100 UNITS/ML	N87905 001 APR 20, 1983
@		100 UNITS/ML	N87905 001 APR 20, 1983

HEPARIN SODIUM

AP	LILLY	1,000 UNITS/ML	N05521 001
AP		20,000 UNITS/ML	N05521 004
@		1,000 UNITS/ML	N05521 001
@		20,000 UNITS/ML	N05521 004
AP	MARSAM	1,000 UNITS/ML	N40007 001 JUN 07, 1996
AP	ORGANON	1,000 UNITS/ML	N00552 008
AP		5,000 UNITS/ML	N00552 009
AP		10,000 UNITS/ML	N00552 010
@		1,000 UNITS/ML	N00552 008
@		5,000 UNITS/ML	N00552 009
@		10,000 UNITS/ML	N00552 010
AP	PHARM SPEC ASSOC	20,000 UNITS/ML	N17780 004
@		1,000 UNITS/ML	N17780 001
@		5,000 UNITS/ML	N17780 002
@		10,000 UNITS/ML	N17780 003
@		20,000 UNITS/ML	N17780 004
AP	PHARM SPECLTS ASSOC	1,000 UNITS/ML	N17780 001
AP		5,000 UNITS/ML	N17780 002
AP		10,000 UNITS/ML	N17780 003
AP	SANOFI WINTHROP	10,000 UNITS/ML	N40095 001 JUL 26, 1996
AP	SOLOPAK	1,000 UNITS/ML	N87043 001
AP		5,000 UNITS/ML	N87077 001
AP		10,000 UNITS/ML	N87107 001
AP		5,000 UNITS/0.5ML	N87395 001
@		1,000 UNITS/ML	N87043 001
@		5,000 UNITS/ML	N87077 001
@		10,000 UNITS/ML	N87107 001
@		5,000 UNITS/0.5ML	N87395 001
AP	WYETH AYERST	5,000 UNITS/0.5ML	N17007 010

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	5,000 UNITS/100ML	N19134 001 MAR 29, 1985
@		5,000 UNITS/100ML	N19134 001 MAR 29, 1985

HEXACHLOROPHENE

SPONGE; TOPICAL

E-Z SCRUB

+	BECTON DICKINSON	450MG	N17452 001
+	DESERET	450MG	N17452 001

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

AA	BARR	10MG	N88728 001 APR 11, 1985
AA		25MG	N84106 002
AA		50MG	N84107 002
AA		100MG	N88729 001 APR 11, 1985
@		10MG	N88728 001 APR 11, 1985
@		25MG	N84106 002
@		50MG	N84107 002
@		100MG	N88729 001 APR 11, 1985
AA	HALSEY	10MG	N89218 001 JAN 22, 1986
@		10MG	N89218 001 JAN 22, 1986

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

BP	BARR	25MG;15MG;0.1MG	N88570 001 APR 10, 1984
@		25MG;15MG;0.1MG	N88570 001 APR 10, 1984

> ADD >
> ADD >
> ADD >
> ADD >

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

MICROZIDE

+	WATSON LABS	12.5MG	N20504 001 DEC 27, 1996

TABLET; ORAL

HYDRO-D

AB	HALSEY	25MG	N86504 001
AB		50MG	N83891 002
@		25MG	N86504 001
@		50MG	N83891 002

HYDROCHLOROTHIAZIDE

AB	BARR	50MG	N84771 001
AB		100MG	N83972 003
@		50MG	N84771 001
@		100MG	N83972 003
AB	SUPERPHARM	25MG	N88827 001 DEC 28, 1984
AB		50MG	N88828 001 DEC 28, 1984
AB		100MG	N88829 001 DEC 28, 1984
@		25MG	N88827 001 DEC 28, 1984
@		50MG	N88828 001 DEC 28, 1984
@		100MG	N88829 001 DEC 28, 1984

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

AB	NOVOPHARM	15MG;250MG	N71819 001 APR 08, 1988
AB		25MG;250MG	N71820 001 APR 08, 1988
AB		30MG;500MG	N71821 001 APR 08, 1988
AB		50MG;500MG	N71822 001 APR 08, 1988
@		15MG;250MG	N71819 001 APR 08, 1988
@		25MG;250MG	N71820 001 APR 08, 1988

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE

	@	NOVOPHARM	30MG;500MG	N71821 001 APR 08, 1988
	@		50MG;500MG	N71822 001 APR 08, 1988
AB		PARKE DAVIS	15MG;250MG	N71897 001 NOV 23, 1987
AB			25MG;250MG	N71898 001 NOV 23, 1987
AB			30MG;500MG	N71899 001 NOV 23, 1987
AB			50MG;500MG	N71900 001 NOV 23, 1987
	@		15MG;250MG	N71897 001 NOV 23, 1987
	@		25MG;250MG	N71898 001 NOV 23, 1987
	@		30MG;500MG	N71899 001 NOV 23, 1987
	@		50MG;500MG	N71900 001 NOV 23, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE

AB		WARNER CHILCOTT	25MG;40MG	N71771 001 JAN 26, 1988
	@		25MG;40MG	N71771 001 JAN 26, 1988

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
DYAZIDE

AB	+	SMITHKLINE BEECHAM	25MG;37.5MG	N16042 003 MAR 03, 1994

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	25MG;37.5MG	N74701 001 JUN 07, 1996

TABLET; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		SIDMAK LABS NJ	25MG;37.5MG	N74026 001 APR 26, 1996

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		SIDMAK LABS NJ	50MG;75MG	N73467 001 JAN 31, 1996

HYDROCORTISONE

CREAM; TOPICAL
CORT-DOME

AT		BAYER	0.5%	N09585 003
AT			1%	N09585 001
	@		0.5%	N09585 003
	@		1%	N09585 001

HYDROCORTISONE

AT		AMBIX	1%	N86080 001
AT			2.5%	N86271 001
	@		1%	N86080 001
	@		2.5%	N86271 001
AT		SYOSSET	1%	N85733 001
AT		ZENITH GOLDLINE	1%	N85733 001

NOGENIC HC

AT		SYOSSET	1%	N87427 001 APR 04, 1988
AT		ZENITH GOLDLINE	1%	N87427 001 APR 04, 1988

OINTMENT; TOPICAL
HYDROCORTISONE

AT		AMBIX	1%	N86079 001
AT			2.5%	N86272 001
	@		1%	N86079 001
	@		2.5%	N86272 001

PENECORT

AT		ALLERGAN HERBERT	2.5%	N88217 001 JUN 06, 1984
	@		2.5%	N88217 001 JUN 06, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC
OTICAIR

AT		BAUSCH AND LOMB	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N64065 001 AUG 28, 1996

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC
OTOBIOTIC

AT	+ SCHERING	5MG/ML; EQ 10,000 UNITS BASE/ML	N62302 001	
	+	5MG/ML; EQ 10,000 UNITS BASE/ML	N62302 001	

PYOCIDIN

AT	FOREST LABS	5MG/ML; EQ 10,000 UNITS BASE/ML	N61606 001	
	@	5MG/ML; EQ 10,000 UNITS BASE/ML	N61606 001	

HYDROCORTISONE ACETATE

CREAM; TOPICAL
HYDROCORTISONE ACETATE

AT	+ CENCI	1%	N80419 001 JAN 25, 1982	
	@	1%	N80419 001 JAN 25, 1982	
AT	PUREPAC PHARM	1%	N86052 001	
AT	+	1%	N86052 001	

PASTE; TOPICAL
ORABASE HCA

	COLGATE	0.5%	N83205 001	> DLT >
	HOYT LABS	0.5%	N83205 001	> DLT > > ADD > > ADD >

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-HYDROCORT

AP	ABBOTT	EQ 100MG BASE/VIAL	N85928 001	
	@	EQ 100MG BASE/VIAL	N85928 001	

HYDROXOCOBALAMIN

INJECTABLE; INJECTION
ALPHAREDISOL

AP	+ MERCK SHARP DOHME	1MG/ML	N80778 001	
	@	1MG/ML	N80778 001	

HYDROXOCOBALAMIN

AP	STERIS	1MG/ML	N85528 001	
AP		1MG/ML	N85998 001	

HYDROXOCOBALAMIN

INJECTABLE; INJECTION
HYDROXOCOBALAMIN

	@ STERIS	1MG/ML	N85528 001
	+	1MG/ML	N85998 001

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

AB	INVAMED	200MG	N40150 001 JAN 27, 1996

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

AP	SOLOPAK	25MG/ML	N86822 001
AP		50MG/ML	N87310 001
	@	25MG/ML	N86822 001
	@	50MG/ML	N87310 001

SYRUP; ORAL
HYDROXYZINE HCL

AA	KV PHARM	10MG/5ML	N87730 001 JUL 01, 1982
	@	10MG/5ML	N87730 001 JUL 01, 1982

TABLET; ORAL
HYDROXYZINE HCL

AB	HALSEY	10MG	N89366 001 MAY 02, 1988
	@	10MG	N89366 001 MAY 02, 1988
AB	SUPERPHARM	10MG	N88794 001 DEC 05, 1984
AB		25MG	N88795 001 DEC 05, 1984
AB		50MG	N88796 001 DEC 05, 1984
	@	10MG	N88794 001 DEC 05, 1984
	@	25MG	N88795 001 DEC 05, 1984

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

	HYDROXYZINE HCL			
	@ SUPERPHARM	50MG	N88796 001	DEC 05, 1984

HYDROXYZINE PAMOATE

CAPSULE; ORAL

	HYDROXYZINE PAMOATE			
AB	CHELSEA LABS	EQ 25MG HCL	N40156 001	JUL 15, 1996
AB		EQ 50MG HCL	N40156 002	JUL 15, 1996

IBUPROFEN

SUSPENSION; ORAL

	CHILDREN'S ADVIL			
BX	AM HOME PRODS	100MG/5ML	N19833 002	SEP 19, 1989
BX	WHITEHALL LABS	100MG/5ML	N19833 002	SEP 19, 1989
	CHILDREN'S MOTRIN			
BX	+ MCNEIL CONS PRODS	100MG/5ML	N19842 001	SEP 19, 1989
	IBU			
BX	KNOLL PHARM	100MG/5ML	N19784 001	DEC 18, 1989
	MOTRIN			
BX	+ MCNEIL CONS PRODS	100MG/5ML	N19842 001	SEP 19, 1989
	RUFEN			
BX	KNOLL PHARM	100MG/5ML	N19784 001	DEC 18, 1989

TABLET; ORAL

	IBU			
AB	KNOLL PHARM	400MG	N18197 001	
AB		400MG	N70083 001	FEB 22, 1985
AB		600MG	N70088 001	FEB 08, 1985
AB		600MG	N70099 001	MAR 29, 1985

IBUPROFEN

TABLET; ORAL

	IBU			
AB	KNOLL PHARM	800MG	N70745 001	JUL 23, 1986
	IBUPROFEN			
AB	BARR	400MG	N70079 001	JUL 24, 1985
AB		600MG	N70080 001	JUL 24, 1985
AB		800MG	N71448 001	FEB 18, 1987
	@	400MG	N70079 001	JUL 24, 1985
	@	600MG	N70080 001	JUL 24, 1985
	@	800MG	N71448 001	FEB 18, 1987
AB	HALSEY	300MG	N71028 001	MAR 23, 1987
AB		400MG	N71029 001	MAR 23, 1987
AB		600MG	N71030 001	MAR 23, 1987
AB		800MG	N72137 001	FEB 05, 1988
	@	300MG	N71028 001	MAR 23, 1987
	@	400MG	N71029 001	MAR 23, 1987
	@	600MG	N71030 001	MAR 23, 1987
	@	800MG	N72137 001	FEB 05, 1988
AB	KNOLL PHARM	400MG	N70083 001	FEB 22, 1985
	RUFEN			
AB	KNOLL PHARM	400MG	N18197 001	
AB		600MG	N70088 001	FEB 08, 1985
AB		600MG	N70099 001	MAR 29, 1985
AB		800MG	N70745 001	JUL 23, 1986

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDAMYCIN

+	PHARMACIA AND UPJOHN	20MG/VIAL		N50661 003 APR 25, 1995

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL
IMIPRAMINE HCL

AB	EON LABS	10MG	**N85200 001**
AB		25MG	**N84869 002**
AB		50MG	**N85133 001**
@	EON LABS MFG	10MG	N85200 001
@		25MG	N84869 002
@		50MG	N85133 001

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

AB	INVAMED	1.25MG	**N74594 001** MAY 23, 1996
AB		2.5MG	**N74594 002** MAY 23, 1996
AB	LEMMON	2.5MG	**N74498 001** OCT 31, 1996
AB	MYLAN	2.5MG	**N74461 001** MAR 27, 1996
AB	PUREPAC PHARM	1.25MG	**N74722 001** JUN 17, 1996
AB		2.5MG	**N74722 002** JUN 17, 1996
AB	WATSON LABS	1.25MG	**N74585 001** SEP 26, 1996
AB		2.5MG	**N74585 002** SEP 26, 1996
AB	ZENITH GOLDLINE	1.25MG	**N74299 002** APR 29, 1996
AB		2.5MG	**N74299 001** JUL 27, 1995
AB	ZENITH LABS	2.5MG	**N74299 001** JUL 27, 1995

LOZOL

AB	RHONE POULENC RORER	1.25MG	**N18538 002** APR 29, 1993

INDINAVIR SULFATE

CAPSULE; ORAL
CRIXIVAN

	MERCK	EQ 200MG BASE	N20685 003 MAR 13, 1996
+		EQ 400MG BASE	N20685 001 MAR 13, 1996

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

AB	BARR	25MG	**N70067 001** OCT 03, 1986
AB		50MG	**N70068 001** OCT 03, 1986
@		25MG	N70067 001 OCT 03, 1986
@		50MG	N70068 001 OCT 03, 1986
AB	HALSEY	25MG	**N70782 001** JUN 03, 1987
AB		50MG	**N70635 001** JUN 03, 1987
@		25MG	N70782 001 JUN 03, 1987
@		50MG	N70635 001 JUN 03, 1987
AB	PARKE DAVIS	25MG	**N18806 001** NOV 23, 1984
AB		50MG	**N18806 002** NOV 23, 1984
@		25MG	N18806 001 NOV 23, 1984
@		50MG	N18806 002 NOV 23, 1984

INSULIN LISPRO

INJECTABLE; INJECTION
HUMALOG

+	LILLY	100 UNITS/ML	N20563 001 JUN 14, 1996

IODIXANOL

INJECTABLE; INJECTION
VISIPAQUE 270
+ NYCOMED 55% N20351 001
MAR 22, 1996

VISIPAQUE 320
+ NYCOMED 65.2% N20351 002
MAR 22, 1996

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL
AP ELKINS SINN **41%** **N74629 001**
NOV 06, 1996
AP **61%** **N74629 002**
NOV 06, 1996
AP **76%** **N74629 003**
NOV 06, 1996
> ADD > **AP** FAULDING **61%** **N74734 001**
> ADD > DEC 10, 1996
> ADD > **AP** **76%** **N74734 002**
> ADD > DEC 10, 1996

ISOVUE-200
AP + BRACCO **41%** **N18735 006**
JUL 07, 1987
@ 41% N20327 001
OCT 12, 1994
@ 41% N20327 001
OCT 12, 1994

ISOVUE-250
BRACCO 51% N20327 002
OCT 12, 1994
+ 51% N20327 002
OCT 12, 1994

ISOVUE-300
AP + BRACCO **61%** **N18735 002**
DEC 31, 1985
AP + **61%** **N20327 003**
OCT 12, 1994
+ 61% N20327 003
OCT 12, 1994

ISOVUE-370
AP + BRACCO **76%** **N18735 003**
DEC 31, 1985
AP + **76%** **N20327 004**
OCT 12, 1994

IOPAMIDOL

INJECTABLE; INJECTION
ISOVUE-370
+ BRACCO 76% N20327 004
OCT 12, 1994

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
CAMPTOSAR
+ PHARMACIA AND UPJOHN 20MG/ML N20571 001
JUN 14, 1996

IRON DEXTRAN

INJECTABLE; INJECTION
DEXFERRUM
BP LUITPOLD EQ 50MG IRON/ML N40024 001
FEB 23, 1996

ISONIAZID

TABLET; ORAL
ISONIAZID
AA DANBURY PHARMA 50MG N80522 001
AA 100MG N80523 001
@ 50MG N80522 001
@ 100MG N80523 001
AA DURAMED 100MG N88231 001
MAR 17, 1983
@ 100MG N88231 001
MAR 17, 1983
@ GLOBAL PHARM 100MG N80153 001
AA GLOBAL PHARMS 100MG N80153 001
AA HALSEY 50MG N83632 001
@ 50MG N83632 001
AA PHOENIX LABS NY 50MG N80368 001
AA 100MG N80368 002
@ 50MG N80368 001
@ 100MG N80368 002
AA ZENITH LABS 100MG N80270 001
AA 300MG N83610 001
@ 100MG N80270 001
@ 300MG N83610 001

LANIAZID
AA LANNETT 50MG N80140 001

ISONIAZID

TABLET; ORAL
LANIAZID
LANNETT 50MG N80140 001

ISOSORBIDE DINITRATE

TABLET; ORAL
ISOSORBIDE DINITRATE
AB BARR 5MG N86166 002 SEP 19, 1986
AB 10MG N86169 001 SEP 19, 1986
AB 20MG N86167 001 SEP 19, 1986
AB 30MG N87564 001 SEP 18, 1986
@ 5MG N86166 002 SEP 19, 1986
@ 10MG N86169 001 SEP 19, 1986
@ 20MG N86167 001 SEP 19, 1986
@ 30MG N87564 001 SEP 18, 1986

SORBITRATE
BX ZENECA 5MG N16192 001 APR 01, 1996
BX 10MG N16192 002 APR 01, 1996

TABLET; SUBLINGUAL
ISORDIL
AB + WYETH AYERST 10MG N12940 005 JUL 29, 1988
+ 10MG N12940 005 JUL 29, 1988

ISOSORBIDE DINITRATE
AB BARR 2.5MG N84204 001 SEP 18, 1986
AB 5MG N86168 001 SEP 18, 1986
AB 10MG N87545 001 SEP 18, 1986
@ 2.5MG N84204 001 SEP 18, 1986

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL
ISOSORBIDE DINITRATE
@ BARR 5MG N86168 001 SEP 18, 1986
@ 10MG N87545 001 SEP 18, 1986

SORBITRATE
BX ZENECA 2.5MG N16191 002 APR 01, 1996
BX 5MG N16191 001 APR 01, 1996

TABLET, CHEWABLE; ORAL
SORBITRATE
ZENECA 5MG N16776 002 APR 01, 1996
+ 10MG N16776 003 APR 01, 1996

ISOSORBIDE MONONITRATE

TABLET; ORAL
MONOKET
SCHWARZ 10MG N20215 002 JUN 30, 1993
10MG N20215 002 JUN 30, 1993

TABLET, EXTENDED RELEASE; ORAL
IMDUR
@ SCHERING 30MG N20225 001 AUG 12, 1993
+ 30MG N20225 001 AUG 12, 1993

IVERMECTIN

TABLET; ORAL
STROMECTOL
+ MERCK 6MG N50742 001 NOV 22, 1996

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	KETALAR			
AP	+ PARKE DAVIS	EQ 50MG BASE/ML	N16812 002	
AP	+	EQ 100MG BASE/ML	N16812 003	
	KETAMINE HCL			
AP	BEDFORD	EQ 50MG BASE/ML	N74524 001	MAR 22, 1996
AP		EQ 100MG BASE/ML	N74524 002	MAR 22, 1996
AP	SANOFI WINTHROP	EQ 50MG BASE/ML	N74549 001	JUN 27, 1996
AP		EQ 100MG BASE/ML	N74549 002	JUN 27, 1996

KETOPROFEN

CAPSULE; ORAL

		KETOPROFEN			
> ADD >	AB	MYLAN	50MG	N74035 002	DEC 31, 1996
> ADD >	AB		75MG	N74035 003	DEC 31, 1996

LACTULOSE

SOLUTION; ORAL

	LACTULOSE			
AA	MORTON GROVE	10GM/15ML	N74602 001	NOV 14, 1996
AA	PHARM ASSOC	10GM/15ML	N74623 001	JUL 30, 1996

SOLUTION; ORAL, RECTAL

	CEPHULAC			
AA	~~HOECHST MARION RSSL~~	~~10GM/15ML~~	~~N17657 001~~	
AA	+	10GM/15ML	N17657 001	
	GENERLAC			
AA	MORTON GROVE	10GM/15ML	N74603 001	OCT 31, 1996

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

	XALATAN		
	+ PHARMACIA AND UPJOHN	0.005%	N20597 001 JUN 05, 1996

LEUCOVORIN CALCIUM

~~POWDER FOR RECONSTITUTION; ORAL~~

	~~LEUCOVORIN CALCIUM~~		
	~~IMMUNEX~~	~~EQ 60MG BASE/VIAL~~	~~N08107 003 JAN 30, 1987~~
	@	EQ 60MG BASE/VIAL	N08107 003 JAN 30, 1987

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	AKBETA		
AT	AKORN	0.25%	**N74779 001** OCT 29, 1996
AT		0.5%	**N74780 001** OCT 29, 1996
	LEVOBUNOLOL HCL		
AT	ALCON	0.25%	**N74851 001** OCT 28, 1996
AT		0.5%	**N74850 001** OCT 28, 1996

> ADD > LEVOFLOXACIN

> ADD > INJECTABLE; INJECTION

LEVAQUIN		
+ JOHNSON RW	25MG/ML	N20635 001 DEC 20, 1996
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER		
+ JOHNSON RW	5MG/ML	N20635 002 DEC 20, 1996
+	500MG/100ML	N20635 003 DEC 20, 1996

> ADD > TABLET; ORAL

LEVAQUIN		
JOHNSON RW	250MG	N20634 001 DEC 20, 1996

> ADD >	LEVOFLOXACIN			
> ADD >	TABLET; ORAL			
> ADD >	LEVAQUIN			
> ADD >	+ JOHNSON RW	500MG	N20634 002	
> ADD >			DEC 20, 1996	
	LEVONORGESTREL			
	IMPLANT; IMPLANTATION			
	LEVONORGESTREL			
BX	+ WYETH AYERST	75MG/IMPLANT	N20627 001	
			AUG 15, 1996	
	NORPLANT II			
BX	POPULATION COUNCIL	75MG/IMPLANT	N20544 001	
			NOV 01, 1996	
	NORPLANT SYSTEM			
	WYETH AYERST	36MG/IMPLANT	N20088 001	
			DEC 10, 1990	
	+	36MG/IMPLANT	N20088 001	
			DEC 10, 1990	
	LIDOCAINE			
	FILM, EXTENDED RELEASE; BUCCAL			
	LIDOCAINE			
	+ NOVEN	23MG/PATCH	N20575 001	
			MAY 21, 1996	
	+	46.1MG/PATCH	N20575 002	
			MAY 21, 1996	
	OINTMENT; TOPICAL			
	ALPHACAINE			
AT	CARLISLE	5%	N84944 001	
AT		5%	N84946 001	
	@	5%	N84944 001	
	@	5%	N84946 001	
	LIDOCAINE HYDROCHLORIDE			
	INJECTABLE; INJECTION			
	ALPHACAINE HCL			
AP	CARLISLE	2%	N84721 001	
	@	2%	N84721 001	
	LIDOCAINE HCL			
AP	ABBOTT	20%	N89362 001	
			MAY 25, 1988	

	LIDOCAINE HYDROCHLORIDE			
	INJECTABLE; INJECTION			
	LIDOCAINE HCL			
	@ ABBOTT	20%	N89362 001	
			MAY 25, 1988	
AP	DELL LABS	1%	N83387 001	
AP		2%	N83388 001	
	@	1%	N83387 001	
	@	2%	N83388 001	
AP	FUJISAWA	2%	N17508 001	
AP		4%	N17508 002	
AP		20%	N17508 004	
	@	2%	N17508 001	
	@	4%	N17508 002	
	@	20%	N17508 004	
AP	INTL MEDICATION	1%	N17701 002	
AP		2%	N17701 001	
	@	1%	N17701 002	
	@	2%	N17701 001	
	SOLUTION; ORAL			
	LIDOCAINE HCL			
AT	MORTON GROVE	2%	N87872 001	
			NOV 18, 1982	
	LIDOCAINE HCL VISCOUS			
AT	INTL MEDICATION	2%	N86389 001	
			FEB 02, 1982	
	@	2%	N86389 001	
			FEB 02, 1982	
	MYLOCAINE			
AT	MORTON GROVE	2%	N87872 001	
			NOV 18, 1982	
	SOLUTION; TOPICAL			
	ANESTACON			
AT	+ ALCON	2%	N80429 001	
AT	+ POLYMEDICA	2%	N80429 001	
	LIDOCAINE HCL			
AT	MORTON GROVE	4%	N87881 001	
			NOV 18, 1982	
	MYLOCAINE			
AT	MORTON GROVE	4%	N87881 001	
			NOV 18, 1982	

LINDANE

CREAM; TOPICAL
KWELL
+ REED AND CARNRICK 1% N06309 001
1% N84218 001
@ 1% N06309 001
+ 1% N84218 001

LOTION; TOPICAL
KWELL
AT + REED AND CARNRICK 1% N06309 003
AT 1% N84218 002
AT + 1% N84218 002
@ 1% N06309 003

SHAMPOO; TOPICAL
KWELL
AT + REED AND CARNRICK 1% N10718 001 > ADD >
AT 1% N84219 001 > ADD >
AT + 1% N84219 001 > ADD >
@ 1% N10718 001

LISINOPRIL

TABLET; ORAL
ZESTRIL
AB ZENECA 2.5MG N19777 005
APR 29, 1993
AB + 2.5MG N19777 005
APR 29, 1993

LITHIUM CITRATE

SYRUP; ORAL
CIBALITH-S
AA SOLVAY EQ 300MG CARBONATE/5ML N17672 001
LITHONATE
@ SOLVAY EQ 300MG CARBONATE/5ML N17672 001

LORACARBEF

CAPSULE; ORAL
LORABID
+ LILLY 200MG N50668 001
DEC 31, 1991

LORACARBEF

CAPSULE; ORAL
LORABID
LILLY 200MG N50668 001
DEC 31, 1991
+ 400MG N50668 002
APR 05, 1996

LORATADINE

SYRUP; ORAL
CLARITIN
+ SCHERING 1MG/ML N20641 001
OCT 10, 1996

TABLET; ORAL
CLARITIN REDITABS
SCHERING 10MG N20704 001
DEC 23, 1996

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
CLARITIN-D 24 HOUR
+ SCHERING 10MG;240MG N20470 001
AUG 23, 1996

LORAZEPAM

INJECTABLE; INJECTION
LORAZEPAM
AP MARSAM 2MG/ML N74535 001
SEP 12, 1996
AP 2MG/ML N74551 001
SEP 12, 1996
AP 1MG/0.5ML N74551 003
SEP 12, 1996
AP 4MG/ML N74535 002
SEP 12, 1996
AP 4MG/ML N74551 002
SEP 12, 1996

TABLET; ORAL
LORAZEPAM
AB BARR 0.5MG N70472 001
DEC 10, 1985

LORAZEPAM

TABLET; ORAL
LORAZEPAM

AB	BARR	1MG	N70473 001 DEC 10, 1985
AB		2MG	N70474 001 DEC 10, 1985
@		0.5MG	N70472 001 DEC 10, 1985
@		1MG	N70473 001 DEC 10, 1985
@		2MG	N70474 001 DEC 10, 1985
AB	HALSEY	0.5MG	N71434 001 SEP 01, 1987
AB		1MG	N71435 001 SEP 01, 1987
AB		2MG	N71436 001 SEP 01, 1987
@		0.5MG	N71434 001 SEP 01, 1987
@		1MG	N71435 001 SEP 01, 1987
@		2MG	N71436 001 SEP 01, 1987
AB	SUPERPHARM	0.5MG	N71245 001 FEB 09, 1987
AB		1MG	N71246 001 FEB 09, 1987
AB		2MG	N71247 001 FEB 09, 1987
@		0.5MG	N71245 001 FEB 09, 1987
@		1MG	N71246 001 FEB 09, 1987
@		2MG	N71247 001 FEB 09, 1987

MANGANESE CHLORIDE

INJECTABLE; INJECTION
MANGANESE CHLORIDE IN PLASTIC CONTAINER

@	ABBOTT	EQ 0.1MG MANGANESE/ML	N18962 001 JUN 26, 1986
		EQ 0.1MG MANGANESE/ML	N18962 001 JUN 26, 1986

MANGANESE SULFATE

INJECTABLE; INJECTION
MANGANESE SULFATE

	FUJISAWA	EQ 0.1MG MANGANESE/ML	N19228 001 MAY 05, 1987
@		EQ 0.1MG MANGANESE/ML	N19228 001 MAY 05, 1987

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL
MECLAN

+	J AND J	1%	N50518 001
#	JOHNSON RW	1%	N50518 001

MECLOFENAMATE SODIUM

CAPSULE; ORAL
MECLOFENAMATE SODIUM

AB	BARR	EQ 50MG BASE	N72848 001 MAR 20, 1989
AB		EQ 100MG BASE	N72809 001 MAR 20, 1989
@		EQ 50MG BASE	N72848 001 MAR 20, 1989
@		EQ 100MG BASE	N72809 001 MAR 20, 1989

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL
MEDROXYPROGESTERONE ACETATE

AB	BARR	2.5MG	N40159 001 AUG 09, 1996
AB		5MG	N40159 002 AUG 09, 1996
AB		10MG	N40159 003 AUG 09, 1996

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

AB	BARR	20MG	N74621 002 AUG 16, 1996

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

AP	+	SANOFI WINTHROP	25MG/ML	N05010 007
AP	+		50MG/ML	N05010 002
AP	+		75MG/ML	N05010 009
AP	+		100MG/ML	N05010 003
AP	+	STERLING WINTHROP	25MG/ML	N05010 007
AP	+		50MG/ML	N05010 002
AP	+		75MG/ML	N05010 009
AP	+		100MG/ML	N05010 003

SYRUP; ORAL

DEMEROL

AA	+	SANOFI WINTHROP	50MG/5ML	N05010 005
AA		STERLING WINTHROP	50MG/5ML	N05010 005

TABLET; ORAL

DEMEROL

AA	+	SANOFI WINTHROP	50MG	N05010 001
AA	+		100MG	N05010 004
AA	+	STERLING WINTHROP	50MG	N05010 001
AA	+		100MG	N05010 004

MEPROBAMATE

CAPSULE, EXTENDED RELEASE; ORAL

MEPROSPAN

		WALLACE PHARMS	200MG	N11284 001
	+		400MG	N11284 002
	@		200MG	N11284 001
	@		400MG	N11284 002

TABLET; ORAL

MEPROBAMATE

AA		BARR	200MG	N80699 001
AA			600MG	N84230 001
	@		200MG	N80699 001
	@		600MG	N84230 001
AA		MK LABS	200MG	N14368 004
AA			400MG	N14368 002
	@		200MG	N14368 004
	@		400MG	N14368 002

NEURAMATE

AA		HALSEY	200MG	N14359 002
AA			400MG	N14359 001
	@		200MG	N14359 002

MEPROBAMATE

TABLET; ORAL

NEURAMATE

	@	HALSEY	400MG	N14359 001

MEROPENEM

INJECTABLE; INJECTION

MERREM I.V.

	+	ZENECA	500MG/VIAL	N50706 003 JUN 21, 1996
	+		1GM/VIAL	N50706 001 JUN 21, 1996

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADOSE

AA		MALLINCKRODT	10MG/ML	N17116 002
AA	+	MALLINCKRODT CHEM	10MG/ML	N17116 002

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB		INVAMED	25MG	N40102 001 AUG 28, 1996
AB			50MG	N40102 002 AUG 28, 1996

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA		BARR	750MG	N84486 001

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

	@	BARR	750MG	N84486 001
> DLT >	AA	KV PHARM	500MG	N85660 001
> DLT >	AA		750MG	N85658 001
> ADD >	@		500MG	N85660 001
> ADD >	@		750MG	N85658 001

METHYLDOPA

TABLET; ORAL
METHYLDOPA

	AB	BARR	125MG	N70073 001 OCT 09, 1986
	AB		250MG	N70060 001 OCT 09, 1986
	AB		500MG	N70074 001 OCT 09, 1986
	@		125MG	N70073 001 OCT 09, 1986
	@		250MG	N70060 001 OCT 09, 1986
	@		500MG	N70074 001 OCT 09, 1986
	AB	HALSEY	500MG	N71753 001 MAR 28, 1988
	@		500MG	N71753 001 MAR 28, 1988
	AB	NOVOPHARM	125MG	N71105 001 DEC 05, 1986
	AB		250MG	N71106 001 DEC 05, 1986
	AB		500MG	N71067 001 DEC 05, 1986
	@		125MG	N71105 001 DEC 05, 1986
	@		250MG	N71106 001 DEC 05, 1986
	@		500MG	N71067 001 DEC 05, 1986

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

	AP	MARSAM	50MG/ML	N71812 001 DEC 22, 1987
	@		50MG/ML	N71812 001 DEC 22, 1987

METHYLTESTOSTERONE

TABLET; ORAL
ORETON METHYL

	BP	SCHERING	25MG	N03158 002
	@		25MG	N03158 002

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

	AP	ABBOTT	EQ 10MG BASE/2ML	N70505 001 JUN 23, 1989
	AP		EQ 5MG BASE/ML	N70505 001 JUN 23, 1989
	AP		EQ 10MG BASE/2ML	N70506 001 JUN 22, 1989
	AP		EQ 5MG BASE/ML	N70506 001 JUN 22, 1989
	AP		EQ 10MG BASE/2ML	N73117 001 JAN 17, 1991
	AP		EQ 5MG BASE/ML	N73117 001 JAN 17, 1991
	AP		EQ 10MG BASE/2ML	N73118 001 JAN 17, 1991
	AP		EQ 5MG BASE/ML	N73118 001 JAN 17, 1991
	AP	BULL D	EQ 10MG BASE/2ML	N71990 001 JAN 18, 1989
	AP	CETUS BEN VENUE	EQ 10MG BASE/2ML	N72155 001 MAR 30, 1992
	AP		EQ 5MG BASE/ML	N72155 001 MAR 30, 1992
	AP		EQ 10MG BASE/2ML	N72244 001 MAR 30, 1992
	AP		EQ 5MG BASE/ML	N72244 001 MAR 30, 1992

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	CETUS BEN VENUE	EQ 10MG BASE/2ML	N72247 001 MAY 18, 1992		
AP		EQ 5MG BASE/ML	N72247 001 MAY 18, 1992		
AP	FAULDING	EQ 10MG BASE/2ML	N70847 001 NOV 07, 1988		
AP		EQ 5MG BASE/ML	N70847 001 NOV 07, 1988		
AP		EQ 10MG BASE/2ML	N71291 001 MAR 03, 1989		
AP		EQ 5MG BASE/ML	N71291 001 MAR 03, 1989		
AP		EQ 5MG BASE/ML	N71990 001 JAN 18, 1989		
AP	GENSIA	EQ 10MG BASE/2ML	N73135 001 NOV 27, 1991		
AP		EQ 5MG BASE/ML	N73135 001 NOV 27, 1991	> ADD >	
AP	SANOFI WINTHROP	EQ 5MG BASE/ML	N74147 001 AUG 02, 1996	> ADD >	
AP	SMITH AND NEPHEW	EQ 10MG BASE/2ML	N70623 001 MAR 02, 1987	> ADD >	
AP		EQ 5MG BASE/ML	N70623 001 MAR 02, 1987		

REGLAN

AP	+ ROBINS AH	EQ 10MG BASE/2ML	N17862 001		
AP	+	EQ 5MG BASE/ML	N17862 001		

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	HALSEY	EQ 10MG BASE	N70906 001 OCT 28, 1986		
	@	EQ 10MG BASE	N70906 001 OCT 28, 1986		
AB	SCHERING	EQ 10MG BASE	N70598 001 FEB 02, 1987		
	@	EQ 10MG BASE	N70598 001 FEB 02, 1987		
AB	SUPERPHARM	EQ 10MG BASE	N70926 001 JUN 26, 1987		
	@	EQ 10MG BASE	N70926 001 JUN 26, 1987		

METOLAZONE

TABLET; ORAL
MYKROX

	FISONS	0.5MG	N19532 001 OCT 30, 1987		
	MEDEVA PHARMS	0.5MG	N19532 001 OCT 30, 1987		

ZAROXOLYN

	FISONS	2.5MG	N17386 001		
		5MG	N17386 002		
+		10MG	N17386 003		
	MEDEVA PHARMS	2.5MG	N17386 001		
		5MG	N17386 002		
+		10MG	N17386 003		

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

AB	CARACO	50MG	N74644 001 DEC 10, 1996		
AB		100MG	N74644 002 DEC 10, 1996		

METRONIDAZOLE

GEL; VAGINAL
METROGEL

+	CURATEK	0.75%	N20208 001 AUG 17, 1992		

METROGEL-VAGINAL

+	CURATEK	0.75%	N20208 001 AUG 17, 1992		

TABLET; ORAL
METROMIDOL

AB	LABS AF	250MG	N74523 001 OCT 24, 1996		
AB		500MG	N74523 002 OCT 24, 1996		

METRONIDAZOLE

AB	BARR	250MG	N18818 001 FEB 16, 1983		
AB		500MG	N18818 002 FEB 16, 1983		

METRONIDAZOLE

TABLET: ORAL
METRONIDAZOLE

	@ BARR	250MG	N18818 001	FEB 16, 1983
	@	500MG	N18818 002	FEB 16, 1983
AB	HALSEY	250MG	N70021 001	APR 02, 1985
AB		500MG	N70593 001	FEB 27, 1986
	@	250MG	N70021 001	APR 02, 1985
	@	500MG	N70593 001	FEB 27, 1986
> ADD > AB	LEMMON	250MG	N70035 001	DEC 20, 1984
> ADD > AB		500MG	N70044 001	FEB 08, 1985
AB	ZENITH GOLDLINE	250MG	N18517 001	MAY 05, 1982
AB		500MG	N18517 002	MAY 05, 1982
AB	ZENITH LABS	250MG	N18517 001	MAY 05, 1982
AB		500MG	N18517 002	MAY 05, 1982
> DLT >	METRYL			
> DLT > AB	LEMMON	250MG	N70035 001	DEC 20, 1984
> DLT >	METRYL 500			
> DLT > AB	LEMMON	500MG	N70044 001	FEB 08, 1985

METYRAPONE

CAPSULE; ORAL
METOPIRONE

+	CIBA	250MG	N12911 002 AUG 09, 1996

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	GENEVA PHARMS	**150MG**	**N74450 001** MAY 16, 1996

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	GENEVA PHARMS	**200MG**	**N74450 002** MAY 16, 1996
AB		**250MG**	**N74450 003** MAY 16, 1996

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT DUAL PAK

+	JOHNSON RW	2%,200MG	N18884 002 OCT 17, 1988

MIDODRINE HYDROCHLORIDE

TABLET; ORAL
PROAMATINE

	ROBERTS LABS	2.5MG	N19815 001 SEP 06, 1996
+		5MG	N19815 002 SEP 06, 1996

> ADD > MIGLITOL

> ADD > TABLET; ORAL
> ADD > GLYSET

> ADD >	BAYER	25MG	N20682 001 DEC 18, 1996
> ADD >		50MG	N20682 002 DEC 18, 1996
> ADD >	+	100MG	N20682 003 DEC 18, 1996

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL
MINOCYCLINE HCL

	LEDERLE	EQ 100MG BASE	N50451 002 AUG 10, 1982
+		EQ 100MG BASE	N50451 002 AUG 10, 1982

MINOXIDIL

SOLUTION; TOPICAL
ROCAINE
+ UPJOHN 2% N19501 001 AUG 17, 1988

MIRTAZAPINE

TABLET; ORAL
REMERON
ORGANON 15MG N20415 001 JUN 14, 1996
+ 30MG N20415 002 JUN 14, 1996

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
KADIAN
+ FAULDING SVCS 20MG N20616 001 JUL 03, 1996
+ 50MG N20616 002 JUL 03, 1996
+ 100MG N20616 003 JUL 03, 1996

INJECTABLE; INJECTION
MORPHINE SULFATE
AP MALLINCKRODT CHEM **1MG/ML** **N20631 001** JUL 03, 1996
+ 2MG/ML N20631 002 JUL 03, 1996

MOXALACTAM DISODIUM

INJECTABLE; INJECTION
MOXAM
+ LILLY EQ 250MG BASE/VIAL N50550 001
+ EQ 500MG BASE/VIAL N50550 002
+ EQ 1GM BASE/VIAL N50550 003
+ EQ 2GM BASE/VIAL N50550 004
+ EQ 10GM BASE/VIAL N50550 008
@ EQ 250MG BASE/VIAL N50550 001
@ EQ 500MG BASE/VIAL N50550 002
@ EQ 1GM BASE/VIAL N50550 003

MOXALACTAM DISODIUM

INJECTABLE; INJECTION
MOXAM
@ LILLY EQ 2GM BASE/VIAL N50550 004
@ EQ 10GM BASE/VIAL N50550 008

NADOLOL

TABLET; ORAL
NADOLOL
AB ZENITH GOLDLINE **20MG** **N74229 001** AUG 30, 1996
AB **40MG** **N74229 002** AUG 30, 1996
AB **80MG** **N74255 001** JAN 24, 1996
AB **120MG** **N74255 002** JAN 24, 1996
AB **160MG** **N74255 003** JAN 24, 1996
AB ZENITH LABS **80MG** **N74255 001** JAN 24, 1996
AB **120MG** **N74255 002** JAN 24, 1996
AB **160MG** **N74255 003** JAN 24, 1996

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL
+ ABBOTT 1.5MG/ML N20200 001 MAR 12, 1993

NALBUPHINE HYDROCHLORIDE
ABBOTT 1.5MG/ML N20200 001 MAR 12, 1993

NALIDIXIC ACID

TABLET; ORAL
NALIDIXIC ACID
AB BARR **250MG** **N70270 001** JUN 29, 1988
AB **500MG** **N70271 001** JUN 29, 1988

NALIDIXIC ACID

TABLET; ORAL
NALIDIXIC ACID

AB	BARR	1GM	N70272 001 JUN 29, 1988
	@	250MG	N70270 001 JUN 29, 1988
	@	500MG	N70271 001 JUN 29, 1988
	@	1GM	N70272 001 JUN 29, 1988

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

AP	SMITH AND NEPHEW	0.4MG/ML	N71682 001 NOV 17, 1987
	@	0.4MG/ML	N71682 001 NOV 17, 1987

NAPROXEN

TABLET; ORAL
NAPROXEN

AB	BIOCRAFT	250MG	N74216 001 APR 11, 1996
AB		375MG	N74216 002 APR 11, 1996
AB		500MG	N74216 003 APR 11, 1996
AB	SIDMAK LABS NJ	250MG	N74182 001 JUN 27, 1996
AB		375MG	N74182 002 JUN 27, 1996
AB		500MG	N74182 003 JUN 27, 1996

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB	AL HIKMA	EQ 500MG BASE	N74480 001 MAY 14, 1996

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB	SIDMAK LABS NJ	EQ 250MG BASE	N74242 001 JUN 20, 1996
AB		EQ 500MG BASE	N74242 002 JUN 20, 1996
AB	WEST WARD PHARM	EQ 500MG BASE	N74480 001 MAY 14, 1996

TABLET, EXTENDED RELEASE; ORAL
NAPRELAN

+	ELAN PHARM	EQ 375MG BASE	N20353 001 JAN 05, 1996
+		EQ 500MG BASE	N20353 002 JAN 05, 1996
+		EQ 750MG BASE	N20353 003 JAN 05, 1996

NEOMYCIN SULFATE

INJECTABLE; INJECTION
MYCIFRADIN

AP	+ UPJOHN	EQ 350MG BASE/VIAL	N60477 001

NEOMYCIN SULFATE

AP	PFIZER	EQ 350MG BASE/VIAL	N61084 001
AP	SQUIBB	EQ 350MG BASE/VIAL	N60366 001

POWDER; FOR RX COMPOUNDING
NEO-RX

AA	PHARMA TEK	100%	N61579 001
		100%	N61579 001

NEOMYCIN SULFATE

	@ ELKINS SINN	100%	N61698 001
AA	PADDOCK	100%	N62385 001 JUN 01, 1982

NEVIRAPINE

TABLET; ORAL
VIRAMUNE

+	BOEHRINGER INGELHEIM	200MG	N20636 001 JUN 21, 1996

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

		CARDENE			
AB		SYNTEX	20MG	N19488 001	DEC 21, 1988
AB	+		30MG	N19488 002	DEC 21, 1988
		NICARDIPINE HCL			
AB		CHELSEA LABS	20MG	N74670 001	OCT 28, 1996
AB			30MG	N74670 002	OCT 28, 1996
AB		LEMMON	20MG	N74540 001	OCT 28, 1996
AB			30MG	N74540 002	OCT 28, 1996
AB		MYLAN	20MG	N74642 001	JUL 18, 1996
AB			30MG	N74642 002	JUL 18, 1996
>ADD> AB		ZENITH GOLDLINE	20MG	N74439 001	DEC 10, 1996
>ADD> AB			30MG	N74439 002	DEC 10, 1996

NICLOSAMIDE

TABLET, CHEWABLE; ORAL

		NICLOCIDE			
	+	BAYER	500MG	N18669 001	MAY 14, 1982
	@		500MG	N18669 001	MAY 14, 1982

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

		HABITROL			
BC	+	CIBA	7MG/24HR	N20076 001	NOV 27, 1991
BC	+		14MG/24HR	N20076 002	NOV 27, 1991
BC	+		21MG/24HR	N20076 003	NOV 27, 1991
	+		7MG/24HR	N20076 001	NOV 27, 1991
	+		14MG/24HR	N20076 002	NOV 27, 1991
	+		21MG/24HR	N20076 003	NOV 27, 1991
		NICODERM			
BC	+	HOECHST MARION RSSL	7MG/24HR	N20165 001	NOV 07, 1991
BC	+		14MG/24HR	N20165 002	NOV 07, 1991
BC	+		21MG/24HR	N20165 003	NOV 07, 1991
		NICOTROL			
	+	PHARMACIA	5MG/16HR	N20150 001	APR 22, 1992
	+		10MG/16HR	N20150 002	APR 22, 1992
	+		15MG/16HR	N20150 003	APR 22, 1992

SPRAY, METERED; NASAL

		NICOTROL			
	+	PHARMACIA AND UPJOHN	0.5MG/INH	N20385 001	MAR 22, 1996

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

		NICORETTE			
	+	SMITHKLINE BEECHAM	EQ 2MG BASE	N18612 001	JAN 13, 1984
		NICORETTE DS			
	+	SMITHKLINE BEECHAM	EQ 4MG BASE	N20066 001	JUN 08, 1992

NILUTAMIDE

TABLET; ORAL

		NILANDRON			
	+	ROUSSEL UCLAF	50MG	N20169 001	SEP 19, 1996

NITROFURANTOIN

SUSPENSION; ORAL
FURADANTIN

	+	DURA	25MG/5ML	N09175 001
	+	PROCTER AND GAMBLE	25MG/5ML	N09175 001

NITROFURAZONE

OINTMENT; TOPICAL
NITROFURAZONE

AT		AMBIX	0.2%	N86077 001
	@		0.2%	N86077 001

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
MINITRAN

AB1		3M	0.1MG/HR	N89771 001 AUG 30, 1996
AB1			0.2MG/HR	N89772 001 AUG 30, 1996
AB1			0.4MG/HR	N89773 001 AUG 30, 1996
AB1			0.6MG/HR	N89774 001 AUG 30, 1996

NITRO-DUR

BX	+	KEY PHARMS	0.1MG/HR	N20145 001 APR 04, 1995
BX	+		0.2MG/HR	N20145 002 APR 04, 1995
BX	+		0.4MG/HR	N20145 004 APR 04, 1995
BX	+		0.6MG/HR	N20145 005 APR 04, 1995
AB1	+	KEY PHARMS	0.1MG/HR	N20145 001 APR 04, 1995
AB1	+		0.2MG/HR	N20145 002 APR 04, 1995
AB1	+		0.4MG/HR	N20145 004 APR 04, 1995
AB1	+		0.6MG/HR	N20145 005 APR 04, 1995
BX	+		0.8MG/HR	N20145 006 APR 04, 1995

NITROGLYCERIN

AB2		MYLAN	0.2MG/HR	N74609 001 AUG 30, 1996

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
NITROGLYCERIN

AB2		MYLAN	0.4MG/HR	N74607 001 AUG 30, 1996
AB2			0.6MG/HR	N74559 001 AUG 30, 1996

TRANSDERM-NITRO

BX	+	CIBA	0.2MG/HR	N20144 002 FEB 27, 1996
BX	+		0.4MG/HR	N20144 003 FEB 27, 1996
BX	+		0.6MG/HR	N20144 004 FEB 27, 1996
AB2	+	CIBA	0.2MG/HR	N20144 002 FEB 27, 1996
AB2	+		0.4MG/HR	N20144 003 FEB 27, 1996
AB2	+		0.6MG/HR	N20144 004 FEB 27, 1996
BX			0.1MG/HR	N20144 001 FEB 27, 1996
BX	+		0.1MG/HR	N20144 001 FEB 27, 1996
BX			0.8MG/HR	N20144 005 FEB 27, 1996
BX	+		0.8MG/HR	N20144 005 FEB 27, 1996

NORETHINDRONE

TABLET; ORAL
NOR-Q.D.

		SEARLE	0.35MG	N17060 001

NOR-QD

	+	SEARLE	0.35MG	N17060 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL

AB		BIOCRAFT	EQ 10MG BASE	N73667 001 APR 11, 1996
AB			EQ 25MG BASE	N73667 002 APR 11, 1996

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL

AB	BIOCRAFT	EQ 50MG BASE	N73667 003 APR 11, 1996	> ADD >
AB		EQ 75MG BASE	N73667 004 APR 11, 1996	> ADD >

NYSTATIN

POWDER; TOPICAL
MYCOSTATIN

AT	+ WESTWOOD SQUIBB	100,000 UNITS/GM	N60578 001	

NYSTOP

AT	PADDOCK	100,000 UNITS/GM	N64118 001 AUG 16, 1996	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
MYCOLOG-II

AT	+ APOTHECON	100,000 UNITS/GM;0.1%	N60576 002 MAY 01, 1985	
AT		100,000 UNITS/GM;0.1%	N62606 001 MAY 15, 1985	
AT	+	100,000 UNITS/GM;0.1%	N62606 001 MAY 15, 1985	
	@	100,000 UNITS/GM;0.1%	N60576 002 MAY 01, 1985	

OLANZAPINE

TABLET; ORAL
ZYPREXA

	@ LILLY	2.5MG	N20592 001 SEP 30, 1996	
		5MG	N20592 002 SEP 30, 1996	
		7.5MG	N20592 003 SEP 30, 1996	
	+	10MG	N20592 004 SEP 30, 1996	

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
PATANOL

	+ ALCON	EQ 0.1% BASE	N20688 001 DEC 18, 1996	

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ZOFRAN PRESERVATIVE FREE

	+ GLAXO WELLCOME	EQ 2MG BASE/ML	N20007 003 DEC 10, 1993	

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

AB	BARR	10MG	N70957 001 AUG 10, 1987	
AB		15MG	N71025 001 AUG 10, 1987	
AB		30MG	N71026 001 AUG 10, 1987	
	@	10MG	N70957 001 AUG 10, 1987	
	@	15MG	N71025 001 AUG 10, 1987	
	@	30MG	N71026 001 AUG 10, 1987	

TABLET; ORAL
OXAZEPAM

AB	BARR	15MG	N70683 001 JAN 16, 1987	
	@	15MG	N70683 001 JAN 16, 1987	
AB	PARKE DAVIS	15MG	N71508 001 FEB 02, 1987	
	@	15MG	N71508 001 FEB 02, 1987	

OXTRIPHYLLINE

SOLUTION; ORAL
CHOLEDYL
PARKE DAVIS 100MG/5ML N09268 012 NOV 27, 1984
@ 100MG/5ML N09268 012 NOV 27, 1984

SYRUP; ORAL
CHOLEDYL
PARKE DAVIS 50MG/5ML N09268 011
@ 50MG/5ML N09268 011

TABLET, DELAYED RELEASE; ORAL
CHOLEDYL
+ PARKE DAVIS 100MG N09268 003
+ 200MG N09268 007
@ 100MG N09268 003
@ 200MG N09268 007

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
DITROPAN
AA + HOECHST MARION RSSL **5MG/5ML** **N18211 001**
OXYBUTYNIN CHLORIDE
AA SILARX **5MG/5ML** **N74520 001** MAR 29, 1996

TABLET; ORAL
OXYBUTYNIN CHLORIDE
AB ROSEMONT **5MG** **N74625 001** JUL 31, 1996

> ADD > PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

> ADD > CAPSULE; ORAL
> ADD > COTAZYM
> ADD > + ORGANON 30,000 USP UNITS;8,000 USP UNITS; 30,000 USP UNITS N20580 001 DEC 09, 1996

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAXIL
@ SMITHKLINE BEECHAM EQ 10MG BASE N20031 001 DEC 29, 1992
+ EQ 30MG BASE N20031 003 DEC 29, 1992
@ EQ 40MG BASE N20031 005 DEC 29, 1992
EQ 10MG BASE N20031 001 DEC 29, 1992
EQ 30MG BASE N20031 003 DEC 29, 1992
+ EQ 40MG BASE N20031 005 DEC 29, 1992

PENCICLOVIR

CREAM; TOPICAL
DENAVIR
+ SMITHKLINE BEECHAM 1% N20629 001 SEP 24, 1996

PENICILLIN G POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
PENICILLIN
AA BIOCRAFT **400,000 UNITS/5ML** **N60307 004**
400,000 UNITS/5ML N60307 004
PFIZERPEN G
AA PFIZER **400,000 UNITS/5ML** **N60587 001**
@ 400,000 UNITS/5ML N60587 001

TABLET; ORAL
PENICILLIN G POTASSIUM
AB MYLAN **800,000 UNITS** **N60781 004**
+ 800,000 UNITS N60781 004
PFIZERPEN G
AB PFIZER **200,000 UNITS** **N60075 003**
AB **250,000 UNITS** **N60075 004**
AB **400,000 UNITS** **N60075 005**
AB + **800,000 UNITS** **N60075 006**
50,000 UNITS N60075 001
100,000 UNITS N60075 002
@ 50,000 UNITS N60075 001
@ 100,000 UNITS N60075 002

PENICILLIN G POTASSIUM

TABLET; ORAL
PFIZERPEN G

@	PFIZER	200,000 UNITS	N60075 003
@		250,000 UNITS	N60075 004
@		400,000 UNITS	N60075 005
@		800,000 UNITS	N60075 006

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
PFIZERPEN VK

AA	PFIZER	EQ 125MG BASE/5ML	N61815 001
AA		EQ 250MG BASE/5ML	N61815 002
@		EQ 125MG BASE/5ML	N61815 001
@		EQ 250MG BASE/5ML	N61815 002

TABLET; ORAL
PFIZERPEN VK

AB	PFIZER	EQ 250MG BASE	N61836 001
AB		EQ 500MG BASE	N61836 002
@		EQ 250MG BASE	N61836 001
@		EQ 500MG BASE	N61836 002

PENTAMIDINE ISETHIONATE

POWDER FOR RECONSTITUTION; INHALATION
NEBUPENT

	FUJISAWA	600MG/VIAL	N19887 002 MAR 22, 1996

PENTOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM PENTOBARBITAL

AA	HALSEY	100MG	N84677 001
@		100MG	N84677 001

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL
ELMIRON

+	BAKER NORTON	100MG	N20193 001 SEP 26, 1996

PENTOSTATIN

INJECTABLE; INJECTION
NIPENT

+	PARKE DAVIS	10MG/VIAL	N20122 001 OCT 11, 1991
+	SUPERGEN	10MG/VIAL	N20122 001 OCT 11, 1991

PERFLUBRON

LIQUID; ORAL
IMAGENT

+	ALLIANCE PHARM	100%	N20091 001 AUG 13, 1993
@		100%	N20091 001 AUG 13, 1993

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

	AMARIC	2MG	N20184 001 DEC 30, 1993
		4MG	N20184 002 DEC 30, 1993
+		8MG	N20184 003 DEC 30, 1993
	RHONE POULENC RORER	2MG	N20184 001 DEC 30, 1993
		4MG	N20184 002 DEC 30, 1993
+		8MG	N20184 003 DEC 30, 1993

PHENSUXIMIDE

CAPSULE; ORAL
MILONTIN

+	PARKE DAVIS	500MG	N08855 004
@		500MG	N08855 004

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL
UMI-PEX 30

	FERNDALE LABS	30MG	N88605 001 SEP 28, 1987
+		30MG	N88605 001 SEP 28, 1987

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
IONAMIN

	PISONS	EQ 15MG BASE	N11613 004
+		EQ 30MG BASE	N11613 002
	MEDEVA PHARMS	EQ 15MG BASE	N11613 004
+		EQ 30MG BASE	N11613 002

PHENYLBUTAZONE

CAPSULE; ORAL
PHENYLBUTAZONE

+	BARR	100MG	N88994 001 DEC 04, 1985
@		100MG	N88994 001 DEC 04, 1985

TABLET; ORAL
PHENYLBUTAZONE

+	BARR	100MG	N88863 001 DEC 04, 1985
@		100MG	N88863 001 DEC 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PHERAZINE VC

AA	HALSEY	5MG/5ML;6.25MG/5ML	N88868 001 MAR 02, 1987
@		5MG/5ML;6.25MG/5ML	N88868 001 MAR 02, 1987

PROMETHAZINE VC PLAIN

AA	CENCI	5MG/5ML;6.25MG/5ML	N88815 001 NOV 22, 1985

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE VC PLAIN

@	CENCI	5MG/5ML;6.25MG/5ML	N88815 001 NOV 22, 1985

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM

AP	FUJISAWA	50MG/ML	N89003 001 MAY 31, 1985
@		50MG/ML	N89003 001 MAY 31, 1985
AP	MARSAM	50MG/ML	N89501 001 OCT 13, 1987
AP		50MG/ML	N89779 001 NOV 27, 1992
@		50MG/ML	N89501 001 OCT 13, 1987
@		50MG/ML	N89779 001 NOV 27, 1992
AP	SOLOPAK	50MG/ML	N88520 001 DEC 17, 1984
@		50MG/ML	N88520 001 DEC 17, 1984

PIMOZIDE

TABLET; ORAL
ORAP

+	LEMMON	2MG	N17473 001 JUL 31, 1984
+	TEVA	2MG	N17473 001 JUL 31, 1984

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	MARTEC	5MG	N74474 001 OCT 28, 1996
AB		10MG	N74474 002 OCT 28, 1996

PIROXICAM

CAPSULE; ORAL

		PIROXICAM		
AB		DANBURY PHARMA	10MG	N74287 001 MAY 16, 1996
AB			20MG	N74287 002 MAY 16, 1996
AB		ZENITH GOLDLINE	10MG	N74148 001 JUN 03, 1996
AB			20MG	N74148 002 JUN 03, 1996

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION

			ESTRADURIN		
	+		NYETH AYERST	40MG/AMP	N10753 001
	@			40MG/AMP	N10753 001

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

			POTASSIUM CHLORIDE		
AB			BIOCRAFT	8MEQ	N73531 001 APR 26, 1996
AB				10MEQ	N73532 001 APR 26, 1996

INJECTABLE; INJECTION

			POTASSIUM CHLORIDE		
AP			FUJISAWA	2MEQ/ML	N87787 001 APR 20, 1982
	@			2MEQ/ML	N87787 001 APR 20, 1982

TABLET, EXTENDED RELEASE; ORAL

			K-DUR 10		
BC	+		KEY PHARMS	10MEQ	N19439 002 JUN 13, 1986
BC	+		SCHERING	10MEQ	N19439 002 JUN 13, 1986
			K-DUR 20		
	+		KEY PHARMS	20MEQ	N19439 001 JUN 13, 1986
	+		SCHERING	20MEQ	N19439 001 JUN 13, 1986

PREDNISOLONE

SYRUP; ORAL

		PRELONE		
		MURO	5MG/5ML	N89654 001 JAN 17, 1989
			15MG/5ML	N89081 001 FEB 04, 1986
	+		5MG/5ML	N89654 001 JAN 17, 1989
	+		15MG/5ML	N89081 001 FEB 04, 1986

PREDNISOLONE ACETATE

SUSPENSION, OPHTHALMIC

			PRED FORTE		
BX	+		ALLERGAN	1%	N17011 001

SUSPENSION/DROPS; OPHTHALMIC

			PRED FORTE		
AB	+		ALLERGAN	1%	N17011 001

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

			SULSTER		
AT	+		AKORN	EQ 0.23% PHOSPHATE;10%	N74511 001 JUL 30, 1996

PREDNISONE

TABLET; ORAL

			PREDNISONE		
AB			BARR	5MG	N80701 001
AB				20MG	N84634 001
	@			5MG	N80701 001
	@			20MG	N84634 001
AB			INTERPHARM	5MG	N89597 001 OCT 05, 1987
AB				10MG	N89598 001 OCT 05, 1987
AB				20MG	N89599 001 OCT 05, 1987
	@			5MG	N89597 001 OCT 05, 1987

PREDNISONE

TABLET; ORAL

		PREDNISONE		
		@ INTERPHARM	10MG	N89598 001 OCT 05, 1987
		@	20MG	N89599 001 OCT 05, 1987
AB		SUPERPHARM	**5MG**	**N88865 001** OCT 25, 1984
AB			**10MG**	**N88866 001** OCT 25, 1984
AB			**20MG**	**N88867 001** OCT 25, 1984
		@	5MG	N88865 001 OCT 25, 1984
		@	10MG	N88866 001 OCT 25, 1984
		@	20MG	N88867 001 OCT 25, 1984

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		PROCAINAMIDE HCL		
> ADD >	**AB**	COPLEY PHARM	**1GM**	**N40111 001** DEC 13, 1996
> ADD >				
		PROCAN SR		
> ADD >	**AB**	+ PARKE DAVIS	**1GM**	**N88489 001** JAN 16, 1985
> ADD >				
		PROCANBID		
		+ PARKE DAVIS	500MG	N20545 001 JAN 31, 1996
		+	1GM	N20545 002 JAN 31, 1996

PROCHLORPERAZINE MALEATE

TABLET; ORAL

		COMPAZINE		
AB		SMITHKLINE BEECHAM	**EQ 5MG BASE**	**N10571 001**
AB			**EQ 10MG BASE**	**N10571 002**
AB	+		**EQ 25MG BASE**	**N10571 003**
		PROCHLORPERAZINE MALEATE		
AB		COPLEY PHARM	**EQ 5MG BASE**	**N40120 001** JUL 11, 1996

PROCHLORPERAZINE MALEATE

TABLET; ORAL

		PROCHLORPERAZINE MALEATE		
AB		COPLEY PHARM	**EQ 10MG BASE**	**N40120 002** JUL 11, 1996
AB		INVAMED	**EQ 5MG BASE**	**N40101 001** JUL 19, 1996
AB			**EQ 10MG BASE**	**N40101 002** JUL 19, 1996
AB			**EQ 25MG BASE**	**N40101 003** JUL 19, 1996
AB		MYLAN	**EQ 5MG BASE**	**N40185 002** OCT 28, 1996
AB			**EQ 10MG BASE**	**N40185 001** OCT 28, 1996

PROMAZINE HYDROCHLORIDE

TABLET; ORAL

	SPARINE		
	WYETH AYERST	50MG	N10348 002
	+	100MG	N10348 003
	+	50MG	N10348 002
	@	100MG	N10348 003

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHENERGAN FORTIS		
AA	WYETH AYERST	**25MG/5ML**	**N08381 003**
	+	25MG/5ML	N08381 003
	PROMETH		
AA	BARRE	**6.25MG/5ML**	**N85953 001**
AA		**25MG/5ML**	**N84772 001**
	PROMETH FORTIS		
	@ ALPHARMA	25MG/5ML	N84772 001
	PROMETH PLAIN		
AA	ALPHARMA	**6.25MG/5ML**	**N85953 001**
	PROMETHAZINE		
AA	CENCI	**6.25MG/5ML**	**N89013 001** SEP 20, 1985
	@	6.25MG/5ML	N89013 001 SEP 20, 1985

PROPANTHELINE BROMIDE

TABLET; ORAL

	PRO-BANTHINE			
AA	* ROBERTS LABS	7.5MG	N08732 003	
AA	*	15MG	N08732 002	
BP	+	7.5MG	N08732 003	
BP	+	15MG	N08732 002	
	PROPANTHELINE BROMIDE			
AA	PAR PHARM	15MG	N88377 001	DEC 08, 1983
BP		15MG	N88377 001	DEC 08, 1983
AA	ROXANE	7.5MG	N80927 001	
AA		15MG	N80927 002	
BP		7.5MG	N80927 001	
BP		15MG	N80927 002	

PROPOFOL

INJECTABLE; INJECTION

	DIPRIVAN			
	* ZENECA	10MG/ML	N19627 001	OCT 02, 1989
	@	10MG/ML	N19627 001	OCT 02, 1989
	+	10MG/ML	N19627 002	JUN 11, 1996

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

	PROPHENE 65			
AA	HALSEY	65MG	N83538 002	
	@	65MG	N83538 002	

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	PROPRANOLOL HCL			
AB	BARR	10MG	N70319 001	OCT 22, 1985
AB		20MG	N70320 001	OCT 22, 1985
AB		40MG	N70103 001	OCT 22, 1985

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	PROPRANOLOL HCL			
AB	BARR	60MG	N70321 001	SEP 24, 1986
AB		80MG	N70322 001	AUG 04, 1986
	@	10MG	N70319 001	OCT 22, 1985
	@	20MG	N70320 001	OCT 22, 1985
	@	40MG	N70103 001	OCT 22, 1985
	@	60MG	N70321 001	SEP 24, 1986
	@	80MG	N70322 001	AUG 04, 1986

PROPYLTHIOURACIL

TABLET; ORAL

	PROPYLTHIOURACIL			
BD	BARR	50MG	N83982 001	
	@	50MG	N83982 001	
BD	HALSEY	50MG	N80015 001	
	@	50MG	N80015 001	

PROTIRELIN

INJECTABLE; INJECTION

	THYPINONE			
AP	* ABBOTT	0.5MG/ML	N17638 001	
	@	0.5MG/ML	N17638 001	
	THYREL TRH			
AP	FERRING LABS	0.5MG/ML	N18087 001	
	+	0.5MG/ML	N18087 001	

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	NOVAFED			
	* DOW PHARM	120MG	N17603 001	
	+ HOECHST MARION RSSL	120MG	N17603 001	

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTAHIST

AA	CENCI	30MG/5ML;1.25MG/5ML	N88344 001 FEB 09, 1984		
@		30MG/5ML;1.25MG/5ML	N88344 001 FEB 09, 1984		

TRILITRON

AA	NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	N88474 001 FEB 12, 1985	> DLT >	
+		30MG/5ML;1.25MG/5ML	N88474 001 FEB 12, 1985	> ADD >	

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HCL

AP	DELL LABS	100MG/ML	N83772 001
		50MG/ML	N83771 001
@		50MG/ML	N83771 001
@		100MG/ML	N83772 001

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

AB	HALSEY	324MG	N89476 001 APR 10, 1987
@		324MG	N89476 001 APR 10, 1987

QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

AB	SOLVAY	200MG	N85296 001
		300MG	N85297 001
		200MG	N85296 001
+		300MG	N85297 001

QUINIDINE SULFATE

AB	* LILLY	200MG	N85103 001
@		200MG	N85103 001

TABLET; ORAL

QUINIDINE SULFATE

AB	IST TX	200MG	N85066 001

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

AB	BARR	200MG	N84177 001
@		200MG	N84177 001
AB	HALSEY	200MG	N83583 001
@		200MG	N83583 001
AB	ICN	200MG	N83393 001
@		200MG	N83393 001
AB	KV PHARM	200MG	N85276 001
@		200MG	N85276 001
AB	* LILLY	200MG	N85038 001
@		200MG	N85038 001
AB	ROXANE	200MG	N83640 001
AB	+	200MG	N83640 001
AB		300MG	N85632 001
AB	+	300MG	N85632 001
@	SCHERER	200MG	N85068 001

QUINORA

AB	* KEY PHARMS	300MG	N85222 001
@	SCHERING	300MG	N85222 001

RAMIPRIL

CAPSULE; ORAL

ALTACE

	HOECHST MARION RSSL	1.25MG	N19901 001 JAN 28, 1991
		2.5MG	N19901 002 JAN 28, 1991
		5MG	N19901 003 JAN 28, 1991
+		10MG	N19901 004 JAN 28, 1991
	HOECHST ROUSSEL	1.25MG	N19901 001 JAN 28, 1991
		2.5MG	N19901 002 JAN 28, 1991
		5MG	N19901 003 JAN 28, 1991
*		10MG	N19901 004 JAN 28, 1991

RANITIDINE BISMUTH CITRATE

TABLET; ORAL
TRITEC
+ GLAXO WELLCOME 400MG N20559 001 AUG 08, 1996

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUVAL
BP PAL PAK 50MG N09108 002
BP + 100MG N09108 004
BP VALE 50MG N09108 002
BP + 100MG N09108 004

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
ULTIVA
GLAXO WELLCOME EQ 1MG BASE/VIAL N20630 001 JUL 12, 1996
EQ 2MG BASE/VIAL N20630 002 JUL 12, 1996
+ EQ 5MG BASE/VIAL N20630 003 JUL 12, 1996

RIBAVIRIN

POWDER FOR RECONSTITUTION; INHALATION
VIRAZOLE
>ADD> + ICN 6GM/VIAL N18859 001 DEC 31, 1985
>ADD> + VIRATEK 6GM/VIAL N18859 001 DEC 31, 1985
>DLT>
>DLT>

RISPERIDONE

SOLUTION; ORAL
RISPERDAL
+ JANSSEN 1MG/ML N20588 001 JUN 10, 1996

RITONAVIR

CAPSULE; ORAL
NORVIR
+ ABBOTT 100MG N20680 001 MAR 01, 1996

SOLUTION; ORAL
NORVIR
ABBOTT 80MG/ML N20659 001 MAR 01, 1996

ROPIVACAINE HYDROCHLORIDE MONOHYDRATE

INJECTABLE; INJECTION
NAROPIN
ASTRA 2MG/ML N20533 001 SEP 24, 1996
5MG/ML N20533 003 SEP 24, 1996
7.5MG/ML N20533 004 SEP 24, 1996
+ 10MG/ML N20533 005 SEP 24, 1996

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
ELDEPRYL
+ SOMERSET 5MG N20647 001 MAY 15, 1996

TABLET; ORAL
ELDEPRYL
+ SOMERSET 5MG N19334 001 JUN 05, 1989
@ 5MG N19334 001 JUN 05, 1989

SELEGILINE HCL
AB ENDO LABS 5MG N74565 001 AUG 02, 1996
AB LEDERLE 5MG N74641 001 AUG 02, 1996
AB NOVOPHARM 5MG N74537 001 AUG 02, 1996

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE

AT	SYOSSET	2.5%	N85777 001	
AT	ZENITH GOLDLINE	2.5%	N85777 001	

SERTRALINE HYDROCHLORIDE

TABLET; ORAL
ZOLOFT

	PFIZER	EQ 25MG BASE	N19839 005 MAR 06, 1996

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	MCGAW	450MG/100ML	N18184 001	
	@	450MG/100ML	N18184 001	

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

AP	MCGAW	1.87GM/100ML	N18186 001	
	@	1.87GM/100ML	N18186 001	

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NIPRIDE

AP	+ ROCHE	50MG/VIAL	N17546 001	
	@	50MG/VIAL	N17546 001	
	SODIUM NITROPRUSSIDE			> ADD >
AP	ELKINS SINN	50MG/VIAL	N18581 001 JUL 28, 1982	> ADD >
AP	+	50MG/VIAL	N18581 001 JUL 28, 1982	> ADD > > ADD > > ADD >

SODIUM PHENYLBUTYRATE

POWDER; ORAL
BUPHENYL

+	UCYCLYD	3GM/TEASPOONFUL	N20573 001 APR 30, 1996

TABLET; ORAL
BUPHENYL

+	UCYCLYD	500MG	N20572 001 MAY 13, 1996

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
SAIZEN

BX	SERONO	5MG/VIAL	N19764 002 OCT 08, 1996
BX		6MG/VIAL	N19764 001 OCT 08, 1996

SEROSTIM

BX	SERONO	5MG/VIAL	N20604 002 AUG 23, 1996
BX +		6MG/VIAL	N20604 001 AUG 23, 1996
	+	6MG/VIAL	N20604 001 AUG 23, 1996

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 20%

AP	PHARMACIA AND UPJOHN	20%	N20248 001 AUG 07, 1996

> ADD > SPARFLOXACIN

TABLET; ORAL
ZAGAM

+	RHONE POULENC RORER	200MG	N20677 001 DEC 19, 1996

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL
RENORMAX
SANDOZ

	3MG	N20240 001	DEC 29, 1994
	6MG	N20240 002	DEC 29, 1994
	12MG	N20240 003	DEC 29, 1994
+	24MG	N20240 004	DEC 29, 1994
@ SCHERING	3MG	N20240 001	DEC 29, 1994
@	6MG	N20240 002	DEC 29, 1994
@	12MG	N20240 003	DEC 29, 1994
@	24MG	N20240 004	DEC 29, 1994

SPIRONOLACTONE

TABLET; ORAL
ALDACTONE

AB	+ SEARLE	**25MG**	**N12151 009**		DEC 30, 1983
AB		**25MG**	**N12151 009**	> ADD >	DEC 30, 1983
		100MG	**N12151 010**	> ADD >	DEC 30, 1983
	+	100MG	N12151 010		DEC 30, 1983

SUCCIMER

CAPSULE; ORAL
CHEMET

	+ ECK PHARMA	100MG	N19998 002	> ADD >
				> ADD >
				> ADD >
				> ADD >
	+ SANOFI WINTHROP	100MG	N19998 002	

JAN 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
QUELICIN

AP	+ ABBOTT	**20MG/ML**	**N08845 001**
AP	+	**20MG/ML**	**N08845 006**
	+	**50MG/ML**	**N08845 002**
	+	**100MG/ML**	**N08845 004**

QUELICIN PRESERVATIVE FREE

AP	+ ABBOTT	**20MG/ML**	**N08845 001**
	+	50MG/ML	N08845 002
	+	100MG/ML	N08845 004

SUCRALFATE

TABLET; ORAL
CARAFATE

AB	+ BLUE RIDGE	**1GM**	**N18333 001**

SUCRALFATE

AB	BIOCRAFT	**1GM**	**N70848 001** MAR 29, 1996

SUFENTANIL CITRATE

INJECTABLE; INJECTION
SULFENTANIL CITRATE

AP	ABBOTT	**EQ 0.05MG BASE/ML**	**N74534 001** DEC 11, 1996

SULFACETAMIDE SODIUM

LOTION; TOPICAL
KLARON

+	DERMIK LABS	10%	N19931 001 DEC 23, 1996

SOLUTION/DROPS; OPHTHALMIC
OCUSULF-30

AT	OPTOPICS	**30%**	**N80660 002**
	@	30%	N80660 002

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	BARR	400MG;80MG	N70006 001	> DLT >	
			NOV 14, 1984	> DLT >	
	@	400MG;80MG	N70006 001	> DLT >	
			NOV 14, 1984	> ADD >	

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

AB	BARR	800MG;160MG	N70007 001
			NOV 14, 1984
	@	800MG;160MG	N70007 001
			NOV 14, 1984

SULFATRIM-DS

AB	SUPERPHARM	800MG;160MG	N70066 001
			JUN 24, 1985
	@	800MG;160MG	N70066 001
			JUN 24, 1985

SULFATRIM-SS

AB	SUPERPHARM	400MG;80MG	N70065 002
			JUN 24, 1985
	@	400MG;80MG	N70065 002
			JUN 24, 1985

SULFISOXAZOLE

TABLET; ORAL

GANTRISIN

AB	+ ROCHE	500MG	N06525 001	
	@	500MG	N06525 001	

SULFISOXAZOLE

AB	ZENITH LABS	500MG	N80142 001
AB	+	500MG	N80142 001

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

@	ZENECA	EQ 20MG BASE	N17970 002
			MAR 21, 1994
+		EQ 20MG BASE	N17970 002
			MAR 21, 1994

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION; ORAL

TECHNETIUM TC 99M SULFUR COLLOID

	MALLINCKRODT	3mCi/ML	N17724 001
@	MALLINCKRODT MEDCL	3mCi/ML	N17724 001

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVIEW

	MEDI PHYSICS	N/A	N20372 001
			FEB 09, 1996

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB	BARR	15MG	N71174 001
			JUL 10, 1986
AB		30MG	N71175 001
			JUL 10, 1986
	@	15MG	N71174 001
			JUL 10, 1986
	@	30MG	N71175 001
			JUL 10, 1986

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL

HYTRIN

@	ABBOTT	EQ 1MG BASE	N19057 001
			AUG 07, 1987
@		EQ 2MG BASE	N19057 002
			AUG 07, 1987
@		EQ 5MG BASE	N19057 003
			AUG 07, 1987
@		EQ 10MG BASE	N19057 004
			AUG 07, 1987
		EQ 1MG BASE	N19057 001
			AUG 07, 1987
+		EQ 2MG BASE	N19057 002
			AUG 07, 1987
		EQ 5MG BASE	N19057 003
			AUG 07, 1987

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL
HYTRIN
ABBOTT — EQ 10MG BASE — N19057 004 AUG 07, 1987

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL
LAMISIL
+ SANDOZ — EQ 250MG BASE — N20539 001 MAY 10, 1996

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL
AB SUPERPHARM — 250MG — N62540 001 MAR 21, 1985
AB — 500MG — N62540 002 MAR 21, 1985
@ — 250MG — N62540 001 MAR 21, 1985
@ — 500MG — N62540 002 MAR 21, 1985

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201
MEDI PHYSICS — 2mCi/ML — N18110 001 FEB 01, 1982
— 1mCi/ML — N18110 002 FEB 27, 1996

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEOVENT
BC SCHERING — 125MG — N87010 001 JAN 31, 1985
BC — 250MG — N87910 001 JAN 31, 1985

> DLT >
> ADD >

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEOVENT
@ SCHERING — 125MG — N87010 001 JAN 31, 1985
@ — 250MG — N87910 001 JAN 31, 1985

ELIXIR; ORAL
ELIXOMIN
AA CENCI — 80MG/15ML — N88303 001 JAN 25, 1984
@ — 80MG/15ML — N88303 001 JAN 25, 1984

THEOPHYLLINE
AA HALSEY — 80MG/15ML — N85169 001
@ — 80MG/15ML — N85169 001

INJECTABLE; INJECTION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW — 40MG/100ML — N19083 001 NOV 07, 1984
@ — 40MG/100ML — N19083 001 NOV 07, 1984

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW — 80MG/100ML — N19083 002 NOV 07, 1984
@ — 80MG/100ML — N19083 002 NOV 07, 1984

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW — 160MG/100ML — N19083 003 NOV 07, 1984
@ — 160MG/100ML — N19083 003 NOV 07, 1984

THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW — 200MG/100ML — N19826 004 AUG 14, 1992
@ — 200MG/100ML — N19826 004 AUG 14, 1992

THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW — 400MG/100ML — N19826 005 AUG 14, 1992
@ — 400MG/100ML — N19826 005 AUG 14, 1992

SUSPENSION, ORAL
ELIXICON
+ FOREST LABS — 100MG/5ML — N85502 001

THEOPHYLLINE

SUSPENSION; ORAL

ELIXICON

	@	FOREST LABS	100MG/5ML	N85502 001

TABLET, EXTENDED RELEASE; ORAL

UNI-DUR

BC	+	KEY PHARMS	400MG	N89822 001 JAN 04, 1995
BC	+		600MG	N89823 001 JAN 04, 1995
BC	+	SCHERING	400MG	N89822 001 JAN 04, 1995
BC	+		600MG	N89823 001 JAN 04, 1995

UNIPHYL

BC		PURDUE FREDERICK	600MG	N40086 001 APR 15, 1996

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

AP		DELL LABS	**100MG/ML**	**N83775 001**
	@		100MG/ML	N83775 001
AP		SANOFI WINTHROP	**100MG/ML**	**N40079 001** MAY 03, 1996

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

MELLARIL

AA		SANDOZ	**30MG/ML**	**N11808 012**
AA	+		**30MG/ML**	**N11808 012**
AA			**100MG/ML**	**N11808 018**
AA	+		**100MG/ML**	**N11808 018**

THIORIDAZINE HCL

AA		HI TECH PHARMA	**30MG/ML**	**N40125 001** AUG 16, 1996
AA			**100MG/ML**	**N40126 001** AUG 16, 1996

TABLET; ORAL

THIORIDAZINE HCL

AB		BARR	**10MG**	**N88375 001 NOV 18, 1983**

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

AB		BARR	**15MG**	**N88461 001 NOV 18, 1983**
AB			**25MG**	**N87264 001 NOV 18, 1983**
AB			**100MG**	**N88379 001 NOV 16, 1983**
AB			**150MG**	**N88737 001 SEP 26, 1984**
AB			**200MG**	**N88738 001 OCT 16, 1984**
	@		10MG	N88375 001 NOV 18, 1983
	@		15MG	N88461 001 NOV 18, 1983
	@		25MG	N87264 001 NOV 18, 1983
	@		100MG	N88379 001 NOV 16, 1983
	@		150MG	N88737 001 SEP 26, 1984
	@		200MG	N88738 001 OCT 16, 1984
AB		SUPERPHARM	**10MG**	**N89103 001 JUL 02, 1985**
AB			**25MG**	**N89104 001 JUL 02, 1985**
AB			**50MG**	**N89105 001 JUL 02, 1985**
	@		10MG	N89103 001 JUL 02, 1985
	@		25MG	N89104 001 JUL 02, 1985
	@		50MG	N89105 001 JUL 02, 1985

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOPTIC-XE

	+	MERCK	EQ 0.25% BASE	N20330 001 NOV 04, 1993
	+		EQ 0.5% BASE	N20330 002 NOV 04, 1993

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

	TIMOPTIC-XE			
+	MERCK	EQ 0.25% BASE	N20310 001	NOV 04, 1993
+		EQ 0.5% BASE	N20330 002	NOV 04, 1993

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

	ZANAFLEX			
+	ATHENA	EQ 4MG BASE	N20397 001	NOV 27, 1996

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

	AKTOB			
AT	AKORN	0.3%	N64096 001	JAN 31, 1996

TOLAZAMIDE

TABLET; ORAL

	TOLAZAMIDE			
AB	BARR	100MG	N70162 001	JAN 14, 1986
AB		250MG	N70163 001	JAN 14, 1986
AB		500MG	N70164 001	JAN 14, 1986
	@	100MG	N70162 001	JAN 14, 1986
	@	250MG	N70163 001	JAN 14, 1986
	@	500MG	N70164 001	JAN 14, 1986
AB	ZENITH GOLDLINE	100MG	N18894 001	NOV 02, 1984
AB		250MG	N18894 002	NOV 02, 1984
AB		500MG	N18894 003	NOV 02, 1984

TOLAZAMIDE

TABLET; ORAL

	TOLAZAMIDE			
AB	ZENITH LABS	100MG	N18894 001	NOV 02, 1984
AB		250MG	N18894 002	NOV 02, 1984
AB		500MG	N18894 003	NOV 02, 1984

TOLBUTAMIDE

TABLET; ORAL

	ORINASE			
	@ PHARMACIA AND UPJOHN	500MG	N10670 001	
AB	+ UPJOHN	500MG	N10670 001	
	TOLBUTAMIDE			
AB	BARR	500MG	N87121 001	
	@	500MG	N87121 001	
AB	EON LABS	500MG	N12678 001	
AB	+ EON LABS MFG	500MG	N12678 001	
AB	SUPERPHARM	500MG	N88893 001	NOV 19, 1984
	@	500MG	N88893 001	NOV 19, 1984

TOLMETIN SODIUM

TABLET; ORAL

	TOLMETIN SODIUM			
AB	BAKER NORTON	EQ 600MG BASE	N74399 001	MAR 28, 1996

TOPIRAMATE

TABLET; ORAL

	TOPAMAX			
	JOHNSON RW	25MG	N20505 004	DEC 24, 1996
	@	50MG	N20505 005	DEC 24, 1996
		100MG	N20505 001	DEC 24, 1996
	+	200MG	N20505 002	DEC 24, 1996

> ADD > TOPIRAMATE

> ADD > TABLET; ORAL
> ADD > TOPAMAX
> ADD > @ JOHNSON RW 300MG N20505 003
> ADD > DEC 24, 1996

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
HYCAMTIN
\+ SMITHKLINE BEECHAM EQ 4MG BASE/VIAL N20671 001
MAY 28, 1996

TRANDOLAPRIL

TABLET; ORAL
MAVIK
KNOLL PHARM 1MG N20528 001
APR 26, 1996
2MG N20528 002
APR 26, 1996
\+ 4MG N20528 003
APR 26, 1996

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
TARKA
\+ KNOLL PHARM 1MG;240MG N20591 003
OCT 22, 1996
\+ 2MG;180MG N20591 001
OCT 22, 1996
\+ 2MG;240MG N20591 004
OCT 22, 1996
\+ 4MG;240MG N20591 002
OCT 22, 1996

TRANEXAMIC ACID

TABLET; ORAL
CYKLOKAPRON
\+ PHARMACIA 500MG N19280 001
DEC 30, 1986

TRANEXAMIC ACID

TABLET; ORAL
CYKLOKAPRON
@ PHARMACIA AND UPJOHN 500MG N19280 001
DEC 30, 1986

TRETINOIN

CREAM; TOPICAL
RENOVA
J AND J 0.05% N19963 001
DEC 29, 1995

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
FLUTEX
AT SYOSSET 0.025% N85539 001
AT 0.1% N85539 002
AT 0.5% N85539 003
AT ZENITH GOLDLINE 0.025% N85539 001
AT 0.1% N85539 002
AT 0.5% N85539 003
KENALOG-H
AT APOTHECON 0.1% N86240 001
@ 0.1% N86240 001
TRIATEX
AT SYOSSET 0.025% N87430 001
NOV 01, 1988
AT 0.1% N87429 001
NOV 01, 1988
AT 0.5% N87428 001
NOV 01, 1988
AT ZENITH GOLDLINE 0.025% N87430 001
NOV 01, 1988
AT 0.1% N87429 001
NOV 01, 1988
AT 0.5% N87428 001
NOV 01, 1988

OINTMENT; TOPICAL
ARISTOCORT A
AT LEDERLE 0.5% N80745 003
AT \+ 0.5% N80745 003
FLUTEX
AT SYOSSET 0.025% N87375 001
NOV 01, 1988

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

	FLUTEX			
AT	SYOSSET	0.1%	N87377 001	NOV 01, 1988
AT		0.5%	N87376 001	NOV 01, 1988
AT	ZENITH GOLDLINE	0.025%	N87375 001	NOV 01, 1988
AT		0.1%	N87377 001	NOV 01, 1988
AT		0.5%	N87376 001	NOV 01, 1988
	KENALOG			
AT	* APOTHECON	0.5%	N83944 001	
	@	0.5%	N83944 001	

SPRAY, METERED; NASAL

	NASACORT AQ			
	+ RHONE POULENC RORER	0.055MG/INH	N20468 001	MAY 20, 1996

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

	TRIFLUOPERAZINE HCL			
AB	INVAMED	EQ 1MG BASE	N40153 001	OCT 25, 1996
AB		EQ 2MG BASE	N40153 002	OCT 25, 1996
AB		EQ 5MG BASE	N40153 003	OCT 25, 1996
AB		EQ 10MG BASE	N40153 004	OCT 25, 1996

TRIMETHOPRIM

TABLET; ORAL

	TRIMETHOPRIM			
AB	BARR	100MG	N70494 001	JAN 22, 1986
	@	100MG	N70494 001	JAN 22, 1986

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL

	TRIPLE SULFA			
AT	ALPHARMA	3.7%;2.86%;3.42%	N87864 001	SEP 01, 1982
AT	NMC	3.7%;2.86%;3.42%	N87864 001	SEP 01, 1982

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

	TRIPROLIDINE HCL			
	HALSEY	1.25MG/5ML	N88735 001	JAN 17, 1985
	@	1.25MG/5ML	N88735 001	JAN 17, 1985

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET; ORAL

	TRIPLE SULFOID			
AB	PAL PAK	167MG;167MG;167MG	N80094 001	
AB	VALE	167MG;167MG;167MG	N80094 001	

UREA, C-13

POWDER FOR RECONSTITUTION; ORAL

	MERETEK UBT KIT (W/ PRANACTIN)			
	+ MERETEK	125MG/VIAL	N20586 001	SEP 17, 1996

UROFOLLITROPIN

INJECTABLE; INJECTION

	METRODIN			
	+ SERONO	75 IU/AMP	N19415 002	SEP 18, 1986
		150 IU/AMP	N19415 003	SEP 18, 1986

INJECTABLE; INTRAMUSCULAR

	METRODIN			
	+ SERONO	75 IU/AMP	N19415 002	SEP 18, 1986

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR
METRODIN
+ SERONO 150 IU/AMP N19415 003 SEP 18, 1986

INJECTABLE; SUBCUTANEOUS
FERTINEX
+ SERONO 75 IU/AMP N19415 005 AUG 23, 1996
150 IU/AMP N19415 004 AUG 23, 1996

> ADD > VALPROATE SODIUM

> ADD > INJECTABLE; INJECTION
> ADD > DEPACON
> ADD > + ABBOTT EQ 100MG BASE/ML N20593 001 DEC 30, 1996

> ADD > VALSARTAN

> ADD > CAPSULE; ORAL
> ADD > DIOVAN
> ADD > CIBA GEIGY 80MG N20665 001 DEC 23, 1996
> ADD > + 160MG N20665 002 DEC 23, 1996

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN
> DLT > + ELAN PHARM 120MG N19614 001 MAY 29, 1990
> DLT > + 180MG N19614 003 JAN 09, 1992
> DLT > + 240MG N19614 002 MAY 29, 1990
> ADD > + LEDERLE 120MG N19614 001 MAY 29, 1990
> ADD > + 180MG N19614 003 JAN 09, 1992
> ADD > + 240MG N19614 002 MAY 29, 1990

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN
+ LEDERLE 360MG N19614 004 MAY 10, 1996

TABLET; ORAL
VERAPAMIL HCL
AB BARR **80MG** **N70482 001** SEP 24, 1986
AB **120MG** **N70483 001** SEP 24, 1986
@ 80MG N70482 001 SEP 24, 1986
@ 120MG N70483 001 SEP 24, 1986
AB SIDMAK LABS NJ **40MG** **N72751 001** FEB 23, 1996

TABLET, EXTENDED RELEASE; ORAL
COVERA-HS
BC SEARLE 180MG N20552 001 FEB 26, 1996
BC 240MG N20552 002 FEB 26, 1996

VERAPAMIL HCL
AB MYLAN **240MG** **N74587 001** MAR 23, 1996
AB SIDMAK LABS NJ **240MG** **N72922 001** MAR 01, 1996

VIDARABINE

INJECTABLE; INJECTION
VIRA-A
+ PARKE DAVIS EQ 187.4MG BASE/ML N50523 001
@ EQ 187.4MG BASE/ML N50523 001

WARFARIN SODIUM

TABLET; ORAL
COUMADIN
DUPONT MERCK 3MG N09218 025 NOV 18, 1996
6MG N09218 026 NOV 18, 1996

ZAFIRLUKAST

TABLET; ORAL			
ACCOLATE			
+	ZENECA	20MG	N20547 001 SEP 26, 1996

ZIDOVUDINE

TABLET; ORAL			
RETROVIR			
+	GLAXO WELLCOME	300MG	N20518 002 OCT 04, 1996

> ADD > ZILEUTON

> ADD >	TABLET; ORAL		
> ADD >	ZYFLO		
> ADD >	ABBOTT	300MG	N20471 001 DEC 09, 1996
> ADD >	+	600MG	N20471 003 DEC 09, 1996

ASPIRIN

TABLET, EXTENDED RELEASE; ORAL

	8-HOUR BAYER		
+	BAYER	650MG	N16030 001
+	STERLING	650MG	N16030 001
	MEASURIN		
+	BAYER	650MG	N16030 002
+	STERLING	650MG	N16030 002

BENTOQUATAM

LOTION; TOPICAL

	IVY BLOCK		
+	ENVIRODERM	5%	N20532 001 AUG 26, 1996

BROMPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

	DIMETANE		
+	ROBINS AH	8MG	N10799 010 JUN 10, 1983
+		12MG	N10799 011 JUN 10, 1983
@	WHITEHALL ROBINS	8MG	N10799 010 JUN 10, 1983
	DIMETAPP		
+	WHITEHALL ROBINS	12MG	N10799 011 JUN 10, 1983

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL

	DIMETAPP		
+	ROBINS AH	2MG/5ML;12.5MG/5ML	N13087 003 MAR 29, 1984
+	WHITEHALL ROBINS	2MG/5ML;12.5MG/5ML	N13087 003 MAR 29, 1984

TABLET, EXTENDED RELEASE; ORAL

	DIMETAPP		
+	ROBINS AH	12MG;75MG	N12436 003 MAY 14, 1985
+	WHITEHALL ROBINS	12MG;75MG	N12436 003 MAY 14, 1985

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE		
+	ALZA	16MG;240MG	N19672 001 MAR 29, 1996

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CODIMAL-L.A. 12		
	CENT PHARMS	12MG;120MG	N18935 001 APR 15, 1985
+		12MG;120MG	N18935 001 APR 15, 1985
	PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE		
+	CENT PHARMS	8MG;120MG	N19428 001 AUG 02, 1988
	PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE		
+	GRAHAM	8MG;120MG	N18844 001 MAR 20, 1985
+		12MG;120MG	N18843 001 MAR 18, 1985
@		8MG;120MG	N18844 001 MAR 20, 1985
@		12MG;120MG	N18843 001 MAR 18, 1985
	PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE		
	CENT PHARMS	8MG;120MG	N19428 001 AUG 02, 1988

CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

	CORSYM		
@	PISONS	EQ 4MG MALEATE/5ML; EQ 37.5MG HCL/5ML	N18050 001 JAN 04, 1984
@	MEDEVA PHARMS	EQ 4MG MALEATE/5ML; EQ 37.5MG HCL/5ML	N18050 001 JAN 04, 1984

CIMETIDINE

TABLET; ORAL
TAGAMET HB
* SMITHKLINE BEECHAM 100MG N20238 001 JUN 19, 1995
100MG N20238 001 JUN 19, 1995
+ 200MG N20238 002 AUG 21, 1996

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
TAVIST-D
SANDOZ 1.34MG;75MG N20640 001 AUG 09, 1996

CLOTRIMAZOLE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
GYNE-LOTRIMIN 3 COMBINATION PACK
+ SCHERING PLOUGH 1%,200MG N20526 002 JUL 29, 1996

SUPPOSITORY; VAGINAL
GYNE-LOTRIMIN
+ SCHERING PLOUGH 100MG N17717 002 NOV 30, 1990

GYNE-LOTRIMIN 3
+ SCHERING PLOUGH 200MG N20525 001 JUL 29, 1996

MYCELEX-7
BAYER 100MG N18182 002 DEC 26, 1991

TABLET, VAGINAL
GYNE-LOTRIMIN
* SCHERING PLOUGH 100MG N17717 002 NOV 30, 1990

MYCELEX-7
BAYER 100MG N18182 002 DEC 26, 1991

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
DELSYM
* FISONS EQ 30MG HBR/5ML N18658 001
+ MEDEVA PHARMS EQ 30MG HBR/5ML N18658 001

DOXYLAMINE SUCCINATE

TABLET; ORAL
DOXYLAMINE SUCCINATE
PERRIGO 25MG N40167 001 SEP 18, 1996

IBUPROFEN

CAPSULE; ORAL
MIDOL
@ BAYER 200MG N70626 001 SEP 02, 1987
@ 200MG N71002 001 SEP 02, 1987
@ WINTHROP 200MG N70626 001 SEP 02, 1987
@ 200MG N71002 001 SEP 02, 1987

PROVEL
* SANDOZ 200MG N20402 001 APR 20, 1995
@ 200MG N20402 001 APR 20, 1995

SUSPENSION; ORAL
CHILDREN'S ADVIL
WHITEHALL ROBINS 100MG/5ML N20589 001 JUN 27, 1996

SUSPENSION/DROPS; ORAL
CHILDREN'S MOTRIN
+ MCNEIL CONS PRODS 40MG/ML N20603 001 JUN 10, 1996

TABLET; ORAL
IBUPROFEN
BARR 200MG N70493 001 DEC 24, 1985

IBUPROFEN

TABLET; ORAL
IBUPROFEN

	BARR	200MG	N70908 001 SEP 26, 1986
		200MG	N71462 001 OCT 02, 1986
	@	200MG	N70493 001 DEC 24, 1985
	@	200MG	N70908 001 SEP 26, 1986
	@	200MG	N71462 001 OCT 02, 1986
	HALSEY	200MG	N71027 001 SEP 29, 1987
	@	200MG	N71027 001 SEP 29, 1987
	@ LEMMON	200MG	N73141 001 MAY 29, 1992
	MCNEIL CONS PRODS	200MG	N73019 001 MAR 30, 1994
	+	200MG	N73019 001 MAR 30, 1994
	TAG PHARMS	200MG	N73141 001 MAY 29, 1992
> ADD >	JUNIOR STRENGTH ADVIL		
> ADD >	WHITEHALL ROBINS	100MG	N20267 002 DEC 13, 1996
> ADD >			
	JUNIOR STRENGTH MOTRIN		
	MCNEIL CONS PRODS	100MG	N20602 001 JUN 10, 1996
	MIDOL		
	@ BAYER	200MG	N70591 001 SEP 02, 1987
	@	200MG	N71001 001 SEP 02, 1987
	@ WINTHROP	200MG	N70591 001 SEP 02, 1987
	@	200MG	N71001 001 SEP 02, 1987
	NUPRIN		
	+ BRISTOL MYERS	200MG	N72035 001 FEB 16, 1988
		200MG	N72035 001 FEB 16, 1988

TABLET, CHEWABLE; ORAL
CHILDREN'S MOTRIN

	MCNEIL CONS PRODS	50MG	N20601 001 NOV 15, 1996

IBUPROFEN

TABLET, CHEWABLE; ORAL
JUNIOR STRENGTH MOTRIN

	MCNEIL CONS PRODS	100MG	N20601 002 NOV 15, 1996

INSULIN PURIFIED BEEF

INJECTABLE; INJECTION
REGULAR ILETIN II

	+ LILLY	100 UNITS/ML	N18478 001
	@	100 UNITS/ML	N18478 001

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
NOVOLIN N

	+ NOVO NORDISK	100 UNITS/ML	N19065 001 JAN 23, 1985
	@	100 UNITS/ML	N19065 001 JAN 23, 1985

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION
PROTAMINE ZINC INSULIN

	+ SQUIBB	40 UNITS/ML	N17928 001
	+	100 UNITS/ML	N17928 003
	@	40 UNITS/ML	N17928 001
	@	100 UNITS/ML	N17928 003

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION
LENTE INSULIN

> DLT >	+ NOVO NORDISK	100 UNITS/ML	N17998 003
> DLT >	@	100 UNITS/ML	N17998 003
> DLT >			
> ADD >			

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION
ULTRALENTE

	+ NOVO NORDISK	100 UNITS/ML	N18385 001

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION			
ULTRALENTE			
@ NOVO NORDISK	100 UNITS/ML	N18385 001	> ADD >
			> ADD >

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE; INJECTION			
SEMILENTE			
+ NOVO NORDISK	100 UNITS/ML	N18382 001	
@	100 UNITS/ML	N18382 001	

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION			
LENTE ILETIN II			
@ LILLY	100 UNITS/ML	N18477 001	
+	100 UNITS/ML	N18477 001	

MICONAZOLE NITRATE

CREAM; VAGINAL			
MICONAZOLE 7			
NMC	2%	N74164 001	
		MAR 29, 1996	
MICONAZOLE NITRATE			
GW LABS	2%	N74366 001	
		FEB 22, 1996	
CREAM, SUPPOSITORY; TOPICAL, VAGINAL			
MONISTAT-3 COMBINATION PACK			
+ ADV CARE	2%,200MG	N20670 002	
		APR 16, 1996	

MINOXIDIL

SOLUTION; TOPICAL			
MINOXIDIL (FOR MEN)			
ALPHARMA	2%	N74588 001	
		APR 05, 1996	
BAUSCH AND LOMB	2%	N74643 001	
		APR 09, 1996	
COPLEY PHARM	2%	N74500 001	
		MAY 23, 1996	

MINOXIDIL

SOLUTION; TOPICAL			
MINOXIDIL (FOR MEN)			
HI TECH PHARMA	2%	N74731 001	
		DEC 24, 1996	
LEMMON	2%	N74589 001	
		APR 05, 1996	
SIGHT PHARMS	2%	N74743 002	
		OCT 18, 1996	
MINOXIDIL (FOR WOMEN)			
SIGHT PHARMS	2%	N74743 001	
		OCT 18, 1996	
ROGAINE (FOR MEN)			
+ PHARMACIA AND UPJOHN	2%	N19501 002	
		FEB 09, 1996	
ROGAINE (FOR WOMEN)			
+ PHARMACIA AND UPJOHN	2%	N19501 003	
		FEB 09, 1996	

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC			
OCUHIST			
AKORN	0.025%;0.3%	N20485 001	
		JAN 31, 1996	
OPCON-A			
+ BAUSCH AND LOMB	0.027%;0.315%	N20065 001	
		JUN 08, 1994	
+	0.02675%;0.315%	N20065 001	
		JUN 08, 1994	

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL			
NICODERM CQ			
+ HOECHST MARION RSSL	7MG/24HR	N20165 006	
		AUG 02, 1996	
+	14MG/24HR	N20165 005	
		AUG 02, 1996	
+	21MG/24HR	N20165 004	
		AUG 02, 1996	
NICOTROL			
+ MCNEIL CONS PRODS	15MG/16HR	N20536 001	
		JUL 03, 1996	

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

	NICORETTE		
+	SMITHKLINE BEECHAM	EQ 2MG BASE	N18612 002 FEB 09, 1996
+		EQ 4MG BASE	N20066 002 FEB 09, 1996

NIZATIDINE

TABLET; ORAL

	AXID AR		
+	WHITEHALL ROBINS	75MG	N20555 001 MAY 09, 1996

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	EFIDAC 24 PSEUDOEPHEDRINE HCL		
+	ALZA	240MG	N20021 002 DEC 15, 1992
#	CIBA	240MG	N20021 002 DEC 15, 1992

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

	PSEUDO-12		
@	PISONS	EQ 60MG HCL/5ML	N19401 001 JUN 19, 1987
@	MEDEVA PHARMS	EQ 60MG HCL/5ML	N19401 001 JUN 19, 1987

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 12/ DEC '96

NO DECEMBER 1996 APPROVALS

LIST of ORPHAN PRODUCTS DESIGNATIONS and APPROVALS

January 1, 1996 thru December, 1996

NAME Generic Name TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
2'-deoxycytidine TN=	As a host-protective agent in the treatment of acute myelogenous leukemia.	Grant, Steven M.D. Massey Cancer Center, VCU P.O. Box 980230 Richmond, VA 23298 DD=09/09/96 MA= / /
9-nitro-20-(S)-camptothecin (9-NC) TN=	Treatment of pancreatic cancer.	Stehlin Foundation for Cancer Research 1315 Calhoun, Suite 1818 Houston, TX 77002 DD=09/16/96 MA= / /
Albendazole TN= Albenza	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	SmithKline Beecham Pharmaceuticals One Franklin Plaza P.O. Box 7929 Philadelphia, PA 19101 DD=01/17/96 MA=06/11/96
Albendazole TN= Albenza	Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.	SmithKline Beecham Pharmaceuticals One Franklin Plaza P.O. Box 7929 Philadelphia, PA 19101 DD=01/18/96 MA=06/11/96
Allopurinol sodium TN= Zyloprim for Injection	Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.	Glaxo Wellcome Inc. Five Moore Drive P.O. Box 13398 Research Triangle Park, NC 27709 DD=10/16/92 MA=05/17/96
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive fungal infections.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=12/03/96 MA=10/18/96
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive candidiasis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=06/27/96 MA= / /
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive zygomycosis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=05/06/96 MA= / /
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive coccidioidomycosis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=05/06/96 MA= / /
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive sporotrichosis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=09/23/96 MA= / /

LIST of ORPHAN PRODUCTS DESIGNATIONS and APPROVALS

January 1, 1996 thru December, 1996

NAME Generic Name TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive protothecosis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=08/21/96 MA= / /
Antihemophilic factor (human) TN= Alphanate	Treatment of von Willebrand's disease.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles, CA 90032 DD=01/05/96 MA= / /
Arcitumomab TN= 99m Tc-labeled CEA-Scan	Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.	Immunomedics, Inc. 300 American Road Morris Plains, NJ 07950 DD=05/10/96 MA= / /
Betaine TN= Cystadane	Treatment of homocystinuria.	Orphan Medical 13911 Ridgedale Drive, Suite 475 Minnetonka, MN 55305 DD=05/16/94 MA=10/25/96
Bleomycin sulfate TN= Blenoxane	Treatment of malignant pleural effusion.	Bristol-Myers Squibb P.O. Box 4000 Princeton, NJ 08543 DD=09/17/93 MA=02/20/96
Buffered intrathecal electrolyte/dextrose injection TN= Elliotts B Solution	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma.	Orphan Medical 13911 Ridgedale Drive Minnetonka, MN 55305 DD=08/24/94 MA=09/27/96
C1 esterase inhibitor (human) TN=	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles, CA 90032 DD=08/21/96 MA= / /
Clonidine TN= Duraclon	For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=01/24/89 MA=10/02/96
Clostridial collagenase TN=	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	Hurst, L. M.D. & Badalamente, M. Ph.D. State University of New York at Stony Brook School of Medicine, Health Sciences Center T18-020 Stony Brook, NY 11794 DD=05/23/96 MA= / /
Collagenase (lyophilized) for injection TN= Plaquase	Treatment of Peyronie's disease.	Advance Biofactures Corporation 35 Wilbur Street Lynbrook, NY 11563 DD=03/12/96 MA= / /

LIST of ORPHAN PRODUCTS DESIGNATIONS and APPROVALS

January 1, 1996 thru December, 1996

NAME Generic Name TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
Corticorelin ovine triflutate TN= Acthrel	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 Suffern, NY 10901 DD=11/24/89 MA=05/23/96
DAB389IL-2 TN=	Treatment of cutaneous T-cell lymphoma.	Seragen, Inc. 97 South Street Hopkinton, MA 01748 DD=08/21/96 MA= / /
DMP 777 TN=	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	DuPont Merck Pharmaceutical Company Dupont Merck Plaza, Maple Run 2110 Wilmington, DE 19805 DD=06/04/96 MA= / /
Daunorubicin citrate liposome injection TN= DaunoXome	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc. 650 Cliffside Drive San Dimas, CA 91773 DD=05/14/93 MA=04/08/96
Dihydrotestosterone TN= Androgel -DHT	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road, Suite 210 Buffalo Grove, IL 60089 DD=02/05/96 MA= / /
Etiocholanedione TN=	Treatment of Prader-Willi syndrome.	SuperGen, Inc. 3158 Des Plaines Avenue Suite 10 Des Plaines, IL 60018 DD=05/07/96 MA= / /
Filgrastim TN= Neupogen	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320 DD=11/07/96 MA= / /
Fosphenytoin TN=	For the acute treatment of patients with status epilepticus of the grand mal type.	Warner-Lambert Company 2800 Plymouth Road Ann Arbor, MI 48106 DD=06/04/91 MA=08/05/96
Ganciclovir intravitreal implant TN= Vitrasert Implant	Treatment of cytomegalovirus retinitis.	Chiron Vision 9342 Jeronimo Road Irvine, CA 92718 DD=06/07/95 MA=03/04/96
Glatiramer acetate TN= Copaxone	Treatment of multiple sclerosis.	Teva Pharmaceuticals USA 1510 Delp Drive Kulpsville, PA 19443 DD=11/09/87 MA=12/20/96

LIST of ORPHAN PRODUCTS DESIGNATIONS and APPROVALS

January 1, 1996 thru December, 1996

NAME Generic Name TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
Guspcrimus TN= Spanidin	Treatment of acute renal graft rejection episodes.	Bristol-Myers Squibb Company 5 Research Parkway P.O. Box 5100 Wallingford, CT 06492 DD=06/27/96 MA= / /
Human acid alpha-glucosidase TN=	Treatment of glycogen storage disease type II.	Pharming B.V. Niels Bohrweg 11-13 2333 CA Leiden The Netherlands, DD=09/10/96 MA= / /
Ibuprofen i.v. solution TN= Salprofen	Prevention of patent ductus arteriosus.	Farmacon, Inc. 90 Grove Street, Suite 109 Ridgefield, CT 06877 DD=10/29/96 MA= / /
Ibuprofen i.v. solution TN=	Treatment of patent ductus arteriosus.	Farmacon, Inc. 90 Grove Street Ridgefield, CT 06877 DD=10/29/96 MA= / /
Idoxuridinc TN=	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc. 225 East Deerpath, Suite 250 Lake Forest, IL 60045 DD=04/08/96 MA= / /
Imexon TN=	Treatment of multiple mycloma.	Amplimed Corporation 2321 Camino La Zorrela Tucson, AZ 85718 DD=11/08/96 MA= / /
Interferon beta-1a TN= Avonex	Treatment of multiple sclerosis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=12/16/91 MA=05/17/96
Interferon beta-1a TN= Rebif	Treatment of patients with secondary progressive multiple sclerosis.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=03/11/96 MA= / /
Interferon gamma-1b TN= Actimmune	Treatment of severe congenital osteopetrosis.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco, CA 94080 DD=09/30/96 MA= / /
KL4-surfactant TN=	Treatment of meconium aspiration syndrome in newborn infants.	Acute Therapeutics, Inc. 3359 Durham Road Doylestown, PA 18901 DD=07/30/96 MA= / /

LIST of ORPHAN PRODUCTS DESIGNATIONS and APPROVALS

January 1, 1996 thru December, 1996

NAME Generic Name TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
L-2-oxothiazolidine-4-carboxylic acid TN= Procysteine	Treatment of amyotrophic lateral sclerosis.	Transcend Therapeutics, Inc. 640 Memorial Drive, 3rd Floor West Cambridge, MA 02139 DD=07/30/96 MA= / /
Leflunomide TN=	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	James W. Williams, M.D. 655 Superior Oak Park, IL 60302 DD=10/18/96 MA= / /
Lipid/DNA human cystic fibrosis gene TN=	Treatment of cystic fibrosis.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=04/08/96 MA= / /
Liposomal amphotericin B TN= AmBisome	Treatment of cryptococcal meningitis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=12/10/96 MA= / /
Liposomal amphotericin B TN= AmBisome	Treatment of visceral leishmaniasis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=12/06/96 MA= / /
Liposomal amphotericin B TN= AmBisome	Treatment of histoplasmosis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=12/10/96 MA= / /
Liposomal prostaglandin E1 injection TN=	Treatment of acute respiratory distress syndrome.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=04/25/96 MA= / /
Methionine/L-methionine TN=	Treatment of AIDS myelopathy.	Di Rocco, Alessandro M.D. The Mount Sinai Medical Center One Gustave L. Levy Place, Box 1139 New York, NY 10029 DD=08/21/96 MA= / /
Methylnaltrexone TN=	Treatment of chronic opioid-induced constipation unresponsive to conventional therapy.	The University of Chicago 5841 South Maryland Avenue MC 4028 Chicago, IL 60637 DD=06/17/96 MA= / /
Midodrine HCl TN= Amatine	Treatment of patients with symptomatic orthostatic hypotension.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown, NJ 07724 DD=12/05/96 MA=09/06/96

LIST of ORPHAN PRODUCTS DESIGNATIONS and APPROVALS

January 1, 1996 thru December, 1996

NAME Generic Name TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
Mitoxantrone TN= Novantrone	Treatment of hormone refractory prostate cancer.	Immunex Corporation 51 University Street Seattle, WA 98101 DD=08/21/96 MA=11/13/96
Monoclonal antibody-B43.13 TN= Ovarex MAb-B43.13	Treatment of epithelial ovarian cancer.	AltaRex, Inc. 1134 Dentistry-Pharmacy Building University of Alberta Edmonton, Alberta, Canada, DD=11/25/96 MA= / /
N-acetyl-procainamide TN=	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induce lupus.	NAPA of the Bahamas 3560 Pennsylvania Avenue, Suite 7 Dubuque, IA 52002 DD=12/10/96 MA= / /
Nitazoxanide TN=	Treatment of immunocompromised patients with cryptosporidiosis.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road, Suite 210 Buffalo Grove, IL 60089 DD=12/12/96 MA= / /
Ofloxacin TN= Ocuflox Ophthalmic Solution	Treatment of bacterial corneal ulcers.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92713 DD=04/18/91 MA=05/22/96
Pentosan polysulfate sodium TN= Elmiron	Treatment of interstitial cystitis.	Baker Norton Pharmaceuticals 4400 Biscayne Boulevard Miami, FL 33137 DD=08/07/85 MA=09/26/96
Polifeprosan 20 with carmustine TN= Gliadel	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc. 6611 Tributary Street Baltimore, MD 21224 DD=12/13/89 MA=09/23/96
Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation TN= NeuroCell-PD	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin, Inc. Building 39, 13th Street Charlestown, MA 02129 DD=12/17/96 MA= / /
Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation. TN= NeuroCell-PD	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin, Inc. Building 96, 13th Street Charlestown Navy Yard Charlestown, MA 02129 DD=12/17/96 MA= / /

LIST of ORPHAN PRODUCTS DESIGNATIONS and APPROVALS

January 1, 1996 thru December, 1996

NAME Generic Name TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebrall implantation TN= NeuroCell-HD	Treatment of Huntington's disease.	Diacrin, Inc. Building 96, 13th Street Charlestown, MA 02129 DD=12/10/96 MA= / /
Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease. TN= NeuroCell-HD	Treatment of Huntington's disease.	Diacrin, Inc. Building 96, 13th Street Charlestown Navy Yard Charlestown, MA 02129 DD=12/10/96 MA= / /
Prostaglandin E1 in lipid emulsion TN=	Treatment of ischemic ulceration of the lower limbs due to peripheral arterial disease.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles, CA 90032 DD=09/10/96 MA= / /
R-VIII SQ TN= REFACTO	For long-term and/or hospital treatment of hemophilia A or for treatment of patients with hemophilia A in connection with surgical procedures.	Pharmacia & Upjohn 7000 Portage Road Kalamazoo, MI 49001 DD=02/08/96 MA= / /
Recombinant human interleukin-11 TN= Neumega rhIL-11 Growth Factor	Prevention of severe chemotherapy-induced thrombocytopenia.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 DD=12/17/96 MA= / /
Respiratory syncytial virus immune globulin (human) TN= Respigam	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	MedImmune, Inc. 35 West Watkins Mill Road Gaithersburg, MD 20878 DD=09/27/90 MA=01/18/96
Rifapentine TN=	Prophylactic treatment of Mycobacterium avium complex in patients with acquired immunodeficiency syndrome and a CD4+ count less than or equal to 75/mm3.	Marion Merrell Dow Inc. P.O. Box 9627 (Park A) Kansas City, MO 64137 DD=03/12/96 MA= / /
Riluzole TN= Rilutek	Treatment of Huntington's disease.	Rhone-Poulenc Rorer Pharmaceuticals, Inc. 500 Arcola Road Collegeville, PA 19426 DD=10/15/96 MA= / /
SU101 TN=	Treatment of ovarian cancer.	Sugen, Inc. 515 Galveston Drive Redwood City, CA 94063 DD=03/12/96 MA= / /
Sodium phenylbutyrate TN= Buphenyl	Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.	Ucyclyd Pharma 10819 Gilroy Road Suite 100 Hunt Valley, MD 21031 DD=11/22/93 MA=04/30/96

LIST of ORPHAN PRODUCTS DESIGNATIONS and APPROVALS

January 1, 1996 thru December, 1996

NAME Generic Name TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
Somatropin for injection TN= Nutropin	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco, CA 94080 DD=03/23/89 MA=12/30/96
Somatropin for injection TN= Serostim	Treatment of AIDS-associated catabolism/weight loss.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=11/15/91 MA=08/23/96
Somatropin for injection TN= Serostim	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=03/26/96 MA= / /
Somatropin for injection TN= Nutropin	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco, CA 94080 DD=11/18/96 MA= / /
Testosterone TN= Androgel	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road Buffalo Grove, IL 60089 DD=02/05/96 MA= / /
Thalidomide TN= Synovir	Treatment of HIV-associated wasting syndrome.	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren, NJ 07059 DD=03/11/96 MA= / /
Uridine 5'-triphosphate TN=	To facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.	Inspire Pharmaceuticals, Inc. 4222 Emperor Boulevard, Suite 470 Durham, NC 27703 DD=06/26/96 MA= / /
Valine, isoleucine and leucine TN= VIL	Treatment of hyperphenylalaninemia.	Leas Research Products 4 Brookview Lane Troy, NY 12180 DD=01/05/96 MA= / /

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO DECEMBER 1996 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 7500 STANDISH PLACE, ROCKVILLE, MD 20855. COPIES OF THESE GUIDANCES MAY ALSO BE OBTAINED FROM THE DIVISION OF COMMUNICATION MANAGEMENT, CENTER FOR DRUG EVALUATION AND RESEARCH, FDA, 5600 FISHERS LANE (HFD-210) ROCKVILLE, MD 20857 OR BY CALLING (301) 827-4573, FAX: (301) 827-4577.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 16TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

CLOZAPINE *IN VITRO* AND *IN VIVO* (TABLET)	NOV 15, 1995	NOV 15, 1996

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 1-23, PARK BUILDING, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 16TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACETAMINOPHEN; BUTALBITAL; CAFFEINE SOLUTION; ORAL	325MG/15ML 50MG/15ML 40MG/15ML	96 P-0208/ CP1	MIKART	NEW DOSAGE FORM	APPROVED OCT 10, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	325MG 50MG 40MG 7.5MG	95 P-0279/ CP2	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	325MG 50MG 40MG 10MG	95 P-0279/ CP1	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	500MG 50MG 40MG 7.5MG	95 P-0279/ CP4	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	500MG 50MG 40MG 10MG	95 P-0279/ CP3	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 50MG 40MG 7.5MG	95 P-0279/ CP2	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 50MG 40MG 10MG	95 P-0279/ CP1	MIKART	NEW COMBIANTION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08. 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	500MG 50MG 40MG 7.5MG	95 P-0279/ CP4	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	500MG 50MG 40MG 10MG	95 P-0279/ CP3	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08,1996
ACETAMINOPHEN; HYDROCODONE BITARTRATE CAPSULE; ORAL	325MG 5MG	95 P-0278/ CP1	MIKART	NEW STRENGTH	APPROVED MAY 28, 1996
ACYCLOVIR SODIUM INJECTABLE; INJECTION	EQ 5MG BASE/ML (100ML/CONTAINER) (200ML/CONTAINER)	95 P-0268/ CP1	WILMER, CUTLER, & PICKERING	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 27, 1996
ACYCLOVIR SODIUM INJECTABLE; INJECTION	EQ 250MG/VIAL	96 P-0284/ CP1	ABBOTT	NEW STRENGTH	APPROVED OCT 10, 1996
ASPIRIN; BUTALBITAL CAPSULE; ORAL	650MG 50MG	96 P-0021/ CP1	SAVAGE	NEW DOSAGE FORM	APPROVED APR 19, 1996
ATRACURIUM BESYLATE INJECTABLE; INJECTION	0.5MG/ML 1MG/ML (100ML CONTAINER)	95 P-0372/ CP1	ABBOTT	NEW STRENGTH	APPROVED MAR 08, 1996
CARBIDOPA; LEVODOPA POWDER FOR RECONSTITUTION; ORAL	25MG/PACKET 100MG/PACKET	95 P-0100/ CP1	ATHENA	NEW DOSAGE FORM	APPROVED MAY 28, 1996
CARBIDOPA; LEVODOPA POWDER FOR RECONSTITUTION; ORAL	25MG/PACKET 250MG/PACKET	95 P-0100/ CP1	ATHENA	NEW DOSAGE FORM	APPROVED MAY 28, 1996
CHOLESTYRAMINE TABLET, CHEWABLE; ORAL	EQ 2GM RESIN	95 P-0277/ CP1	MAYRAND	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 27, 1996
CYTARABINE INJECTABLE; INJECTION	100MG/ML (1ML/VIAL) (5ML/VIAL)	92 P-0183/ CP1	FAULDING	NEW DOSAGE FORM NEW STRENGTH	APPROVED JUL 26, 1996
CYTARABINE INJECTABLE; INJECTION	100MG/ML (10ML/VIAL) (20ML/VIAL)	92 P-0184/ CP1	FAULDING	NEW DOSAGE FORM	APPROVED JUL 26, 1996
DILTIAZEM HYDROCHLORIDE INJECTABLE, INJECTION	5MG/ML (25ML/SYRINGE) (50ML/SYRINGE)	95 P-0196/ CP1	INTL MEDICATION	NEW STRENGTH	APPROVED FEB 27, 1996
EPINEPHRINE INJECTABLE; SUBCUTANEOUS	0.3MG/DELIVERY	95 P-0190/ CP1	SENETCK PLC	NEW ROUTE OF ADMINISTRATION	APPROVED FEB 15, 1996
ETOPOSIDE CAPSULE; ORAL	25MG	95 P-0142/ CP1	GUIDELINES	NEW STRENGTH	APPROVED SEP 12, 1996

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
HYDROCORTISONE BUTYRATE LOTION; TOPICAL	0.1%	95 P-0223/ CP1	MCKENNA & CUNEO	NEW DOSAGE FORM	APPROVED FEB 21, 1996
LACTULOSE CRYSTALS, FOR RECONSTITUTION; ORAL	20GM/PACKET	95 P-0287/ CP1	BENNETT	NEW DOSAGE FORM NEW STRENGTH	APPROVED APR 19, 1996
MEPERIDINE HYDROCHLORIDE INJECTABLE; INJECTION	10MG/ML (60ML/SYRINGE)	95 P-0348/ CP1	MALLINCKRODT	NEW STRENGTH	APPROVED MAR 08, 1996
METRONIDAZOLE LOTION; TOPICAL	0.75%	95 P-0328/ CP1	RNB PHARM	NEW DOSAGE FORM	APPROVED FEB 23, 1996
NIFEDIPINE CAPSULE, EXTENDED RELEASE; ORAL	30MG 60MG 90MG	95-P-0326/ CP1	KV	NEW DOSAGE FORM	APPROVED FEB 23, 1996
PACLITAXEL INJECTABLE; INJECTION	6MG/ML (16.7ML/VIAL) (33.3ML/VIAL) (50ML/VIAL)	95 P-0360/ CP1	ABBOTT	NEW STRENGTH	APPROVED APR 29, 1996
PENTOXIFYLLINE SUSPENSION, EXTENDED RELEASE; ORAL	400MG/PACKET	96 P-0079/ CP1	KV PHARM	NEW DOSAGE FORM	APPROVED AUG 13, 1996
POTASSIUM CHLORIDE CAPSULE, EXTENDED RELEASE; ORAL	20MEQ	96 P-0018/ CP1	KV PHARM	NEW DOSAGE FORM	APPROVED AUG 19, 1996
POTASSIUM CHLORIDE SUSPENSION, EXTENDED RELEASE; ORAL	10MEQ	96 P-0054/ CP1	KV PHARM	NEW DOSAGE FORM	APPROVED AUG 19, 1996

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
HYDROCODONE BITRATRATE; PHENYLEPHRINE HYDROCHLORIDE SOLUTION; ORAL	2.5MG/5ML 5MG/5ML	95 P-0336/ CP1	BOCK PHARMA	NEW COMBINATION	DENIED AUG 19, 1996
HYDROCODONE BITRATRATE; PHENYLEPHRINE HYDROCHLORIDE SOLUTION; ORAL	5MG/5ML 10MG/5ML	95 P-0336/ CP2	BOCK PHARMA	NEW COMBINATION	DENIED AUG 19, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19821 001	ACITRETIN; SORIATANE				NE	OCT 28, 1999
	19821 002	ACITRETIN; SORIATANE				NE	OCT 28, 1999
	19806 001	ACRIVASTINE; SEMPREX-D	4650807	MAR 26, 2008	U-93		
	20338 001	ADAPALENE; DIFFERIN	4717720	APR 10, 2006	U-134	NCE	MAY 31, 2001
	20380 001	ADAPALENE; DIFFERIN	4717720	APR 10, 2006	U-134	NCE	MAY 31, 2001
	20666 001	ALBENDAZOLE; ALBENZA				ODE	JUN 11, 2003
						NCE	JUN 11, 2001
	20291 001	ALBUTEROL SULFATE; COMBIVENT				NC	OCT 24, 1999
	20503 001	ALBUTEROL SULFATE; PROVENTIL-HFA	5225183	JUL 06, 2010			
	20298 001	ALLOPURINOL SODIUM; ZYLOPRIM				NDF	MAY 17, 1999
						ODE	MAY 17, 2003
	20700 001	ALPROSTADIL; MUSE	5474535	DEC 12, 2012	U-155	NDF	NOV 19, 1999
			5242391	SEP 07, 2010	U-155		
			4801587	JAN 31, 2007	U-155		
	20700 002	ALPROSTADIL; MUSE	5474535	DEC 12, 2012	U-155	NDF	NOV 19, 1999
			5242391	SEP 07, 2010	U-155		
			4801587	JAN 31, 2007	U-155		
	20700 003	ALPROSTADIL; MUSE	5474535	DEC 12, 2012	U-155	NDF	NOV 19, 1999
			5242391	SEP 07, 2010	U-155		
			4801587	JAN 31, 2007	U-155		
	20700 004	ALPROSTADIL; MUSE	5474535	DEC 12, 2012	U-155	NDF	NOV 19, 1999
			5242391	SEP 07, 2010	U-155		
			4801587	JAN 31, 2007	U-155		
	20221 001	AMIFOSTINE; ETHYOL				I-149	MAR 15, 1999
>ADD>	20511 001	AMLEXANOX; APHTHASOL				NCE	DEC 17, 2001
	19787 001	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007		I-156	JUN 14, 1999
	19787 002	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007		I-156	JUN 14, 1999
	19787 003	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007		I-156	JUN 14, 1999
	20508 001	AMMONIUM LACTATE; LAC-HYDRIN				NDF	AUG 29, 1999
>ADD>	50724 001	AMPHOTERICIN B; ABELCET				ODE	OCT 18, 2003
	20541 001	ANASTROZOLE; ARIMIDEX	4935437	JUN 10, 2008			
>ADD>	20702 001	ATORVASTATIN CALCIUM; LIPITOR				NCE	DEC 17, 2001
>ADD>	20702 002	ATORVASTATIN CALCIUM; LIPITOR				NCE	DEC 17, 2001
>ADD>	20702 003	ATORVASTATIN CALCIUM; LIPITOR				NCE	DEC 17, 2001
	20428 001	AZELAIC ACID; AZELEX	4386104	MAY 31, 2000	U-124		
	20114 001	AZELASTINE HYDROCHLORIDE; ASTELIN				NCE	NOV 01, 2001
	20075 001	BACLOFEN; LIORESAL				I-153	JUN 14, 1999
	20075 002	BACLOFEN; LIORESAL				I-153	JUN 14, 1999
	20469 001	BECLOMETHASONE DIPROPIONATE MONOHYDRATE; VANCENASE AQ				NP	JUN 26, 1999
	20532 001	BENTOQUATAM; IVY BLOCK				NCE	AUG 26, 2001
	20576 001	BETAINE, ANHYDROUS; CYSTADANE				NCE	OCT 25, 2001
						ODE	OCT 25, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20498 001	BICALUTAMIDE; CASODEX	4636505	JAN 13, 2004			
	50443 001	BLEOMYCIN SULFATE; BLENOXANE				ODE	FEB 20, 2003
	20613 001	BRIMONIDINE TARTRATE; ALPHAGAN				NCE	SEP 06, 2001
	19672 001	BROMPHENIRAMINE MALEATE; EFIDAC 24	4810502	MAR 14, 2006			
			4801461	MAR 14, 2006			
			4673405	MAR 18, 2003			
			4662880	MAR 14, 2006		NP	MAR 29, 1999
	20358 001	BUPROPION HYDROCHLORIDE; WELLBUTRIN	5427798	AUG 12, 2013			
			5358970	AUG 12, 2013			
			RE33994	AUG 18, 2004			
	20358 002	BUPROPION HYDROCHLORIDE; WELLBUTRIN	5427798	AUG 12, 2013			
			5358970	AUG 12, 2013			
			RE33994	AUG 18, 2004			
	20358 003	BUPROPION HYDROCHLORIDE; WELLBUTRIN	5427798	AUG 12, 2013			
			5358970	AUG 12, 2013			
			RE33994	AUG 18, 2004			
	18731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
			4182763	MAY 22, 2000	U-13		
	18731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
			4182763	MAY 22, 2000	U-13		
	18731 003	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
			4182763	MAY 22, 2000	U-13		
	18731 004	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
			4182763	MAY 22, 2000	U-13		
	20524 001	BUTENAFINE HYDROCHLORIDE; MENTAX				NCE	OCT 18, 2001
>ADD>						I-175	DEC 31, 1999
	19215 001	BUTOCONAZOLE NITRATE; FEMSTAT	4078071	MAR 07, 1997			
	19359 001	BUTOCONAZOLE NITRATE; FEMSTAT	4078071	MAR 07, 1997			
	20421 001	BUTOCONAZOLE NITRATE; FEMSTAT 3	4078071	MAR 07, 1997		NP	DEC 21, 1998
>ADD>	20664 001	CABERGOLINE; DOSTINEX				NCE	DEC 23, 2001
	20273 001	CALCIPOTRIENE; DOVONEX	4866048	DEC 29, 2007	U-88	NCE	DEC 29, 1998
	20554 001	CALCIPOTRIENE; DOVONEX	4866048	SEP 12, 2006		NDF	JUL 22, 1999
	18874 001	CALCITRIOL; CALCIJEX	4308264	JAN 28, 2001			
	18874 002	CALCITRIOL; CALCIJEX	4308264	JAN 28, 2001			
	20577 001	CALCIUM CHLORIDE; ELLIOTTS B SOLUTION				ODE	SEP 27, 2003
	18343 004	CAPTOPRIL; CAPOTEN				I-95	SEP 23, 1996
						I-101	JAN 28, 1997
	18343 007	CAPTOPRIL; CAPOTEN				I-95	SEP 23, 1996
						I-101	JAN 28, 1997
	20234 001	CARBAMAZEPINE; TEGRETOL-XR	5284662	FEB 08, 2011			
			RE34990	JUL 29, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20234 002	CARBAMAZEPINE; TEGRETOL-XR	5284662	FEB 08, 2011			
			RE34990	JUL 29, 2007			
	20234 003	CARBAMAZEPINE; TEGRETOL-XR	5284662	FEB 08, 2011			
			RE34990	JUL 29, 2007			
	19880 001	CARBOPLATIN; PARAPLATIN	4140707	AUG 24, 1998			
	19880 002	CARBOPLATIN; PARAPLATIN	4140707	AUG 24, 1998			
	19880 003	CARBOPLATIN; PARAPLATIN	4140707	AUG 24, 1998			
>ADD>	20637 001	CARMUSTINE; GLIADEL	5179189	JAN 19, 2010		NP	SEP 23, 1999
>ADD>			4789724	JUL 12, 2005		ODE	SEP 23, 2003
>DLT>			~~4789724~~	~~JUL 12, 2005~~		~~ODE~~	~~AUG 23, 1999~~
	19835 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2002			
	19835 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2002			
	20346 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2002		NDF	SEP 27, 1999
						NCE	DEC 08, 2000
	20638 001	CIDOFOVIR; VISTIDE	5142051	AUG 25, 2009		NCE	JUN 26, 2001
	20238 002	CIMETIDINE; TAGAMET HB				NS	JUN 19, 1998
						I-137	NOV 15, 1998
	19847 001	CIPROFLOXACIN; CIPRO	4670444	DEC 09, 2003		I-167	OCT 10, 1999
	19857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%	4957922	SEP 18, 2007		I-167	OCT 10, 1999
	19858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLORIDE 0.9%	4670444	DEC 09, 2003		I-167	OCT 10, 1999
	19537 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-157	APR 08, 1999
						I-164	SEP 11, 1999
						I-167	OCT 10, 1999
	19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-157	APR 08, 1999
						I-164	SEP 11, 1999
						I-167	OCT 10, 1999
	19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-157	APR 08, 1999
						I-164	SEP 11, 1999
						I-167	OCT 10, 1999
	19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-157	APR 08, 1999
						I-164	SEP 11, 1999
						I-167	OCT 10, 1999
	20398 001	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
	20551 001	CISATRACURIUM BESYLATE; NIMBEX	5453510	SEP 26, 2012	U-127		
			4179507	DEC 18, 1996	U-127		
	20551 002	CISATRACURIUM BESYLATE; NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U-127		
			4179507	DEC 18, 1996	U-127		
	20551 003	CISATRACURIUM BESYLATE; NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U-127		
			4179507	DEC 18, 1996	U-127		
	18057 001	CISPLATIN; PLATINOL	5562925	MAY 08, 2012			
	18057 002	CISPLATIN; PLATINOL	5562925	MAY 08, 2012			
	18057 003	CISPLATIN; PLATINOL-AQ	5562925	MAY 08, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18057 004	CISPLATIN; PLATINOL-AQ	5562925	MAY 08, 2012			
>ADD>	17661 003	CLEMASTINE FUMARATE; TAVIST-1				I-171	OCT 31, 1999
>DLT>	~~17661 003~~	~~CLEMASTINE FUMARATE; TAVIST-1~~				~~I-151~~	~~OCT 31, 1999~~
>ADD>	18298 002	CLEMASTINE FUMARATE; TAVIST-D				I-171	OCT 31, 1999
>DLT>	~~18298 002~~	~~CLEMASTINE FUMARATE; TAVIST-D~~				~~I-151~~	~~OCT 31, 1999~~
	20340 001	CLOBETASOL PROPIONATE; TEMOVATE E				D-32	MAY 03, 1999
	20615 001	CLONIDINE HYDROCHLORIDE; DURACLON				NDF	OCT 02, 1999
						ODE	OCT 02, 2003
	20525 001	CLOTRIMAZOLE; GYNE-LOTRIMIN 3				NP	JUL 29, 1999
	20526 002	CLOTRIMAZOLE; GYNE-LOTRIMIN 3 COMBINATION PACK				NP	JUL 29, 1999
>ADD>	20162 001	CORTICORELIN OVINE TRIFLUTATE; ACTHREL	4415558	JUN 08, 2001		NCE	MAY 23, 2001
	20479 001	CROMOLYN SODIUM; GASTROCROM	4515805	MAY 07, 2002	U-130		
			4421762	DEC 20, 2000	U-130		
>ADD>	19722 001	CYANOCOBALAMIN; NASCOBAL	4724231	APR 16, 2005	U-157		
	20287 001	DALTEPARIN SODIUM; FRAGMIN	4303651	JAN 04, 2005		NCE	DEC 22, 1999
						D-30	MAR 18, 1999
	20287 003	DALTEPARIN SODIUM; FRAGMIN	4303651	JAN 04, 2005		NCE	DEC 22, 1999
						D-30	MAR 18, 1999
>ADD>	20430 001	DANAPAROID SODIUM; ORGARAN				NCE	DEC 24, 2001
	50704 002	DAUNORUBICIN CITRATE; DAUNOXOME				ODE	APR 08, 2003
	20118 001	DESFLURANE; SUPRANE	4762856	FEB 02, 2007	U-67	NCE	SEP 18, 1997
	19955 001	DESMOPRESSIN ACETATE; DDAVP	5047398	SEP 10, 2008			
	19955 002	DESMOPRESSIN ACETATE; DDAVP	5047398	SEP 10, 2008			
	20071 001	DESOGESTREL; DESOGEN	3927046	NOV 19, 1995			
	20071 002	DESOGESTREL; DESOGEN	3927046	NOV 19, 1995			
	20301 001	DESOGESTREL; ORTHO-CEPT	3927046	NOV 19, 1995			
	20301 002	DESOGESTREL; ORTHO-CEPT	3927046	NOV 19, 1995			
	20344 001	DEXFENFLURAMINE HYDROCHLORIDE; REDUX	4309445	JUN 16, 2000	U-133		
	20037 001	DICLOFENAC SODIUM; VOLTAREN	4960799	OCT 02, 2007		I-163	JUL 23, 1999
	20254 001	DICLOFENAC SODIUM; VOLTAREN-XR				NDF	MAR 08, 1999
	20092 001	DILTIAZEM HYDROCHLORIDE; DILACOR XR	5422123	JUN 06, 2012			
	20092 002	DILTIAZEM HYDROCHLORIDE; DILACOR XR	5422123	JUN 06, 2012			
	20092 003	DILTIAZEM HYDROCHLORIDE; DILACOR XR	5422123	JUN 06, 2012			
	20401 001	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			
	20401 002	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			
	20401 003	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			
	20401 004	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			
	20401 005	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013		NS	SEP 11, 1998
	20506 001	DILTIAZEM MALATE; TIAMATE	4968507	JUL 25, 2006		NE	OCT 04, 1999
			4880631	SEP 24, 2007			
	20506 002	DILTIAZEM MALATE; TIAMATE	4968507	JUL 25, 2006		NE	OCT 04, 1999
			4880631	SEP 24, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20506 003	DILTIAZEM MALATE; TIAMATE	4968507	JUL 25, 2006		NE	OCT 04, 1999
			4880631	SEP 24, 2007			
	20507 001	DILTIAZEM MALATE; TECZEM	4983598	JAN 08, 2008			
			4968507	JUL 25, 2006			
			4880631	SEP 24, 2007			
			4472380	SEP 18, 2001		NC	OCT 04, 1999
			4374829	FEB 22, 2000	U-3	NE	OCT 04, 1999
	18723 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		I-41	MAR 18, 1999
	18723 002	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		I-41	MAR 18, 1999
	18723 003	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		I-41	MAR 18, 1999
	20449 001	DOCETAXEL; TAXOTERE	5403858	JUL 03, 2012			
			4814470	JUL 14, 2007		NCE	MAY 14, 2001
	20690 001	DONEPEZIL HYDROCHLORIDE; ARICEPT	4895841	JUN 20, 2008		NCE	NOV 25, 2001
	20690 002	DONEPEZIL HYDROCHLORIDE; ARICEPT	4895841	JUN 20, 2008		NCE	NOV 25, 2001
>ADD>	20668 001	ENALPRIL MALEATE; LEXXEL	4264611	JUN 19, 2001	U-3	NC	DEC 27, 1999
>ADD>			4803081	APR 03, 2007			
	20164 001	ENOXAPARIN SODIUM; LOVENOX	5389618	FEB 14, 2012			
			4692435	DEC 24, 2004	U-123		
			4486420	DEC 04, 2001	U-122		
>ADD>	20655 002	ESTRADIOL; ALORA				NS	OCT 28, 1997
	20472 001	ESTRADIOL; ESTRING				NDF	APR 26, 1999
	20538 001	ESTRADIOL; ESTRADIOL	5300291	APR 05, 2011		NS	OCT 28, 1997
			4994278	MAR 04, 2008			
			4994267	MAR 04, 2008			
			4814168	MAR 04, 2008			
	20538 002	ESTRADIOL; ESTRADIOL	5300291	APR 05, 2011			
			4994278	MAR 04, 2008			
			4994267	MAR 04, 2008			
			4814168	MAR 04, 2008			
	20538 003	ESTRADIOL; ESTRADIOL	5300291	APR 05, 2011		NS	OCT 28, 1997
			4994278	MAR 04, 2008			
			4994267	MAR 04, 2008			
			4814168	MAR 04, 2008			
	20538 004	ESTRADIOL; ESTRADIOL	5300291	APR 05, 2011			
			4994278	MAR 04, 2008			
			4994267	MAR 04, 2008			
			4814168	MAR 04, 2008			
>ADD>	20130 001	ETHINYL ESTRADIOL; ESTROSTEP 21	4962098	OCT 09, 2007	U-112	NP	OCT 09, 1999
>ADD>	20130 002	ETHINYL ESTRADIOL; ESTROSTEP FE	4962098	OCT 09, 2007	U-112	NP	OCT 09, 1999
	18922 002	ETODOLAC; LODINE				I-24	JUN 28, 1999
	18922 003	ETODOLAC; LODINE				I-24	JUN 28, 1999
	18922 004	ETODOLAC; LODINE				I-24	JUN 28, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20584 001	ETODOLAC; LODINE XL	4966768	OCT 30, 2007		NDF	OCT 25, 1999
	20584 002	ETODOLAC; LODINE XL	4966768	OCT 30, 2007		NDF	OCT 25, 1999
	20457 001	ETOPOSIDE PHOSPHATE; ETOPOPHOS	5041424	AUG 20, 2008	U-135		
			4904768	FEB 27, 2007		NE	MAY 17, 1999
	20195 001	FENTANYL CITRATE; FENTANYL	4671953	MAY 01, 2005	U-87	NDF	OCT 04, 1996
	20195 002	FENTANYL CITRATE; FENTANYL	4671953	MAY 01, 2005	U-87	NDF	OCT 04, 1996
	20195 003	FENTANYL CITRATE; FENTANYL	4671953	MAY 01, 2005	U-87	NDF	OCT 04, 1996
	20195 007	FENTANYL CITRATE; FENTANYL	4671953	MAY 01, 2005	U-87	NDF	OCT 04, 1996
	20416 001	FERUMOXIDES; FERIDEX I.V.	5248492	SEP 28, 2010		NCE	AUG 30, 2001
			5219554	JUN 15, 2010			
			5102652	FEB 06, 2009			
			5055288	OCT 08, 2008			
			4951675	AUG 28, 2007	U-143		
			4827945	MAY 09, 2006	U-144		
			4770183	SEP 13, 2005	U-145		
>ADD>	20410 001	FERUMOXSIL; GASTROMARK				NCE	DEC 06, 2001
	20625 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	5375693	AUG 03, 2012	U-138	NCE	JUL 25, 2001
			4254129	APR 10, 1999	U-139		
	20180 001	FINASTERIDE; PROSCAR	4760071	JUN 19, 2006			
	18936 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4626549	DEC 02, 2003	U-154	I-166	NOV 21, 1999
	18936 006	FLUOXETINE HYDROCHLORIDE; PROZAC	4626549	DEC 02, 2003	U-154	I-166	NOV 21, 1999
	18554 001	FLUTAMIDE; EULEXIN	4329364	MAY 11, 2001	U-23	I-168	JUN 21, 1999
	20548 001	FLUTICASONE PROPIONATE; FLOVENT	4335121	NOV 14, 2003		NP	MAR 27, 1999
	20548 002	FLUTICASONE PROPIONATE; FLOVENT	4335121	NOV 14, 2003		NP	MAR 27, 1999
	20548 003	FLUTICASONE PROPIONATE; FLOVENT	4335121	NOV 14, 2003		NP	MAR 27, 1999
	20261 001	FLUVASTATIN SODIUM; LESCOL				D-31	MAR 20, 1999
	20261 002	FLUVASTATIN SODIUM; LESCOL				D-31	MAR 20, 1999
	20450 001	FOSPHENYTOIN SODIUM; CEREBYX	4925860	AUG 05, 2007		ODE	AUG 05, 2003
			4260769	APR 07, 1998		NCE	AUG 05, 2001
	20235 001	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-125		
			4894476	MAY 02, 2008			
			4087544	JAN 17, 2001	U-86	NCE	DEC 30, 1998
	20235 002	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-125		
			4894476	MAY 02, 2008			
			4087544	JAN 17, 2001	U-86	NCE	DEC 30, 1998
	20235 003	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-125		
			4894476	MAY 02, 2008			
			4087544	JAN 17, 2001	U-86	NCE	DEC 30, 1998
	20123 001	GADODIAMIDE; OMNISCAN	4687659	MAY 04, 2007		D-29	FEB 05, 1999
						I-145	FEB 05, 1999
						I-144	FEB 05, 1999
	19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	4647447	MAR 03, 2004		I-146	FEB 28, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20569 001	GANCICLOVIR; VITRASERT	5378475	JAN 03, 2012		NP	MAR 04, 1999
						ODE	MAR 04, 2003
	20509 001	GEMCITABINE HYDROCHLORIDE; GEMZAR	5464826	NOV 07, 2012	U-146		
			4808614	FEB 28, 2006	U-146	NCE	MAY 15, 2001
	20509 002	GEMCITABINE HYDROCHLORIDE; GEMZAR	5464826	NOV 07, 2012	U-146		
			4808614	FEB 28, 2006	U-146	NCE	MAY 15, 2001
>ADD>	20622 001	GLATIRAMER ACETATE; COPAXONE				NCE	DEC 20, 2001
	20329 001	GLIPIZIDE; GLUCOTROL XL	5545413	JUL 02, 2008	U-150		
			5082668	SEP 16, 2003			
	20329 002	GLIPIZIDE; GLUCOTROL XL	5545413	JUL 02, 2008	U-150		
			5082668	SEP 16, 2003			
	19726 001	GOSERELIN ACETATE; ZOLADEX	5366734	NOV 22, 2011			
			4767628	AUG 30, 2005		I-88	FEB 02, 1996
	20578 001	GOSERELIN ACETATE; ZOLADEX	5366734	NOV 22, 2011			
			4767628	AUG 30, 2005			
	20239 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 29, 2007	U-89		
	20305 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 29, 2007	U-105		
	19836 001	HISTRELIN ACETATE; SUPPRELIN	4244946	JAN 13, 2000		NCE	DEC 24, 1996
	19836 002	HISTRELIN ACETATE; SUPPRELIN	4244946	JAN 13, 2000		NCE	DEC 24, 1996
	19836 003	HISTRELIN ACETATE; SUPPRELIN	4244946	JAN 13, 2000		NCE	DEC 24, 1996
	20589 001	IBUPROFEN; CHILDREN'S ADVIL	4788220	JUL 08, 2007		NP	JUN 16, 1998
	20601 001	IBUPROFEN; CHILDREN'S MOTRIN	5215755	JUN 01, 2010		NP	JUN 16, 1998
	20601 002	IBUPROFEN; JUNIOR STRENGTH MOTRIN	5215755	JUN 01, 2010		NP	JUN 16, 1998
	20602 001	IBUPROFEN; JUNIOR STRENGTH MOTRIN				NP	JUN 16, 1998
	20603 001	IBUPROFEN; CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
	20685 001	INDINAVIR SULFATE; CRIXIVAN	5413999	MAY 07, 2013	U-132	NCE	MAR 13, 2001
	20685 003	INDINAVIR SULFATE; CRIXIVAN	5413999	MAY 07, 2013	U-132	NCE	MAR 13, 2001
	20563 001	INSULIN LISPRO; HUMALOG	5514646	MAY 07, 2013	U-111	NCE	JUN 14, 2001
			5474978	JUN 16, 2014			
	20351 001	IODIXANOL; VISIPAQUE 270	5349085	SEP 20, 2011		NCE	MAR 22, 2001
			4396597	JUL 03, 1999			
			4278654	JUL 03, 1999			
	20351 002	IODIXANOL; VISIPAQUE 320	5349085	SEP 20, 2011		NCE	MAR 22, 2001
			4396597	JUL 03, 1999			
			4278654	JUL 03, 1999			
	18735 001	IOPAMIDOL; ISOVUE-M 200	4001323	JAN 04, 1996			
	18735 002	IOPAMIDOL; ISOVUE-300	4001323	JAN 04, 1996			
	18735 003	IOPAMIDOL; ISOVUE-370	4001323	JAN 04, 1996		D-28	MAY 15, 1998
	18735 004	IOPAMIDOL; ISOVUE-M 300	4001323	JAN 04, 1996			
	18735 007	IOPAMIDOL; ISOVUE-250	4001323	JAN 04, 1996			
	20327 001	IOPAMIDOL; ISOVUE-200	4001323	JAN 04, 1996			
	20327 002	IOPAMIDOL; ISOVUE-250	4001323	JAN 04, 1996			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20327 003	IOPAMIDOL; ISOVUE-300	4001323	JAN 04, 1996			
	20327 004	IOPAMIDOL; ISOVUE-370	4001323	JAN 04, 1996			
	20220 001	IOPROMIDE; ULTRAVIST 370	4364921	MAR 06, 2005	U-113	NCE	MAY 10, 2000
	20220 002	IOPROMIDE; ULTRAVIST 300	4364921	MAR 06, 2005	U-113	NCE	MAY 10, 2000
	20220 003	IOPROMIDE; ULTRAVIST 240	4364921	MAR 06, 2005	U-113	NCE	MAY 10, 2000
	20220 004	IOPROMIDE; ULTRAVIST 150	4364921	MAR 06, 2005	U-113	NCE	MAY 10, 2000
	20571 001	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR	4604463	JUL 05, 2004		NCE	JUN 14, 2001
	20083 001	ITRACONAZOLE; SPORANOX				I-155	SEP 28, 1998
	19645 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55		
	19698 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55	NR	DEC 07, 1997
	19698 002	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55	NR	DEC 07, 1997
>ADD>	19700 001	KETOROLAC TROMETHAMINE; ACULAR	4089969	MAY 16, 1997	U-75	I-176	DEC 31, 1999
	20564 001	LAMIVUDINE; EPIVIR	5047407	FEB 08, 2009			
	20596 001	LAMIVUDINE; EPIVIR	5047407	FEB 08, 2009			
	20241 001	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
	20241 002	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
	20241 003	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
	20241 004	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
	20241 005	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
	20241 006	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
>ADD>	20406 001	LANSOPRAZOLE; PREVACID	5433959	SEP 03, 2008			
			4689333	JUL 29, 2005	U-126	I-116	APR 08, 1999
>ADD>			4628098	MAY 10, 2009		NCE	MAY 10, 2000
>DEL>			~~4628098~~	~~JUL 29, 2005~~		~~NCE~~	~~MAY 10, 2000~~
>ADD>	20406 002	LANSOPRAZOLE; PREVACID	5433959	SEP 03, 2008			
			4689333	JUL 29, 2005	U-126	I-116	APR 08, 1999
>ADD>			4628098	MAY 10, 2009		NCE	MAY 10, 2000
>DEL>			~~4628098~~	~~JUL 29, 2005~~		~~NCE~~	~~MAY 10, 2000~~
	20597 001	LATANOPROST; XALATAN				NCE	JUN 05, 2001
>ADD>	19732 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5575987	NOV 19, 2013			
>ADD>	20011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5575987	NOV 19, 2013			
>ADD>	19943 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5575987	NOV 19, 2013			
>ADD>	20263 001	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5575987	NOV 19, 2013			
>ADD>	20263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5575987	NOV 19, 2013			
>ADD>	20263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5575987	NOV 19, 2013			
>ADD>	20263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5575987	NOV 19, 2013			
>ADD>	20263 005	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5575987	NOV 19, 2013			
>ADD>	20263 006	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5575987	NOV 19, 2013			
>ADD>	20517 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5575987	NOV 19, 2013			
			5480656	JAN 02, 2013			
	20219 001	LEVOCABASTINE HYDROCHLORIDE; LIVOSTIN	4369184	DEC 02, 2004		NCE	NOV 10, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20634 001	LEVOFLOXACIN; LEVAQUIN	4382892	SEP 02, 2001			
>ADD>			5053407	OCT 01, 2008			
>ADD>	20634 002	LEVOFLOXACIN; LEVAQUIN	4382892	SEP 02, 2001			
>ADD>			5053407	OCT 01, 2008			
>ADD>	20635 001	LEVOFLOXACIN; LEVAQUIN	4382892	SEP 02, 2001			
>ADD>			5053407	OCT 01, 2008			
>ADD>	20635 002	LEVOFLOXACIN; LEVAQUIN	4382892	SEP 02, 2001			
>ADD>			5053407	OCT 01, 2008			
>ADD>	20635 003	LEVOFLOXACIN; LEVAQUIN	4382892	SEP 02, 2001			
>ADD>			5053407	OCT 01, 2008			
>ADD>	20544 001	LEVONORGESTREL; NORPLANT II				NP	NOV 01, 1999
	20627 001	LEVONORGESTREL; LEVONORGESTREL				NP	AUG 15, 1999
	20575 001	LIDOCAINE; LIDOCAINE	5446070	FEB 27, 2011			
			5332576	JUL 26, 2011			
			5234957	FEB 27, 2011		NDF	MAY 21, 1999
	20575 002	LIDOCAINE; LIDOCAINE	5446070	FEB 27, 2011			
			5332576	JUL 26, 2011			
			5234957	FEB 27, 2011		NDF	MAY 21, 1999
	19558 001	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998
	19558 002	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998
	19558 003	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998
	19558 004	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998
	19558 006	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998
	19777 001	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
	19777 002	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
	19777 003	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
	19777 004	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
	19777 005	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
>ADD>	20013 001	LOMEFLOXACIN HYDROCHLORIDE; MAXAQUIN				I-173	OCT 09, 1999
	19658 001	LORATADINE; CLARITIN	4659716	APR 21, 2004	U-142	I-136	SEP 20, 1998
	19670 001	LORATADINE; CLARITIN-D	4659716	APR 21, 2004	U-142	NC	NOV 14, 1997
	20470 001	LORATADINE; CLARITIN-D 24 HOUR	5314697	OCT 23, 2012			
			4659716	APR 21, 2004	U-142	NP	AUG 23, 1999
			4282233	JUL 19, 2002	U-77	NCE	APR 12, 1998
	20641 001	LORATADINE; CLARITIN	4282233	JUN 19, 2002	U-77	NDF	OCT 10, 1999
>ADD>	20704 001	LORATADINE; CLARITIN REDITABS	4282233	JUN 19, 2002	U-77		
>ADD>			4371516	FEB 01, 2000			
	19940 001	MASOPROCOL; ACTINEX	4695590	APR 17, 2008			
	19651 001	MESALAMINE; ASACOL	5541171	JUL 30, 2013	U-141		
			5541170	JUL 30, 2013	U-141		
	20208 001	METRONIDAZOLE; METROGEL-VAGINAL	5536743	JUL 16, 2013	U-137		
	20670 002	MICONAZOLE NITRATE; MONISTAT-3 COMBINATION PACK				NP	APR 16, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19815 001	MIDODRINE HYDROCHLORIDE; PROAMATINE				NCE	SEP 06, 2001
	19815 002	MIDODRINE HYDROCHLORIDE; PROAMATINE				NCE	SEP 06, 2001
>ADD>	20682 001	MIGLITOL; GLYSET	4639436	JAN 27, 2004	U-111	NCE	DEC 18, 2001
>ADD>	20682 002	MIGLITOL; GLYSET	4639436	JAN 27, 2004	U-111	NCE	DEC 18, 2001
>ADD>	20682 003	MIGLITOL; GLYSET	4639436	JAN 27, 2004	U-111	NCE	DEC 18, 2001
	20415 001	MIRTAZAPINE; REMERON				NCE	JUN 14, 2001
	20415 002	MIRTAZAPINE; REMERON				NCE	JUN 14, 2001
	19297 001	MITOXANTRONE HYDROCHLORIDE; NOVANTRONE	4197249	APR 08, 1997		I-169	NOV 13, 1999
>ADD>			4138415	FEB 06, 1996		ODE	NOV 13, 2003
	20312 001	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4344949	OCT 03, 2000			
	20312 002	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4344949	OCT 03, 2000			
	20616 001	MORPHINE SULFATE; KADIAN	5378474	MAR 23, 2010			
			5202128	APR 13, 2010		NDF	JUL 03, 1999
	20616 002	MORPHINE SULFATE; KADIAN	5378474	MAR 23, 2010			
			5202128	APR 13, 2010		NDF	JUL 03, 1999
	20616 003	MORPHINE SULFATE; KADIAN	5378474	MAR 23, 2010			
			5202128	APR 13, 2010		NDF	JUL 03, 1999
	19886 001	NAFARELIN ACETATE; SYNAREL	4234571	JUN 11, 2011			
	20353 001	NAPROXEN SODIUM; NAPRELAN				NDF	JAN 05, 1999
	20353 002	NAPROXEN SODIUM; NAPRELAN				NDF	JAN 05, 1999
	20353 003	NAPROXEN SODIUM; NAPRELAN				NDF	JAN 05, 1999
	20152 001	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
	20152 002	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
	20152 003	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
	20152 004	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
	20152 005	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
	20152 006	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003	U-12	NCE	DEC 22, 1999
	20636 001	NEVIRAPINE; VIRAMUNE	5366972	NOV 22, 2011		NCE	JUN 21, 2001
	19488 001	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	OCT 12, 1995			
	19488 002	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	OCT 12, 1995			
	19734 001	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	OCT 12, 1995			
	20005 001	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995			
	20005 002	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995			
	20005 003	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995			
>DLT>	~~20165 001~~	~~NICOTINE; NICODERM CQ~~	~~5508038~~	~~APR 16, 2013~~			
>DLT>	~~20165 002~~	~~NICOTINE; NICODERM CQ~~	~~5508038~~	~~APR 16, 2013~~			
>DLT>	~~20165 003~~	~~NICOTINE; NICODERM CQ~~	~~5508038~~	~~APR 16, 2013~~			
>ADD>	20165 004	NICOTINE; NICODERM CQ	5508038	APR 16, 2013		NP	AUG 02, 1999
>ADD>	20165 005	NICOTINE; NICODERM CQ	5508038	APR 16, 2013		NP	AUG 02, 1999
>ADD>	20165 006	NICOTINE; NICODERM CQ	5508038	APR 16, 2013		NP	AUG 02, 1999
	20385 001	NICOTINE; NICOTROL				NP	MAR 22, 1999
>ADD>	20536 001	NICOTINE; NICOTROL				NP	JUL 03, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18612 002	NICOTINE POLACRILEX; NICORETTE				NP	FEB 09, 1999
	20066 002	NICOTINE POLACRILEX; NICORETTE				NP	FEB 09, 1999
	20169 001	NILUTAMIDE; NILANDRON				NCE	SEP 19, 2001
>ADD>	20144 001	NITROGLYCERIN; TRANSDERM-NITRO	4954344	DEC 04, 2001	U-158		
>ADD>			4849226	DEC 04, 2001	U-158		
>ADD>			4812313	DEC 04, 2001	U-158		
>ADD>	20144 002	NITROGLYCERIN; TRANSDERM-NITRO	4954344	DEC 04, 2001	U-158		
>ADD>			4849226	DEC 04, 2001	U-158		
>ADD>			4812313	DEC 04, 2001	U-158		
>ADD>	20144 003	NITROGLYCERIN; TRANSDERM-NITRO	4954344	DEC 04, 2001	U-158		
>ADD>			4849226	DEC 04, 2001	U-158		
>ADD>			4812313	DEC 04, 2001	U-158		
>ADD>	20144 004	NITROGLYCERIN; TRANSDERM-NITRO	4954344	DEC 04, 2001	U-158		
>ADD>			4849226	DEC 04, 2001	U-158		
>ADD>			4812313	DEC 04, 2001	U-158		
>ADD>	20144 005	NITROGLYCERIN; TRANSDERM-NITRO	4954344	DEC 04, 2001	U-158		
>ADD>			4849226	DEC 04, 2001	U-158		
>ADD>			4812313	DEC 04, 2001	U-158		
	20555 001	NIZATIDINE; AXID AR	4375547	OCT 02, 2002		NS	MAY 09, 1999
>ADD>	19735 001	OFLOXACIN; FLOXIN	4382892	SEP 02, 2003		I-174	DEC 19, 1999
>ADD>	19735 002	OFLOXACIN; FLOXIN	4382892	SEP 02, 2003		I-174	DEC 19, 1999
>ADD>	19735 003	OFLOXACIN; FLOXIN	4382892	SEP 02, 2003		I-174	DEC 19, 1999
	19921 001	OFLOXACIN; OCUFLOX				ODE	MAY 22, 2003
						I-160	MAY 22, 1999
>ADD>	20087 001	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001		I-174	DEC 19, 1999
>ADD>	20087 002	OFLOXACIN; FLOXIN	4382892	SEP 02, 2001		I-174	DEC 19, 1999
>ADD>	20087 003	OFLOXACIN; FLOXIN	4382892	SEP 02, 2001		I-174	DEC 19, 1999
>ADD>	20087 004	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001		I-174	DEC 19, 1999
>ADD>	20087 005	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001		I-174	DEC 19, 1999
	20592 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
	20592 002	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
	20592 003	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
	20592 004	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
>ADD>	20688 001	OLOPATADINE HYDROCHLORIDE; PATANOL				NCE	DEC 18, 2001
	19810 001	OMEPRAZOLE; PRILOSEC	4255431	APR 05, 2001	U-108	I-23	MAR 22, 1999
	19810 003	OMEPRAZOLE; PRILOSEC	4853230	APR 20, 2007	U-108	I-23	MAR 22, 1999
>ADD>	20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5578628	JUN 24, 2006	U-44	I-151	MAY 16, 1999
>ADD>	20007 003	ONDANSETRON HYDROCHLORIDE; ZOFRAN PRESERVATIVE FREE	5578628	JUN 24, 2006	U-44		
>ADD>	20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5578628	JUN 24, 2006	U-44	I-110	SEP 26, 1997
>ADD>	20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5578628	JUN 24, 2006	U-44	I-110	SEP 26, 1997
>ADD>	20403 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5578628	JUN 24, 2006	U-44	I-9	AUG 13, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18841 004	OXAPROZIN; DAYPRO				NCE	OCT 29, 1999*
	20553 001	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5549912	FEB 05, 2008			
			5266331	FEB 05, 2008		NDF	DEC 12, 1998
	20553 002	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5549912	FEB 05, 2008			
			5266331	FEB 05, 2008		NDF	DEC 12, 1998
	20553 003	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5549912	FEB 05, 2008			
			5266331	FEB 05, 2008		NDF	DEC 12, 1998
	20036 001	PAMIDRONATE DISODIUM; AREDIA	3962432	JUL 16, 1996		I-158	JUL 16, 1999
	20036 003	PAMIDRONATE DISODIUM; AREDIA	3962432	JUL 16, 1996		I-158	JUL 16, 1999
	20036 004	PAMIDRONATE DISODIUM; AREDIA	3962432	JUL 16, 1996		I-158	JUL 16, 1999
	20031 001	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999
	20031 002	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999
	20031 003	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999
	20031 004	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999
	20031 005	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999
	20629 001	PENCICLOVIR; DENAVIR	5075445	DEC 24, 2008		NCE	SEP 24, 2001
	19887 002	PENTAMIDINE ISETHIONATE; NEBUPENT				I-148	MAR 05, 1999
>ADD>	20193 001	PENTOSAN POLYSULFATE SODIUM; ELMIRON	5180715	JAN 19, 2010	U-159	NCE	SEP 26, 2001
	20184 001	PERINDOPRIL ERBUMINE; ACEON	4508729	AUG 21, 2006			
	20184 002	PERINDOPRIL ERBUMINE; ACEON	4508729	AUG 21, 2006			
	20184 003	PERINDOPRIL ERBUMINE; ACEON	4508729	AUG 21, 2006			
	19918 001	PERMETHRIN; NIX	4024163	MAY 17, 1996		I-170	NOV 01, 1999
	20451 001	PORFIMER SODIUM; PHOTOFRIN	5438071	AUG 01, 2012			
			5145863	JUN 12, 2007	U-129	ODE	DEC 27, 2002
			5028621	MAR 10, 2004			
			4932934	JUN 12, 2007	U-128	NCE	DEC 27, 2000
			4866168	MAR 10, 2004			
			4649151	MAR 10, 2004			
>ADD>	19898 002	PRAVASTATIN SODIUM; PRAVACHOL	5180589	JUL 09, 2008		I-152	MAR 22, 1999
>ADD>			5030447	JUL 09, 2008		I-159	JUL 02, 1999
>ADD>			4346227	OCT 20, 2005			
>ADD>	19898 003	PRAVASTATIN SODIUM; PRAVACHOL	5180589	JUL 09, 2008		I-152	MAR 22, 1999
>ADD>			5030447	JUL 09, 2008		I-159	JUL 02, 1999
>ADD>			4346227	OCT 20, 2005			
>ADD>	19898 004	PRAVASTATIN SODIUM; PRAVACHOL	5180589	JUL 09, 2008		I-152	MAR 22, 1999
>ADD>			5030447	JUL 09, 2008		I-159	JUL 02, 1999
>ADD>			4346227	OCT 20, 2005			

* - In accordance with section 2105(c) of the FDA Export Reform and Enhancement Act of 1996 (Public Law 104-134)

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>DLT>	~~19898 005~~	~~PRAVASTATIN SODIUM; PRAVACHOL~~	~~5180589~~	~~JUL 09, 2008~~		~~I-152~~	~~MAR 22, 1999~~
>DLT>			~~5030447~~	~~JUL 09, 2008~~		~~I-159~~	~~JUL 02, 1999~~
>DLT>			~~4346227~~	~~OCT 20, 2005~~		~~NCE~~	~~OCT 31, 1996~~
>DLT>	~~19898 006~~	~~PRAVASTATIN SODIUM; PRAVACHOL~~	~~5180589~~	~~JUL 09, 2008~~		~~I-152~~	~~MAR 22, 1999~~
>DLT>			~~5030447~~	~~JUL 09, 2008~~		~~I-159~~	~~JUL 02, 1999~~
>DLT>			~~4346227~~	~~OCT 20, 2005~~		~~NCE~~	~~OCT 31, 1996~~
>DLT>	~~19898 007~~	~~PRAVASTATIN SODIUM; PRAVACHOL~~	~~5180589~~	~~JUL 09, 2008~~		~~I-152~~	~~MAR 22, 1999~~
>DLT>			~~5030447~~	~~JUL 09, 2008~~		~~I-159~~	~~JUL 02, 1999~~
>DLT>			~~4346227~~	~~OCT 20, 2005~~		~~NCE~~	~~OCT 31, 1996~~
	20279 001	PREDNICARBATE; DERMATOP				I-154	MAY 03, 1999
	20545 001	PROCAINAMIDE HYDROCHLORIDE; PROCANBID				NP	JAN 31, 1999
	20545 002	PROCAINAMIDE HYDROCHLORIDE; PROCANBID				NP	JAN 31, 1999
	19627 001	PROPOFOL; DIPRIVAN	4056635	NOV 01, 1996		I-90	MAR 08, 1996
	19885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
	19885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
	19885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
	19885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
	20559 001	RANITIDINE BISMUTH CITRATE; TRITEC	5008256	JUL 17, 2009		NE	AUG 08, 1999
	19593 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004			
			4521431	JUN 04, 2002	U-121		
			4128658	JUL 25, 1997	U-121		
	19593 002	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004			
			4521431	JUN 04, 2002	U-121		
			4128658	JUL 25, 1997	U-121		
	20520 001	RANITIDINE HYDROCHLORIDE; ZANTAC 75	4880636	MAY 13, 2008			
			4521431	JUN 04, 2002	U-121		
			4128658	JUL 25, 1997	U-121		
	20630 001	REMIFENTANIL HYDROCHLORIDE; ULTIVA	5466700	AUG 30, 2013	U-156		
			5019583	FEB 15, 2009		NCE	JUL 12, 2001
	20630 002	REMIFENTANIL HYDROCHLORIDE; ULTIVA	5466700	AUG 30, 2013	U-156		
			5019583	FEB 15, 2009		NCE	JUL 12, 2001
	20630 003	REMIFENTANIL HYDROCHLORIDE; ULTIVA	5466700	AUG 30, 2013	U-156		
			5019583	FEB 15, 2009		NCE	JUL 12, 2001
	20272 001	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
	20272 002	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
	20272 003	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
	20272 004	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
	20272 005	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
	20588 001	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90	NCE	DEC 29, 1998
	20659 001	RITONAVIR; NORVIR	5541206	JUL 30, 2013	U-140		
			5484801	JAN 28, 2014		NCE	MAR 01, 2001
	20680 001	RITONAVIR; NORVIR	5541206	JUL 30, 2013	U-140	NCE	MAR 01, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20533 001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE; NAROPIN	4870086	SEP 26, 2006		NCE	SEP 24, 2001
			4695576	SEP 22, 2004			
	20533 003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE; NAROPIN	4870086	SEP 26, 2006		NCE	SEP 24, 2001
			4695576	SEP 22, 2004			
	20533 004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE; NAROPIN	4870086	SEP 26, 2006		NCE	SEP 24, 2001
			4695576	SEP 22, 2004			
	20533 005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE; NAROPIN	4870086	SEP 26, 2006		NCE	SEP 24, 2001
			4695576	SEP 22, 2004			
	20628 001	SAQUINAVIR MESYLATE; INVIRASE	5196438	NOV 19, 2010			
	19839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	4962128	NOV 02, 2009	U-152		
			4536518	DEC 31, 2005	U-152	I-102	OCT 25, 1999
	19839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	4962128	NOV 02, 2009	U-152		
			4536518	DEC 31, 2005	U-152	I-102	OCT 25, 1999
	19839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	4962128	NOV 02, 2009	U-152		
			4536518	DEC 31, 2005	U-152	I-102	OCT 25, 1999
	19839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	4962128	NOV 02, 2009	U-152		
			4536518	DEC 31, 2005	U-152	I-102	OCT 25, 1999
	19839 005	SERTRALINE HYDROCHLORIDE; ZOLOFT	4962128	NOV 02, 2009	U-152		
			4536518	DEC 31, 2005	U-152	I-102	OCT 25, 1999
	20572 001	SODIUM PHENYLBUTYRATE; BUPHENYL	4457942	AUG 20, 2002	U-136	NCE	APR 30, 2001
	20573 001	SODIUM PHENYLBUTYRATE; BUPHENYL	4457942	AUG 20, 2002	U-136	NCE	APR 30, 2001
						ODE	APR 30, 2003
>ADD>	19931 001	SODIUM SULFACETAMIDE; KLARON				NDF	DEC 23, 1999
	19640 001	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				I-161	AUG 01, 1999
	19640 004	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				I-161	AUG 01, 1999
	20280 004	SOMATROPIN, BIOSYNTHETIC; GENOTROPIN				NS	AUG 24, 1998
	20280 006	SOMATROPIN, BIOSYNTHETIC; GENOTROPIN				NS	AUG 24, 1998
	20604 001	SOMATROPIN, BIOSYNTHETIC; SEROSTIM				ODE	AUG 23, 2003
						NP	AUG 23, 1999
	20604 002	SOMATROPIN, BIOSYNTHETIC; SEROSTIM				ODE	AUG 23, 2003
						NP	AUG 23, 1999
>ADD>	20677 001	SPARFLOXACIN; ZAGAM	4795751	OCT 28, 2006	U-160	NCE	DEC 19, 2001
	20240 001	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
	20240 002	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
	20240 003	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
	20240 004	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
	20412 001	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
	20412 002	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
	20412 003	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
	20412 004	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
	20412 005	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
	07073 002	SULFASALAZINE; AZULFIDINE EN-TABS				I-165	OCT 17, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20547 001	ZAFIRLUKAST; ACCOLATE	5482963	JAN 09, 2013			
			5319097	DEC 11, 2011			
			5294636	DEC 11, 2011			
			4859692	AUG 22, 2006		NCE	SEP 26, 2001
>ADD>	20471 001	ZILEUTON; ZYFLO				NCE	DEC 09, 2001
>ADD>	20471 003	ZILEUTON; ZYFLO				NCE	DEC 09, 2001

*U.S. Government Printing Office: 1997 - 417-599/40006

New 17th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7971

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

___ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $77.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account
☐ VISA or MasterCard

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature)

(10/95)

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____) _____
Daytime phone including area code

_____
Purchase Order No. (optional)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.